<?xml version='1.0' encoding='UTF-8'?>
<chapter id="ch0083">
    <title>66 Chlamydia</title>
    <sect1 id="ch0083s0001">
      <title>66 Chlamydia</title>
      <anchor id="ch0083s0001a0001"/>
      <anchor id="ch0083s0001a0002"/>
      <para role="chapterAuthor"><phrase role="center">GILBERT GREUB AND ERIK MUNSON</phrase>
      </para>
      <sect2 id="ch0083s0001s0001">
        <title>TAXONOMY</title>
        <anchor id="ch0083s0001s0001a0001"/>
        <anchor id="ch0083s0001s0001a0002"/>
      </sect2>
    </sect1>
    <sect1 id="ch0083s0002">
      <title>Introduction</title>
      <anchor id="ch0083s0002a0001"/>
      <anchor id="ch0083s0002a0002"/>
      <para id="ch0083s0002p0001">In the past, members of the genus<emphasis>Chlamydia</emphasis> were differentiated from other microorganisms as being obligately intracellular bacteria with a unique biphasic developmental cycle. When these organisms were isolated, they were often given epithets reflecting the host species from which they were isolated (e.g., <emphasis>Chlamydia felis</emphasis> from cats and <emphasis>Chlamydia avium</emphasis> from birds) or the disease with which they were associated (e.g., <emphasis>Chlamydia trachomatis</emphasis> with trachoma and <emphasis>Chlamydia pneumoniae</emphasis> with lung infection). Recently, other obligately intracellular bacteria with similar developmental cycles have been described in a wide variety of hosts, including various mammals, frogs, reptiles, fish, insects, ticks, and free-living amoebae (<link linkend="ch0083s0028s0003li0001">1</link>, <link linkend="ch0083s0028s0003li0002">2</link>). While some morphologic differences exist, the new intracellular bacteria exhibit a biphasic developmental cycle (<link linkend="ch0083s0028s0003li0003">3</link>–<link linkend="ch0083s0028s0003li0005">5</link>) and are therefore commonly named “<emphasis>Chlamydia</emphasis>-related bacteria,” “chlamydia-like organisms” (CLO), or “environmental chlamydiae.” The latter is not appropriate, since some of these novel chlamydiae are also documented in mammals and are sometimes pathogenic.</para>
      <para id="ch0083s0002p0002">Since they exhibit more than 80% 16S rRNA gene sequence similarity, these novel intracellular bacteria all belong to the phylum<emphasis>Chlamydiota</emphasis> (syn. <emphasis>Chlamydiae</emphasis>) and are now classified within the order <emphasis>Chlamydiales</emphasis>, according to the International Committee on Systematics of Prokaryotes subcommittee on the taxonomy of chlamydiae, a group of experts who have met annually since March 2009 to provide advice about chlamydial taxonomy (<link linkend="ch0083s0028s0003li0006">6</link>, <link linkend="ch0083s0028s0003li0007">7</link>).</para>
      <para id="ch0083s0002p0003">Based on 16S and 23S rRNA gene sequences, there are nine family-level lineages within the order<emphasis>Chlamydiales</emphasis> (<link linkend="ch0083s0028s0003li0001">1</link>, <link linkend="ch0083s0028s0003li0008">8</link>), the caveat being that some have not been cultured and have been identified only by DNA sequence relatedness. For most of CLOs, there have been studies of their ability to produce disease in humans (<link linkend="ch0083s0028s0003li0009">9</link>, <link linkend="ch0083s0028s0003li0010">10</link>); for some new species, such as “<emphasis>Estrella lausannensis</emphasis>” and “<emphasis>Candidatus</emphasis> Rhabdochlamydia helvetica,” the evidence is not compelling enough to indicate that they should be included among the microorganisms requiring routine clinical laboratory work at this time.</para>
      <para id="ch0083s0002p0004">This chapter focuses on the important human pathogens within the genus<emphasis>Chlamydia</emphasis>, as well as on <emphasis>Parachlamydia acanthamoebae, Waddlia chondrophila</emphasis>, and <emphasis>Simkania negevensis</emphasis>, for which evidence gathered over the past 20 years supports possible pathogenicity in humans (reviewed in references <link linkend="ch0083s0028s0003li0009">9</link> and <link linkend="ch0083s0028s0003li0011">11</link>–<link linkend="ch0083s0028s0003li0016">16</link>).</para>
    </sect1>
    <sect1 id="ch0083s0003">
      <title>The Pillonel Criteria</title>
      <anchor id="ch0083s0003a0001"/>
      <anchor id="ch0083s0003a0002"/>
      <para id="ch0083s0003p0001">The taxonomy of<emphasis>Chlamydiales</emphasis> is rapidly evolving and progressively moving from a purely phenotypic taxonomy to a polyphasic taxonomy combining phenotypic, molecular, and phylogenetic characteristics. Based on 16S and 23S rRNA gene sequences, some closely related species (e.g., <emphasis>Chlamydia psittaci sensu lato</emphasis>) have been reclassified in two different species (e.g., <emphasis>Chlamydia psittaci</emphasis> and <emphasis>Chlamydia abortus</emphasis>). This reclassification was useful since it reflects (i) different ecology and sources of human infection (i.e., from birds and sheep/goats, respectively), and (ii) different organ tropism and clinical presentation in humans (i.e., pneumonia and miscarriage, respectively). Thus, sequence analysis now plays an important role in species description, but today such description should rely on full bacterial genomic sequences, since 16S and 23S rRNA genes have clearly been shown not to be discriminatory enough to differentiate members of the order <emphasis>Chlamydiales</emphasis> at the genus and species levels. Genes encoding DnaA, ScA, FabI, and a hypothetical protein (Hyp235) have been shown to be the best classification markers for a newly isolated strain at the genus level, whereas genes encoding RpoN, FtsK, PepF, Adk, and HemL have been shown to be the best markers at the species level, with specific cutoffs (<anchor id="ch0083s0003a0003"/><link linkend="ch0083s0004a0005">Table 1</link>). These Pillonel criteria are increasingly used and have been validated by the international subcommittee on taxonomy of chlamydiae.</para>
    </sect1>
    <sect1 id="ch0083s0004">
      <title>Family Chlamydiaceae</title>
      <anchor id="ch0083s0004a0001"/>
      <anchor id="ch0083s0004a0002"/>
      <para id="ch0083s0004p0001">It is noteworthy that the family<emphasis>Chlamydiaceae</emphasis> is composed of only a single validated genus, as an effort to create the genus <emphasis>Chlamydophila</emphasis> was rejected by the scientific community (<link linkend="ch0083s0028s0003li0006">6</link>, <link linkend="ch0083s0028s0003li0018">18</link>, <link linkend="ch0083s0028s0003li0019">19</link>). In this chapter, we focus on <emphasis>C. trachomatis, C. pneumoniae</emphasis>, and <emphasis>C. psittaci</emphasis> infections in humans, but additional species have been reported, many named after the initial host species in reference to the disease they cause in animals (i.e., <emphasis>C. abortus, C. avium, C. felis, Chlamydia gallinacea, Chlamydia muridarum, Chlamydia pecorum</emphasis>, and <emphasis>Chlamydia suis</emphasis>) (<link linkend="ch0083s0028s0003li0018">18</link>). <anchor id="ch0083s0004a0003"/><link linkend="ch0083s0004a0012">Table 2</link> lists all the species-level lineages reported so far, including <emphasis>Candidatus</emphasis> species belonging to the genus <emphasis>Chlamydia</emphasis> and two <emphasis>Candidatus</emphasis> genera consisting of bacteria documented in amphibians and amoebae, namely, “<emphasis>Candidatus</emphasis> Rubidus” and “<emphasis>Candidatus</emphasis> Amphibiichlamydia” (<link linkend="ch0083s0004a0012">Table 2</link>).</para>
      <anchor id="ch0083s0004a0004"/>
      <beginpage pagenum="1261"/>
      <table id="ch0083s0004t0001"><title><emphasis role="strong"><phrase role="figureLabel"><anchor id="ch0083s0004a0005"/><link linkend="ch0083s0003a0003">TABLE 1</link></phrase></emphasis> Pillonel criteria for description of a new species<superscript><emphasis><anchor id="ch0083s0004a0006"/><link linkend="ch0083s0004a0009">a</link></emphasis></superscript>
</title>
        
        <tgroup cols="4">
          <tbody>
            <row>
              <entry><phrase role="center">Clade level</phrase>
              </entry>
              <entry><phrase role="center">Gene</phrase>
              </entry>
              <entry><phrase role="center">Cutoff (%)<superscript><emphasis><anchor id="ch0083s0004a0007"/><link linkend="ch0083s0004a0010">b</link></emphasis></superscript></phrase>
              </entry>
              <entry><phrase role="center">Example with <emphasis>Estrella lausannensis</emphasis><superscript><emphasis><anchor id="ch0083s0004a0008"/><link linkend="ch0083s0004a0011">c</link></emphasis></superscript></phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Order</phrase>
              </entry>
              <entry><phrase role="left">16S rRNA</phrase>
              </entry>
              <entry><phrase role="left">≥80</phrase>
              </entry>
              <entry><phrase role="left">
                  <emphasis>Chlamydiales</emphasis>
                </phrase>
              </entry>
            </row>
            <row>
              <entry/>
              <entry><phrase role="left">23S rRNA</phrase>
              </entry>
              <entry><phrase role="left">≥80</phrase>
              </entry>
              <entry><phrase role="left">
                  <emphasis>Chlamydiales</emphasis>
                </phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Family</phrase>
              </entry>
              <entry><phrase role="left">16S rRNA</phrase>
              </entry>
              <entry><phrase role="left">≥92.5</phrase>
              </entry>
              <entry><phrase role="left">“<emphasis>Candidatus</emphasis> Criblamydiaceae”</phrase>
              </entry>
            </row>
            <row>
              <entry/>
              <entry><phrase role="left">23S rRNA</phrase>
              </entry>
              <entry><phrase role="left">≥91</phrase>
              </entry>
              <entry><phrase role="left">“<emphasis>Candidatus</emphasis> Criblamydiaceae”</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Genus</phrase>
              </entry>
              <entry><phrase role="left">
                  <emphasis>fabI</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="left">≥78</phrase>
              </entry>
              <entry><phrase role="left">
                  <emphasis>Estrella</emphasis>
                </phrase>
              </entry>
            </row>
            <row>
              <entry/>
              <entry><phrase role="left">
                  <emphasis>dnaA</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="left">≥70</phrase>
              </entry>
              <entry><phrase role="left">
                  <emphasis>Estrella</emphasis>
                </phrase>
              </entry>
            </row>
            <row>
              <entry/>
              <entry><phrase role="left">
                  <emphasis>sucA</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="left">≥64</phrase>
              </entry>
              <entry><phrase role="left">
                  <emphasis>Estrella</emphasis>
                </phrase>
              </entry>
            </row>
            <row>
              <entry/>
              <entry><phrase role="left">
                  <emphasis>hyp235</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="left">≥57</phrase>
              </entry>
              <entry><phrase role="left">
                  <emphasis>Estrella</emphasis>
                </phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Species</phrase>
              </entry>
              <entry><phrase role="left">
                  <emphasis>ftsK</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="left">≥98</phrase>
              </entry>
              <entry><phrase role="left">
                  <emphasis>E. lausannensis</emphasis>
                </phrase>
              </entry>
            </row>
            <row>
              <entry/>
              <entry><phrase role="left">
                  <emphasis>rpoN</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="left">≥96</phrase>
              </entry>
              <entry><phrase role="left">
                  <emphasis>E. lausannensis</emphasis>
                </phrase>
              </entry>
            </row>
            <row>
              <entry/>
              <entry><phrase role="left">
                  <emphasis>pepF</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="left">≥96</phrase>
              </entry>
              <entry><phrase role="left">
                  <emphasis>E. lausannensis</emphasis>
                </phrase>
              </entry>
            </row>
            <row>
              <entry/>
              <entry><phrase role="left">
                  <emphasis>adK</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="left">≥95</phrase>
              </entry>
              <entry><phrase role="left">
                  <emphasis>E. lausannensis</emphasis>
                </phrase>
              </entry>
            </row>
            <row>
              <entry/>
              <entry><phrase role="left">
                  <emphasis>hemL</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="left">≥95</phrase>
              </entry>
              <entry><phrase role="left">
                  <emphasis>E. lausannensis</emphasis>
                </phrase>
              </entry>
            </row>
          </tbody>
        </tgroup>
      </table>
      <para role="table-footnote"><superscript><emphasis><anchor id="ch0083s0004a0009"/><link linkend="ch0083s0004a0006">a</link></emphasis></superscript>Description of a new species is based on the availability of draft genome sequences and on the Pillonel criteria shown here. Cutoffs for some taxonomically relevant gene sequences to assign a new strain at the order, family, genus, and species levels are specified. Thus, for example, a new strain exhibiting more than 80% identity for both 16S and 23S rRNA gene sequences is assigned to the same order as the reference strain used for the classification (i.e., the order <emphasis>Chlamydiales</emphasis>).</para>
      <para role="table-footnote"><superscript><emphasis><anchor id="ch0083s0004a0010"/><link linkend="ch0083s0004a0007">b</link></emphasis></superscript>Cut-off provided in this table have been reproduced reference <link linkend="ch0083s0028s0003li0017">17</link>.</para>
      <para role="table-footnote"><superscript><emphasis><anchor id="ch0083s0004a0011"/><link linkend="ch0083s0004a0008">c</link></emphasis></superscript>Using the type strain as reference to classify a new strain and documenting that it always exhibits a high similarity with this species.</para>
      <para id="ch0083s0004p0002">Of the<emphasis>Chlamydiaceae, C. trachomatis</emphasis> is the most common human pathogen and the one that requires the largest volume of laboratory tests. It exhibits 15 major serovars and corresponding genovariants, designated with the letters A through L (<link linkend="ch0083s0028s0003li0020">20</link>). Serovars A, B<subscript>a</subscript>, B, and C are the causative agents of trachoma. Serovars D through K are sexually transmitted, causing ocular and genital tract disease, and serovars L1, L2, and L3 cause lymphogranuloma venereum (LGV).</para>
      <para id="ch0083s0004p0003">The L serovars are sometimes referred to as the LGV biovar, and serovars A through K are called the trachoma biovar (<link linkend="ch0083s0028s0003li0020">20</link>). This differentiation was made based on biological properties. The LGV biovar is easy to cultivate in cell culture, whereas serovars A through K require mechanical assistance (centrifugation), and the LGV serovars are more virulent in laboratory animals. This more aggressive behavior in the laboratory has a parallel in human infection. The LGV biovar is more invasive than the trachoma biovar, where infection is typically seen at mucous membranes. There are no known animal reservoirs for <emphasis>C. trachomatis</emphasis>.</para>
      <para id="ch0083s0004p0004"><emphasis>C. pneumoniae</emphasis> infection is also spread from person to person, but via the respiratory route. It exhibits nearly 5% 16S rRNA gene sequence difference from <emphasis>C. trachomatis</emphasis>; antigenic and morphologic differences further justify its placement in a separate species. It causes outbreaks of community-acquired pneumonia in communities and in settings where individuals live in close quarters (colleges, the military, and long-term care facilities) (<link linkend="ch0083s0028s0003li0021">21</link>, <link linkend="ch0083s0028s0003li0022">22</link>). <emphasis>C. pneumoniae</emphasis> infection is found in some animals, such as koalas (<link linkend="ch0083s0028s0003li0023">23</link>).</para>
      <para id="ch0083s0004p0005">Other organisms within the genus<emphasis>Chlamydia</emphasis> cause human diseases, but such diseases are zoonoses, more typically seen as single infections or as clusters with point source exposures or resulting from occupational exposure, with multiple cases. Humans are usually dead-end hosts. These organisms naturally occur in avian and mammalian species. <emphasis>Chlamydia psittaci</emphasis> is the most common of these in terms of human infections, being reported in Europe in 1% of community-acquired pneumonia cases (<link linkend="ch0083s0028s0003li0024">24</link>). This 1% prevalence was observed not only in studies based on immunofluorescence or enzyme-linked immunosorbent assay (ELISA) but also in the four studies relying on nucleic acid amplification-based assays provided in a recent meta-analysis (<link linkend="ch0083s0028s0003li0025">25</link>). Noteworthily, one of these studies was performed in the Netherlands, where the federal agency reported fivefold fewer cases during the same period, suggesting that underreporting may be the rule outside of clinical studies specifically searching for <emphasis>C. psittaci.</emphasis> The organism is often interrogated only when obvious exposure to birds (in bird owners or coworkers in turkey factories) or bird droppings (in roofers and chimney sweeps) are reported, and broader screening for this pathogen is warranted, at least in Europe. The much lower reporting rate in the United States may reflect a different epidemiology but may also reflect similar underreporting, since most <emphasis>C. psittaci</emphasis> cases may be successfully treated by empiric macrolide therapy and since approximately 50% of community-acquired pneumonia remains of unknown etiology.</para>
      <para id="ch0083s0004p0006">Another anthropozoonotic chlamydial species is<emphasis>C. abortus</emphasis>, a bacterium causing abortion in ovines and caprines and occasionally leading to miscarriage or fetal loss in humans (<link linkend="ch0083s0028s0003li0025">25</link>).</para>
      <table id="ch0083s0004t0002"><title><emphasis role="strong"><phrase role="figureLabel"><anchor id="ch0083s0004a0012"/><link linkend="ch0083s0004a0003">TABLE 2</link></phrase></emphasis> Taxonomic diversity within the order <emphasis>Chlamydiales</emphasis> and human pathogenicity<superscript><emphasis><anchor id="ch0083s0004a0013"/><link linkend="ch0083s0004a0014">a</link></emphasis></superscript>
</title>
        
        <tgroup cols="3">
          <tbody>
            <row>
              <entry><phrase role="center">Clade</phrase>
              </entry>
              <entry><phrase role="center">Species name</phrase>
              </entry>
              <entry><phrase role="center">Pathogenic role in humans (risk factor[s])</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">
                  <emphasis>Chlamydiaceae</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="left">
                  <emphasis role="strong">
                    <emphasis>Chlamydia abortus</emphasis>
                  </emphasis>
                </phrase>
              </entry>
              <entry><phrase role="left">Miscarriage (rare, farming activities)</phrase>
              </entry>
            </row>
            <row>
              <entry/>
              <entry><phrase role="left">
                  <emphasis>Chlamydia avium</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="left">Unknown (birds)</phrase>
              </entry>
            </row>
            <row>
              <entry/>
              <entry><phrase role="left"><emphasis>Chlamydia buteonis</emphasis>*</phrase>
              </entry>
              <entry><phrase role="left">Unknown (birds)</phrase>
              </entry>
            </row>
            <row>
              <entry/>
              <entry><phrase role="left">
                  <emphasis role="strong">
                    <emphasis>Chlamydia caviae*</emphasis>
                  </emphasis>
                </phrase>
              </entry>
              <entry><phrase role="left">Conjunctivitis (rare, exposure to guinea-pigs)</phrase>
              </entry>
            </row>
            <row>
              <entry/>
              <entry><phrase role="left">
                  <emphasis role="strong">
                    <emphasis>Chlamydia felis</emphasis>
                  </emphasis>
                </phrase>
              </entry>
              <entry><phrase role="left">Conjunctivitis (rare, exposure to cats)</phrase>
              </entry>
            </row>
            <row>
              <entry/>
              <entry><phrase role="left">
                  <emphasis>Chlamydia gallinacean</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="left">Unknown (poultry)</phrase>
              </entry>
            </row>
            <row>
              <entry/>
              <entry><phrase role="left"><emphasis>Chlamydia ibidis</emphasis>*</phrase>
              </entry>
              <entry><phrase role="left">Unknown (birds)</phrase>
              </entry>
            </row>
            <row>
              <entry/>
              <entry><phrase role="left">
                  <emphasis>Chlamydia muridarum</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="left">Unknown (mice)</phrase>
              </entry>
            </row>
            <row>
              <entry/>
              <entry><phrase role="left">
                  <emphasis>Chlamydia pecorum</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="left">Unknown</phrase>
              </entry>
            </row>
            <row>
              <entry/>
              <entry><phrase role="left">
                  <emphasis role="strong">
                    <emphasis>Chlamydia pneumoniae</emphasis>
                  </emphasis>
                </phrase>
              </entry>
              <entry><phrase role="left">Lung infection, asthma-like syndrome</phrase>
              </entry>
            </row>
            <row>
              <entry/>
              <entry><phrase role="left"><emphasis>Chlamydia poikilotherma</emphasis>*</phrase>
              </entry>
              <entry><phrase role="left">Unknown (reptiles)</phrase>
              </entry>
            </row>
            <row>
              <entry/>
              <entry><phrase role="left">
                  <emphasis role="strong">
                    <emphasis>Chlamydia psittaci</emphasis>
                  </emphasis>
                </phrase>
              </entry>
              <entry><phrase role="left">Lung infections (exposure to birds and horses)</phrase>
              </entry>
            </row>
            <row>
              <entry/>
              <entry><phrase role="left"><emphasis>Chlamydia serpentis</emphasis>*</phrase>
              </entry>
              <entry><phrase role="left">Unknown (snakes)</phrase>
              </entry>
            </row>
            <row>
              <entry/>
              <entry><phrase role="left">
                  <emphasis>Chlamydia suis</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="left">Unknown (pigs)</phrase>
              </entry>
            </row>
            <row>
              <entry/>
              <entry><phrase role="left">
                  <emphasis role="strong">
                    <emphasis>Chlamydia trachomatis</emphasis>
                  </emphasis>
                </phrase>
              </entry>
              <entry><phrase role="left">Urethritis, cervicitis, PID</phrase>
              </entry>
            </row>
            <row>
              <entry/>
              <entry><phrase role="left"><emphasis>Rubidus massiliensis</emphasis>*</phrase>
              </entry>
              <entry><phrase role="left">Unknown (amoebae)</phrase>
              </entry>
            </row>
            <row>
              <entry/>
              <entry><phrase role="left"><emphasis>Amphibiichlamydia ranarum</emphasis>*</phrase>
              </entry>
              <entry><phrase role="left">Unknown (frogs)</phrase>
              </entry>
            </row>
            <row>
              <entry/>
              <entry><phrase role="left"><emphasis>Amphibiichlamydia salamandrae</emphasis>*</phrase>
              </entry>
              <entry><phrase role="left">Unknown (amphibians)</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">
                  <emphasis>Parachlamydiaceae</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="left"><emphasis>Mesochlamydia elodea</emphasis>*</phrase>
              </entry>
              <entry><phrase role="left">Unknown (amoebae)</phrase>
              </entry>
            </row>
            <row>
              <entry/>
              <entry><phrase role="left"><emphasis>Metachlamydia lacustris</emphasis>*</phrase>
              </entry>
              <entry><phrase role="left">Unknown (amoebae)</phrase>
              </entry>
            </row>
            <row>
              <entry/>
              <entry><phrase role="left"><emphasis>Protochlamydia amoebophila</emphasis>*</phrase>
              </entry>
              <entry><phrase role="left">Unknown (amoebae)</phrase>
              </entry>
            </row>
            <row>
              <entry/>
              <entry><phrase role="left"><emphasis>Protochlamydia massiliensis</emphasis>*</phrase>
              </entry>
              <entry><phrase role="left">Unknown (amoebae)</phrase>
              </entry>
            </row>
            <row>
              <entry/>
              <entry><phrase role="left">
                  <emphasis role="strong">
                    <emphasis>Protochlamydia naegleriophila*</emphasis>
                  </emphasis>
                </phrase>
              </entry>
              <entry><phrase role="left">Lung infection (rare, water aerosols)</phrase>
              </entry>
            </row>
            <row>
              <entry/>
              <entry><phrase role="left">
                  <emphasis>Neochlamydia hartmannellae</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="left">Unknown (amoebae)</phrase>
              </entry>
            </row>
            <row>
              <entry/>
              <entry><phrase role="left">
                  <emphasis>Parachlamydia acanthamoebae</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="left">Lung infection (water aerosols)</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">
                  <emphasis>Waddliaceae</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="left">
                  <emphasis role="strong">
                    <emphasis>Waddlia chondrophila</emphasis>
                  </emphasis>
                </phrase>
              </entry>
              <entry><phrase role="left">Miscarriage, lung infections</phrase>
              </entry>
            </row>
            <row>
              <entry/>
              <entry><phrase role="left">
                  <emphasis>Waddlia malaysiensis</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="left">Unknown (bats)</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">
                  <emphasis>Simkaniaceae</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="left"><emphasis>Fritschea bemisiae</emphasis>*</phrase>
              </entry>
              <entry><phrase role="left">Unknown (arthropods)</phrase>
              </entry>
            </row>
            <row>
              <entry/>
              <entry><phrase role="left"><emphasis>Fritschea eriococci</emphasis>*</phrase>
              </entry>
              <entry><phrase role="left">Unknown (arthropods)</phrase>
              </entry>
            </row>
            <row>
              <entry/>
              <entry><phrase role="left"><emphasis>Neptunochlamydia vexilliferae</emphasis>*</phrase>
              </entry>
              <entry><phrase role="left">Unknown (arthropods)</phrase>
              </entry>
            </row>
            <row>
              <entry/>
              <entry><phrase role="left"><emphasis>Syngnamydia salmonis</emphasis>*</phrase>
              </entry>
              <entry><phrase role="left">Unknown (fish)</phrase>
              </entry>
            </row>
            <row>
              <entry/>
              <entry><phrase role="left"><emphasis>Syngnamydia venezia</emphasis>*</phrase>
              </entry>
              <entry><phrase role="left">Unknown (fish)</phrase>
              </entry>
            </row>
            <row>
              <entry/>
              <entry><phrase role="left">
                  <emphasis role="strong">
                    <emphasis>Simkania negevensis</emphasis>
                  </emphasis>
                </phrase>
              </entry>
              <entry><phrase role="left">Lung infections (no proven pathogenic role)</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left"><emphasis>Clavichlamydiaceae</emphasis>*</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>Clavichlamydia salmonicola</emphasis>*</phrase>
              </entry>
              <entry><phrase role="left">Unknown (fish)</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left"><emphasis>Criblamydiaceae</emphasis>*</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>Criblamydia sequanensis</emphasis>*</phrase>
              </entry>
              <entry><phrase role="left">Unknown (amoebae)</phrase>
              </entry>
            </row>
            <row>
              <entry/>
              <entry><phrase role="left"><emphasis>Estrella lausannensis</emphasis>*</phrase>
              </entry>
              <entry><phrase role="left">Unknown (amoebae)</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left"><emphasis>Rhabdochlamydiaceae</emphasis>*</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>Rhabdochlamydia crassificans</emphasis>*</phrase>
              </entry>
              <entry><phrase role="left">Unknown (arthropods)</phrase>
              </entry>
            </row>
            <row>
              <entry/>
              <entry><phrase role="left"><emphasis>Rhabdochlamydia helvetica</emphasis>*</phrase>
              </entry>
              <entry><phrase role="left">Unknown (arthropods)</phrase>
              </entry>
            </row>
            <row>
              <entry/>
              <entry><phrase role="left"><emphasis>Rhabdochlamydia oedothoracis</emphasis>*</phrase>
              </entry>
              <entry><phrase role="left">Unknown (arthropods)</phrase>
              </entry>
            </row>
            <row>
              <entry/>
              <entry><phrase role="left"><emphasis>Rhabdochlamydia porcellionis</emphasis>*</phrase>
              </entry>
              <entry><phrase role="left">Unknown (arthropods)</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left"><emphasis>Parilichlamydiaceae</emphasis>*</phrase>
              </entry>
              <entry><phrase role="left">
                  <emphasis>Similichlamydia epinepheli</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="left">Unknown (fish)</phrase>
              </entry>
            </row>
            <row>
              <entry/>
              <entry><phrase role="left"><emphasis>Similichlamydia labri</emphasis>*</phrase>
              </entry>
              <entry><phrase role="left">Unknown (fish)</phrase>
              </entry>
            </row>
            <row>
              <entry/>
              <entry><phrase role="left"><emphasis>Similichlamydia laticola</emphasis>*</phrase>
              </entry>
              <entry><phrase role="left">Unknown (fish)</phrase>
              </entry>
            </row>
            <row>
              <entry/>
              <entry><phrase role="left"><emphasis>Similichlamydia latridicola</emphasis>*</phrase>
              </entry>
              <entry><phrase role="left">Unknown (fish)</phrase>
              </entry>
            </row>
            <row>
              <entry/>
              <entry><phrase role="left"><emphasis>Parilichlamydia carangidicola</emphasis>*</phrase>
              </entry>
              <entry><phrase role="left">Unknown (fish)</phrase>
              </entry>
            </row>
            <row>
              <entry/>
              <entry><phrase role="left"><emphasis>Parilichlamydia rohitae</emphasis>*</phrase>
              </entry>
              <entry><phrase role="left">Unknown (fish)</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left"><emphasis>Piscichlamydiaceae</emphasis>*</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>Piscichlamydia cyprini</emphasis>*</phrase>
              </entry>
              <entry><phrase role="left">Unknown (fish)</phrase>
              </entry>
            </row>
            <row>
              <entry/>
              <entry><phrase role="left"><emphasis>Piscichlamydia salmonis</emphasis>*</phrase>
              </entry>
              <entry><phrase role="left">Unknown (fish)</phrase>
              </entry>
            </row>
          </tbody>
        </tgroup>
      </table>
      <para role="table-footnote"><superscript><emphasis><anchor id="ch0083s0004a0014"/><link linkend="ch0083s0004a0013">a</link></emphasis></superscript>Species with an established or likely human pathogenic role are highlighted in bold. Asterisks indicate <emphasis>Candidatus</emphasis> taxa or taxa not yet validly published. Note the huge diversity within this order and a need to better define a pathogenic role in humans for most species listed.</para>
    </sect1>
    <sect1 id="ch0083s0005">
      <title>Family Parachlamydiaceae</title>
      <anchor id="ch0083s0005a0001"/>
      <anchor id="ch0083s0005a0002"/>
      <para id="ch0083s0005p0001">The family<emphasis>Parachlamydiaceae</emphasis> mainly includes species isolated from human-made water systems (including water treatment plants) and/or free-living amoebae, which can present biofilms on water-air and water-soil interfaces. It includes five genus-level lineages: <emphasis>Parachlamydia</emphasis>, “<emphasis>Candidatus</emphasis> Protochlamydia,” <emphasis>Neochlamydia, Metachlamydia</emphasis>, and “<emphasis>Candidatus</emphasis> Mesochlamydia” (<link linkend="ch0083s0004a0012">Table 2</link>). The diversity within the family <emphasis>Parachlamydiaceae</emphasis> is likely broader, since research on this clade has been active for only 2 decades.</para>
      <anchor id="ch0083s0005a0003"/>
      <beginpage pagenum="1262"/>
      <anchor id="ch0083s0005a0004"/>
      <beginpage pagenum="1263"/>
      <para id="ch0083s0005p0002">Most evidence for the pathogenic role of<emphasis>Parachlamydiaceae</emphasis> in humans has been accumulated for <emphasis>P. acanthamoebae</emphasis>, a bacterium initially isolated from the water of a humidifier during an investigation of a fever outbreak (<link linkend="ch0083s0028s0003li0015">15</link>), but it is possible that other members of this family are pathogenic in humans, as suggested in a preliminary report on “<emphasis>Candidatus</emphasis> Protochlamydia naegleriophila” pneumonia (<link linkend="ch0083s0028s0003li0016">16</link>). Serologic data suggesting a role for <emphasis>Parachlamydiaceae</emphasis> family taxa in lower respiratory tract infections have progressively accumulated during the last 2 decades (<link linkend="ch0083s0028s0003li0013">13</link>), but defining the underlying species triggering such a strong association with pneumonia and bronchiolitis is difficult, since serology is not specific at the species or genus level but rather provides robust results only at the family level (<link linkend="ch0083s0028s0003li0026">26</link>, <link linkend="ch0083s0028s0003li0027">27</link>). Hence, serology is of little value to complement genetic and phylogenetic analyses. Matrix-assisted laser desorption ionization–time-of-flight (MALDI-TOF) mass spectrometry appears to provide a reliable basis to describe new species-level lineages and was used to characterize “<emphasis>Estrella lausannensis</emphasis>” (<link linkend="ch0083s0028s0003li0028">28</link>).</para>
    </sect1>
    <sect1 id="ch0083s0006">
      <title>Family Waddliaceae</title>
      <anchor id="ch0083s0006a0001"/>
      <anchor id="ch0083s0006a0002"/>
      <para id="ch0083s0006p0001">The family<emphasis>Waddliaceae</emphasis> contains two species lineages, <emphasis>W. chondrophila</emphasis> and <emphasis>Waddlia malaysiensis</emphasis> (<link linkend="ch0083s0004a0012">Table 2</link>). The latter, documented in bats, has not been shown to have a pathogenic role in humans or other animals. Conversely, <emphasis>W. chondrophila</emphasis> has been shown to recruit mitochondria via microtubules and actin microfilaments in order to use lipids and ATP produced by this organelle (<link linkend="ch0083s0028s0003li0029">29</link>). This characteristic explains its species name, “chondrophila” (mitochondrion lover) (<link linkend="ch0083s0028s0003li0030">30</link>), and its rapid growth in many different cell lines, with a doubling time of less than 2 h in Vero cells, Hep2 cells, A549 pneumocytes, and amoebae (<link linkend="ch0083s0028s0003li0031">31</link>). This also includes a broader cell permissivity to human macrophages, endometrial cells, human pneumocytes, fish and insect cell lines, and amoeba coculture (<link linkend="ch0083s0028s0003li0032">32</link>–<link linkend="ch0083s0028s0003li0034">34</link>).</para>
    </sect1>
    <sect1 id="ch0083s0007">
      <title>Family Simkaniaceae</title>
      <anchor id="ch0083s0007a0001"/>
      <anchor id="ch0083s0007a0002"/>
      <para id="ch0083s0007p0001">The family<emphasis>Simkaniaceae</emphasis> contains four species (<link linkend="ch0083s0004a0012">Table 2</link>), of which only <emphasis>S. negevensis</emphasis> appears to be of possible medical importance (<link linkend="ch0083s0028s0003li0014">14</link>, <link linkend="ch0083s0028s0003li0035">35</link>, <link linkend="ch0083s0028s0003li0036">36</link>). Its genus name is derived from the name of the virologist who isolated this bacterium as a contaminant of cell culture, while its species name refers to the Negev desert, where the discovery was made (<link linkend="ch0083s0028s0003li0037">37</link>). In contrast to <emphasis>Waddlia</emphasis> spp. and <emphasis>C. trachomatis</emphasis> LGV strains, which are easily recovered in culture, <emphasis>S. negevensis</emphasis> has a long doubling time (<link linkend="ch0083s0028s0003li0038">38</link>).</para>
      <sect2 id="ch0083s0007s0001">
        <title>DESCRIPTION OF GENERA OF MEDICAL IMPORTANCE</title>
        <anchor id="ch0083s0007s0001a0001"/>
        <anchor id="ch0083s0007s0001a0002"/>
        <para id="ch0083s0007s0001p0001"><emphasis>Chlamydia, Parachlamydia, Waddlia</emphasis>, and <emphasis>Simkania</emphasis> (like other genera within the order <emphasis>Chlamydiales</emphasis>) all present biphasic developmental stages with elementary body (EB) and reticulate body (RB) formation. The infectious EB is an electron-dense, tightly packaged particle containing RNA and DNA and is metabolically inert (<anchor id="ch0083s0007s0001a0003"/><link linkend="ch0083s0007s0001a0004">Fig. 1</link>, bottom). The EB attaches to susceptible host cells via chlamydial adhesins, induces host cell phagocytosis, and persists within an early endosomal vesicle (<link linkend="ch0083s0028s0003li0039">39</link>). The organism then inhibits phagolysosome fusion using various strategies to avoid the acidic pH and hydrolases of lysosomes.</para>
        <figure id="ch0083s0007s0001f0001"><title><phrase role="figureLabel"><anchor id="ch0083s0007s0001a0004"/><link linkend="ch0083s0007s0001a0003">FIGURE 1</link></phrase> (Top) <emphasis>Waddlia chondrophila</emphasis> in McCoy cells, 16 h postinfection, as seen by immunofluorescence. Bacteria are stained in green, whereas the host cell and its nucleus are in red and blue (DAPI), respectively. Note the very large inclusions with <emphasis>Waddlia</emphasis> reticulate bodies. In some inclusions, the bacteria are located only at the periphery of the vacuole, since the bacteria must interact with the inclusion membranes to secrete effector proteins and obtain nutrients. Epifluorescence microscopy; magnification, ×100. (Bottom) <emphasis>Chlamydia pneumoniae</emphasis> in human embryonic lung fibroblasts (HEL cells). Electron microscopy; magnification, ×23,000. Note the presence of a vast majority of reticulate bodies, including one dividing, as well as 5 electron-dense and much smaller elementary bodies. Pictures courtesy of Carole Kebbi and Gilbert Greub, Lausanne, Switzerland.</title>
          
          <mediaobject>
            <imageobject>
              <imagedata fileref="Ch0083f01.jpg" width="100%" scalefit="1"/>
            </imageobject>
          </mediaobject>
        </figure>
        <para id="ch0083s0007s0001p0002"><emphasis>Chlamydia</emphasis>-containing vacuoles express Golgi markers at their surfaces (<link linkend="ch0083s0028s0003li0040">40</link>), whereas <emphasis>Waddlia</emphasis>- and <emphasis>Simkania-</emphasis>containing vacuoles express endoplasmic reticulum markers, such as calnexin (<link linkend="ch0083s0028s0003li0029">29</link>, <link linkend="ch0083s0028s0003li0036">36</link>). Interestingly, <emphasis>Parachlamydia</emphasis> spp. prevent acidification and cathepsin production by preventing late-endosome maturation into a lysosome (<link linkend="ch0083s0028s0003li0041">41</link>). These different strategies to survive within an intracellular environment likely occur as a result of the diversity of effector proteins, all secreted by the type III secretion system conserved in all <emphasis>Chlamydiale</emphasis><emphasis>s</emphasis> (<link linkend="ch0083s0028s0003li0042">42</link>–<link linkend="ch0083s0028s0003li0044">44</link>).</para>
        <para id="ch0083s0007s0001p0003">Once it is present in its respective replicative vacuole, within ~8 h the EB converts into an RB, which is metabolically active and divides by binary fission in another 24 to 48 h (<link linkend="ch0083s0028s0003li0004">4</link>, <link linkend="ch0083s0028s0003li0045">45</link>, <link linkend="ch0083s0028s0003li0046">46</link>). RBs then reorganize into EBs, which are released from the host cell either as free bacteria or within expelled vesicles (<link linkend="ch0083s0028s0003li0004">4</link>, <link linkend="ch0083s0028s0003li0047">47</link>). This interval is variable even between serovars of <emphasis>C. trachomatis</emphasis> and varies between different family-level lineages, with <emphasis>Simkaniaceae</emphasis> and “<emphasis>Candidatus</emphasis> Rhabdochlamydiaceae” exhibiting cycles of 7 to 14 days (<link linkend="ch0083s0028s0003li0036">36</link>, <link linkend="ch0083s0028s0003li0046">46</link>) and <emphasis>Parachlamydiaceae</emphasis> and <emphasis>Waddliaceae</emphasis> having short developmental cycles, typically 24 h or less (<link linkend="ch0083s0028s0003li0004">4</link>, <link linkend="ch0083s0028s0003li0042">42</link>).</para>
        <anchor id="ch0083s0007s0001a0005"/>
        <beginpage pagenum="1264"/>
        <para id="ch0083s0007s0001p0004">The EB is about 300 to 400 nm in diameter and can be seen by light microscopy. The RB is about twice as large (<link linkend="ch0083s0028s0003li0004">4</link>, <link linkend="ch0083s0028s0003li0048">48</link>). The combination of RBs and/or EBs within the vacuole is called an inclusion. Inclusions can be stained with Giemsa or Gimenez stains and observed by light microscopy. However, inclusions are much better visualized by immunostaining organisms with polyclonal antibodies raised against immunogenic proteins (<link linkend="ch0083s0007s0001a0004">Fig. 1</link>, top).</para>
        <para id="ch0083s0007s0001p0005">Chlamydiae have a specific lipopolysaccharide (LPS) and express peptidoglycan. However, the LPS and the peptidoglycan are not responsible for structural rigidity. Indeed, peptidoglycan is present only in small amounts and is implicated mainly in the division process (<link linkend="ch0083s0028s0003li0049">49</link>–<link linkend="ch0083s0028s0003li0051">51</link>). Disulfide bonds between the major outer membrane protein and minor proteins are responsible for structural rigidity; the changes from EB to RB and vice versa depend on oxidation-reduction of the disulfide bonds (<link linkend="ch0083s0028s0003li0052">52</link>, <link linkend="ch0083s0028s0003li0053">53</link>). The major outer membrane protein of chlamydiae (encoded by <emphasis>ompA</emphasis>) accounts for &gt;40% of the weight of the EB outer membrane (<link linkend="ch0083s0028s0003li0054">54</link>). It has a molecular mass of ~43 kDa and contains variable sites responsible for antigenic specificity (<link linkend="ch0083s0028s0003li0055">55</link>). Interestingly, members of the genus <emphasis>Chlamydia</emphasis> exhibit a single <emphasis>ompA</emphasis> gene and several polymorphic membrane proteins (Pmps) (<link linkend="ch0083s0028s0003li0056">56</link>, <link linkend="ch0083s0028s0003li0057">57</link>). The latter ensures stable host cell adhesion by forming homo- and heteromeric oligomers, and its diversity likely facilitates immune evasion (<link linkend="ch0083s0028s0003li0057">57</link>). Conversely, <emphasis>W. chondrophila</emphasis>, which is the best-studied <emphasis>Chlamydia</emphasis>-related bacterium, exhibits a single Pmp (which also exhibits adhesion properties) and a family of <emphasis>ompA</emphasis> genes, likely implicated in immune evasion (<link linkend="ch0083s0028s0003li0058">58</link>).</para>
        <para id="ch0083s0007s0001p0006">Genomes of the major serovars of<emphasis>C. trachomatis</emphasis> have been sequenced and cover approximately 1 to 1.2 Mbp (ca. 900 to 1,050 genes). High homology between the different serovars exists despite significant phenotypic differences. Although the DNA sequences are almost identical for the trachoma and LGV biovars, they are easily differentiated biologically. Other <emphasis>Chlamydia</emphasis> spp. also exhibit genomes of about 1 to 1.2 Mbp and share strong synteny (conserved order of genes in the different genomes) with <emphasis>C. trachomatis.</emphasis> Conversely, different <emphasis>Chlamydia</emphasis>-related bacteria exhibit much larger genomes (approximately 3 Mbp for <emphasis>Parachlamydiaceae</emphasis> [59] and 2.1 Mbp for <emphasis>Waddliaceae</emphasis> [44]). The large genome size of <emphasis>Parachlamydiaceae</emphasis> is considered to reflect the intra-amoebic tropism, where organisms are exposed to a number of other bacterial species and where genetic exchange can occur (<link linkend="ch0083s0028s0003li0060">60</link>), facilitated by the presence of a conjugative DNA transfer system (<link linkend="ch0083s0028s0003li0061">61</link>).</para>
      </sect2>
      <sect2 id="ch0083s0007s0002">
        <title>CLINICAL SIGNIFICANCE AND EPIDEMIOLOGY</title>
        <anchor id="ch0083s0007s0002a0001"/>
        <anchor id="ch0083s0007s0002a0002"/>
      </sect2>
    </sect1>
    <sect1 id="ch0083s0008">
      <title>C. trachomatis</title>
      <anchor id="ch0083s0008a0001"/>
      <anchor id="ch0083s0008a0002"/>
      <para id="ch0083s0008p0001"><emphasis>C. trachomatis</emphasis> causes trachoma, the leading infectious cause of preventable blindness in the world. The World Health Organization (WHO) estimates that nearly two million individuals are irreversibly blinded by trachoma and that 137 million individuals live in areas where trachoma is endemic and are at risk of blindness (<link linkend="ch0083s0028s0003li0062">62</link>). In communities where disease is hyperendemic, children are infected within the first year of life. Repeated bouts of infection and high infectious loads can result in scarred conjunctivae. Over time, the conjunctival scars contract, causing trichiasis (introversion of the eyelash) and entropion (eyelid distortion) later in life. These conditions result in corneal abrasion and ultimately blindness. In the past, in many communities in areas of endemicity, 20 to 30% of individuals who reached the age of 60 were blinded by trachoma (<link linkend="ch0083s0028s0003li0063">63</link>).</para>
      <para id="ch0083s0008p0002">Trachoma is a disease of poverty and substandard environmental conditions. It has disappeared spontaneously from many countries under the pressure of improved economic conditions and improved sanitation (which often targets fly populations that serve as a vector for transmission). A World Health Assembly initiative adopted in 1998 targeted the year 2020 for global elimination of trachoma. In 2020, this target date was revised to the year 2030. A strategy for elimination is based on the SAFE acronym: S, surgery to treat advanced ocular disease; A, antimicrobial therapy (i.e., mass administration of azithromycin to reduce chlamydial infection); F, facial cleanliness; E, environmental improvement (e.g., improving access to water and sanitation) (<link linkend="ch0083s0028s0003li0062">62</link>). The WHO reports that nearly 100,000 individuals received surgical intervention in 2019, with nearly 100 million receiving azithromycin in communities where trachoma is endemic (<link linkend="ch0083s0028s0003li0062">62</link>).</para>
      <para id="ch0083s0008p0003"><emphasis>C. trachomatis</emphasis> is also the most common bacterial agent of sexually transmitted infection in the world. The WHO estimated the number of new <emphasis>C. trachomatis</emphasis> infections in 2016 to be 127 million (<link linkend="ch0083s0028s0003li0064">64</link>). In 2019, more than 1.8 million cases were reported to the Centers for Disease Control and Prevention (CDC), a 15% increase from 2015 (<link linkend="ch0083s0028s0003li0065">65</link>). Individuals under the age of 25 are more likely to experience <emphasis>C. trachomatis</emphasis> infection than primary/secondary syphilis (<link linkend="ch0083s0028s0003li0065">65</link>), <emphasis>Trichomonas vaginalis</emphasis> infection (<link linkend="ch0083s0028s0003li0066">66</link>), or newly diagnosed human immunodeficiency virus infection (<link linkend="ch0083s0028s0003li0067">67</link>). <emphasis>C. trachomatis</emphasis> is a leading cause of urethritis in males and can cause serious complications, such as epididymitis. However, disease in women causes the greatest concern. Pelvic inflammatory disease (PID) and its sequelae significantly impact women’s health (<link linkend="ch0083s0028s0003li0068">68</link>, <link linkend="ch0083s0028s0003li0069">69</link>). In most women, <emphasis>C. trachomatis</emphasis> infection is asymptomatic, but it is a common cause of mucopurulent endocervicitis. Ascending infection from the cervix to the endometrium and later the fallopian tubes occurs frequently. Some women develop PID, which is usually the clinical expression of severe acute salpingitis, but many upper genital tract infections are asymptomatic. In either case, the late consequences of tubal factor infertility and ectopic pregnancy can result from tubal damage following clinically inapparent infection (<link linkend="ch0083s0028s0003li0070">70</link>). A potential association between <emphasis>C. trachomatis</emphasis> infection and miscarriage has been a source of contention in the literature (<link linkend="ch0083s0028s0003li0071">71</link>, <link linkend="ch0083s0028s0003li0072">72</link>). Pregnant women can transmit the organism to their newborns during passage through an infected birth canal, and the infected infants may develop conjunctivitis and/or pneumonia (<link linkend="ch0083s0028s0003li0073">73</link>). The major risk factor for <emphasis>C. trachomatis</emphasis> infection in virtually all populations studied is youth, as prevalence decreases with increasing age.</para>
      <para id="ch0083s0008p0004">In many countries, control programs aimed at reducing chlamydial infection and preventing late upper tract consequences have been introduced. Such programs, including guidelines from the CDC, typically recommend annual screening of sexually active women between the ages of 16 and 25. In many settings where control programs have been introduced, the prevalence of chlamydial infection has remained stable or has even increased, but typically, sequelae have been reduced (<link linkend="ch0083s0028s0003li0074">74</link>, <link linkend="ch0083s0028s0003li0075">75</link>).</para>
      <anchor id="ch0083s0008a0003"/>
      <beginpage pagenum="1265"/>
      <para id="ch0083s0008p0005">The typical clinical course of LGV is described in stages. The primary lesion is an evanescent small shallow ulcer on the skin or genitalia that may be difficult to observe. The secondary stage follows within a few weeks with the development of regional lymphadenopathy. This bubo formation may be followed by destructive late consequences, such as draining fistulae. Because lymph nodes draining the vagina are retroperitoneal, the inguinal form of the disease is seldom seen in women and more commonly observed in men. Women may still develop serious late consequences, such as anorectal fistulae. LGV has been referred to as “tropical bubo” because it is common in Africa, Southeast Asia, South America, and the Caribbean. However, today LGV is most often seen as a rectal infection in men who participate in receptive anal intercourse (<link linkend="ch0083s0028s0003li0076">76</link>). In the past 2 decades, LGV has gained prevalence in Western and industrialized nations, particularly among HIV-positive individuals (<link linkend="ch0083s0028s0003li0077">77</link>–<link linkend="ch0083s0028s0003li0080">80</link>). One LGV serovar, L2b, was first seen in men who have sex with men (MSM) in the Netherlands in the early 2000s (<link linkend="ch0083s0028s0003li0081">81</link>). However, retrospective examination of archival isolates showed that the L2b serovar was a common cause of proctitis in MSM in San Francisco in the 1980s, 20 years before it was identified in the Netherlands (<link linkend="ch0083s0028s0003li0082">82</link>).</para>
    </sect1>
    <sect1 id="ch0083s0009">
      <title>C. pneumoniae</title>
      <anchor id="ch0083s0009a0001"/>
      <anchor id="ch0083s0009a0002"/>
      <para id="ch0083s0009p0001"><emphasis>C. pneumoniae</emphasis> is a common respiratory pathogen (<link linkend="ch0083s0028s0003li0083">83</link>). It causes upper and lower respiratory tract disease and is one of the agents contributing to community-acquired pneumonia. Infection starts in childhood and reaches high (50 to 70%) seroprevalence rates in adult populations (<link linkend="ch0083s0028s0003li0084">84</link>). There are no clinical findings that differentiate disease caused by <emphasis>C. pneumoniae</emphasis> from disease caused by other respiratory tract pathogens. This organism has caused epidemics in prisons, schools, and the military (<link linkend="ch0083s0028s0003li0085">85</link>). However, in recent years, <emphasis>C. pneumoniae</emphasis> has been less commonly observed in Europe and in the United States. This likely reflects the rare utilization of PCR in bronchitis and in mild cases of community-acquired pneumonia that do not require hospitalization. In Lausanne (Switzerland), it was observed only twice over 10 years (<link linkend="ch0083s0028s0003li0086">86</link>). Interestingly, one of the two cases was documented in a subject with inaugural asthma. PCR analysis was performed in error as a duplex <emphasis>Mycoplasma pneumoniae</emphasis>/<emphasis>C. pneumoniae</emphasis> assay (instead of the requisitioned <emphasis>Mycobacterium tuberculosis</emphasis> PCR) before initiation of a steroid regimen (<link linkend="ch0083s0028s0003li0086">86</link>). Since this case, <emphasis>C. pneumoniae</emphasis> infections in subjects with asthmatic bronchitis have been documented (<link linkend="ch0083s0028s0003li0087">87</link>, <link linkend="ch0083s0028s0003li0088">88</link>). Thus, it is recommended to systematically rule out <emphasis>C. pneumoniae</emphasis> infection in inaugural asthma (<link linkend="ch0083s0028s0003li0087">87</link>, <link linkend="ch0083s0028s0003li0088">88</link>). <emphasis>C. pneumoniae</emphasis> may also be a relevant pathogen in subjects with cystic fibrosis (<link linkend="ch0083s0028s0003li0089">89</link>).</para>
      <para id="ch0083s0009p0002"><emphasis>C. pneumoniae</emphasis> was postulated to cause coronary artery disease (<link linkend="ch0083s0028s0003li0090">90</link>). However, therapeutic trials aimed at preventing secondary coronary artery events using antibiotics active against <emphasis>C. pneumoniae</emphasis> have failed to demonstrate any beneficial effect (<link linkend="ch0083s0028s0003li0091">91</link>), possibly due to the fact that once inflammation has started, antibiotics may not have any significant effect on the underlying immunopathogenetic mechanism at play. <emphasis>C. pneumoniae</emphasis> occurs naturally in some animals (horses, koalas, and snakes), and zoonotic transmission can also occur.</para>
    </sect1>
    <sect1 id="ch0083s0010">
      <title>C. psittaci</title>
      <anchor id="ch0083s0010a0001"/>
      <anchor id="ch0083s0010a0002"/>
      <para id="ch0083s0010p0001"><emphasis>C. psittaci</emphasis> was first recognized as a cause of a pandemic of human psittacosis from 1929 to 1930, spreading worldwide when infected parrots and other psittacine species were exported from South America as pet birds (<link linkend="ch0083s0028s0003li0063">63</link>). Aerosols generated from fecal shedding by psittacine species are typically implicated in disease transmission, although person-to-person transmission is reported (<link linkend="ch0083s0028s0003li0092">92</link>, <link linkend="ch0083s0028s0003li0093">93</link>). <emphasis>C. psittaci</emphasis> causes a wide variety of clinical conditions in humans, ranging from asymptomatic infection to severe, even fatal pneumonia and systemic infections. In the preantibiotic era, human psittacosis had a case fatality rate in excess of 20%, with rates of 50% in patients &gt;60 years of age (<link linkend="ch0083s0028s0003li0063">63</link>).</para>
      <para id="ch0083s0010p0002"><emphasis>C. psittaci</emphasis> remains a pathogen of importance in selected circumstances, particularly associated with avian breeding and food processing. Outbreaks of psittacosis in turkey and duck processing plant employees have been chronicled for decades (<link linkend="ch0083s0028s0003li0094">94</link>–<link linkend="ch0083s0028s0003li0096">96</link>); lower respiratory tract disease appears to be more prevalent in Europe (<link linkend="ch0083s0028s0003li0024">24</link>). Through selective breeding and widespread use of tetracycline-impregnated seed, <emphasis>C. psittaci</emphasis> infection in parakeets and other pet birds has been reduced. While the organism is widely found among wild birds, it is the stress of shipping captured birds in crowded conditions that leads to widespread infections. There are many instances of common-source outbreaks of disease (<link linkend="ch0083s0028s0003li0097">97</link>).</para>
      <para id="ch0083s0010p0003">Chlamydiae from turkeys, from parrots and parakeets, and from other psittacine species all seem capable of causing severe human disease. However, serosurveys of those with occupational exposure to birds (i.e., in turkey plants) often provide evidence of asymptomatic infection, showing that<emphasis>C. psittaci</emphasis> does not always cause a severe disease and that what is observed may be the tip of the iceberg. More bird-associated species were recently identified (e.g., <emphasis>C. ibidis</emphasis> and <emphasis>C. buteonis</emphasis>), but their pathogenic role in human health remains to be determined.</para>
      <para id="ch0083s0010p0004">Noteworthily,<emphasis>C. psittaci</emphasis> was also documented recently in horses in Australia (<link linkend="ch0083s0028s0003li0098">98</link>), and horses should now also be considered as an additional zoonotic source of <emphasis>C. psittaci</emphasis> infection.</para>
    </sect1>
    <sect1 id="ch0083s0011">
      <title>Zoonotic Chlamydiae</title>
      <anchor id="ch0083s0011a0001"/>
      <anchor id="ch0083s0011a0002"/>
      <para id="ch0083s0011p0001">Zoonotic chlamydiae occur naturally in avian and mammalian species. The majority cause enteric infection in their natural hosts. Fecal shedding results in environmental contamination and aerosols that are potential sources of exposure for other animals and occasionally humans.<emphasis>C. abortus</emphasis> is singled out for discussion because of the severity of associated human infection. <emphasis>C. abortus</emphasis>, which is an important cause of abortion in goats and sheep, can cause abortions in humans and is an occupational hazard in the farming community (<link linkend="ch0083s0028s0003li0099">99</link>). In contrast, reported human infections with other mammalian chlamydiae are usually relatively mild (e.g., conjunctivitis caused by <emphasis>C. fel</emphasis><emphasis>is</emphasis>) (<link linkend="ch0083s0028s0003li0100">100</link>).</para>
    </sect1>
    <sect1 id="ch0083s0012">
      <title>Parachlamydia acanthamoebae</title>
      <anchor id="ch0083s0012a0001"/>
      <anchor id="ch0083s0012a0002"/>
      <para id="ch0083s0012p0001"><emphasis>P. acanthamoebae</emphasis> was first recovered during an outbreak of fever in a print shop, suggesting its pathogenic potential. Thereafter, a number of studies supported a role for <emphasis>P. acanthamoebae</emphasis> as an agent of lower respiratory tract infection, in immunosuppressed individuals (organ transplant patients, HIV-infected subjects with low CD4<superscript>+</superscript> T-lymphocyte counts), and immunocompetent persons (reviewed in references <link linkend="ch0083s0028s0003li0012">12</link> and <link linkend="ch0083s0028s0003li0013">13</link>). Seroconversions were also documented in subjects with aspiration pneumonia (<link linkend="ch0083s0028s0003li0101">101</link>) and community-acquired pneumonia (<link linkend="ch0083s0028s0003li0102">102</link>). Molecular evidence of infection based on specific PCR detected <emphasis>P. acanthamoebae</emphasis> in community-acquired pneumonia (<link linkend="ch0083s0028s0003li0013">13</link>) and suggested a role in bronchitis (<link linkend="ch0083s0028s0003li0103">103</link>) and in bronchiolitis in children (<link linkend="ch0083s0028s0003li0104">104</link>). Recent data reveal that as many as 4% of all pneumonias are associated with detection of <emphasis>P. acanthamoebae</emphasis> (N. Casson et al., unpublished data). <emphasis>P. acanthamoebae</emphasis> is also associated with abortion in bovines (<link linkend="ch0083s0028s0003li0105">105</link>, <link linkend="ch0083s0028s0003li0106">106</link>) and conjunctivitis in cats (<link linkend="ch0083s0028s0003li0107">107</link>) and thus might represent a significant zoonotic threat to both farm and companion animals.</para>
      <anchor id="ch0083s0012a0003"/>
      <beginpage pagenum="1266"/>
    </sect1>
    <sect1 id="ch0083s0013">
      <title>Waddlia chondrophila</title>
      <anchor id="ch0083s0013a0001"/>
      <anchor id="ch0083s0013a0002"/>
      <para id="ch0083s0013p0001">Two large studies report a strong association between positive<emphasis>W. chondrophila</emphasis> serology and miscarriage (<link linkend="ch0083s0028s0003li0108">108</link>, <link linkend="ch0083s0028s0003li0109">109</link>). Moreover, the bacterium has been detected in placental lesions by PCR and immunohistochemistry, with some of these subjects also exhibiting a positive serologic response (<link linkend="ch0083s0028s0003li0110">110</link>). <emphasis>W. chondrophila</emphasis> has also been associated with recurrent miscarriage (<link linkend="ch0083s0028s0003li0109">109</link>). Thus, diagnostic workup for this bacterium could be considered in cases of miscarriage of unknown etiology. The bacterium has been shown to cause experimental pneumonia in mice (<link linkend="ch0083s0028s0003li0110">110</link>).</para>
    </sect1>
    <sect1 id="ch0083s0014">
      <title>Simkania negevensis</title>
      <anchor id="ch0083s0014a0001"/>
      <anchor id="ch0083s0014a0002"/>
      <para id="ch0083s0014p0001">Although this<emphasis>Chlamydia</emphasis>-related bacterium was proposed to represent an emerging agent of lower respiratory tract infection (<link linkend="ch0083s0028s0003li0014">14</link>), a number of studies question its pathogenic role in humans (<link linkend="ch0083s0028s0003li0009">9</link>, <link linkend="ch0083s0028s0003li0111">111</link>, <link linkend="ch0083s0028s0003li0112">112</link>).</para>
      <sect2 id="ch0083s0014s0001">
        <title>COLLECTION, TRANSPORT, AND STORAGE OF SPECIMENS</title>
        <anchor id="ch0083s0014s0001a0001"/>
        <anchor id="ch0083s0014s0001a0002"/>
      </sect2>
    </sect1>
    <sect1 id="ch0083s0015">
      <title>General Comments</title>
      <anchor id="ch0083s0015a0001"/>
      <anchor id="ch0083s0015a0002"/>
      <para id="ch0083s0015p0001">When commercially available, the instructions given in the package inserts of<emphasis>Chlamydia</emphasis> sp. diagnostic kits should always be followed. Most manufacturers also supply complete collection kits containing swabs and transport medium. In general, the collected specimens may be sent to the laboratories at ambient temperatures and do not require refrigerated shipping, unless cell culture is foreseen. Indeed, nucleic acids do not require a cold chain to be maintained, and these tests have now completely replaced culture-based approaches, facilitating the transport and handling of samples. Nucleic acid amplification tests (NAATs) also replaced antigen tests given the very low sensitivity of antigen-based tests and the fact that 10 to 15% of the patients have a very low bacterial load (&lt;100 organisms/ml).</para>
    </sect1>
    <sect1 id="ch0083s0016">
      <title>C. trachomatis</title>
      <anchor id="ch0083s0016a0001"/>
      <anchor id="ch0083s0016a0002"/>
      <para id="ch0083s0016p0001">For<emphasis>C. trachomatis</emphasis> infection, the anatomic site and the test performed dictate the type of sample to be collected. When NAATs are being used for routine diagnosis of lower genital tract infection, first-void urine (FVU) samples from men and vaginal swabs from women are considered the specimens of choice (<link linkend="ch0083s0028s0003li0113">113</link>). The rationale for using FVU, rather than midstream urine, is to obtain the human cells that detach following chlamydial infection, since <emphasis>Chlamydia</emphasis> is a strictly intracellular bacterium. Both specimen types are easier to collect than urethral swabs from men or endocervical swabs from women (for which a pelvic examination is needed). One questionnaire-based study showed that women prefer to collect their own vaginal swab specimens (<link linkend="ch0083s0028s0003li0114">114</link>). For NAATs, self-collected vaginal swab specimens and male FVU samples yield sensitivity comparable to that of a traditional reference specimen (<link linkend="ch0083s0028s0003li0113">113</link>, <link linkend="ch0083s0028s0003li0115">115</link>). Urinary meatal swabs are accurate, acceptable (<link linkend="ch0083s0028s0003li0116">116</link>), and especially recommended in presence of urethral discharge.</para>
      <para id="ch0083s0016p0002">In theory, NAATs can also be used with cervical specimens collected into liquid cytology medium for screening of human papillomavirus (HPV)-related lesions (<link linkend="ch0083s0028s0003li0117">117</link>). While some overlap may exist, the population that is screened for cervical atypia is usually older than the population screened for sexually transmitted infections (STIs). Nevertheless, with progressive transition to NAATs for primary or augmented HPV screening (instead of cytology), combined screening of <emphasis>C. trachomatis</emphasis> and HPV is increasingly appealing.</para>
      <para id="ch0083s0016p0003">If isolation of<emphasis>C. trachomatis</emphasis> is being performed, the goal is to collect infected cells, so urethral swabs from men and endocervical swabs from women would then be the specimens of choice. That principle holds true for cytology, when considered.</para>
      <para id="ch0083s0016p0004">If conjunctival infection is being evaluated, swabs from trachoma patients or infants and adults with inclusion conjunctivitis are used for laboratory-developed NAATs or culture; direct scrapings or corneal biopsy samples are preferable for cytologic evaluation. If oropharyngeal infections are being evaluated, swabs should be collected from the posterior oropharynx, and if anorectal infection is being investigated, swabs are inserted 2.0 to 2.5 cm into the anus and rotated several times (<link linkend="ch0083s0028s0003li0080">80</link>).</para>
    </sect1>
    <sect1 id="ch0083s0017">
      <title>C. pneumoniae</title>
      <anchor id="ch0083s0017a0001"/>
      <anchor id="ch0083s0017a0002"/>
      <para id="ch0083s0017p0001">Systematic studies to determine specimens of choice for respiratory tract infection are not available; nasopharyngeal and throat swabs, tracheal aspirates, sputum, biopsy specimens, and bronchoalveolar lavage fluid have been used. Bacterial load seems to be significantly higher in lower respiratory tract specimens, and the latter are preferred over nasopharyngeal swabs when available. Blood or cardiovascular specimen testing is not routinely used or recommended.</para>
    </sect1>
    <sect1 id="ch0083s0018">
      <title>C. psittaci</title>
      <anchor id="ch0083s0018a0001"/>
      <anchor id="ch0083s0018a0002"/>
      <para id="ch0083s0018p0001">Specimens are collected according to the affected organs. In the case of pulmonary infection, lower respiratory tract specimens may be considered for NAAT. In the case of hepatosplenic infection, specimens are collected from liver, spleen, or serofibrinous exudates coating these organs. Impression smears can be made for cytologic evaluation, with tissue suspensions processed for culture. NAAT may be performed from these specimen sources, including direct superficial swabs of these organs and/or the exudates when present. Refer to “Biosafety Considerations,” below.</para>
      <sect2 id="ch0083s0018s0001">
        <title>DIRECT EXAMINATION</title>
        <anchor id="ch0083s0018s0001a0001"/>
        <anchor id="ch0083s0018s0001a0002"/>
      </sect2>
    </sect1>
    <sect1 id="ch0083s0019">
      <title>Nucleic Acid Detection</title>
      <anchor id="ch0083s0019a0001"/>
      <anchor id="ch0083s0019a0002"/>
      <para id="ch0083s0019p0001">While nucleic acid hybridization was once popular for diagnosis of<emphasis>C. trachomatis</emphasis> infection, this modality has been replaced by the more sensitive NAAT assays. Ultimately, NAATs constitute the most sensitive diagnostic tests for <emphasis>C. trachomatis</emphasis> infection, detecting 30 to 50% more infections than earlier technologies. Furthermore, these assays offer several advantages to the provider, as well as the patient and the public health practitioner. Results are typically available within a day, compared to up to 7 days for <emphasis>C. trachomatis</emphasis> isolation in cell culture. As mentioned previously, NAAT can be facilitated by noninvasively collected specimens, such as first-void urine specimens and vaginal swabs. Newer U.S. Food and Drug Administration (FDA) indications include pharyngeal and rectal swabs (discussed below) as well as patient-collected swab specimens in hopes of making STI screening available to a wider populace (<link linkend="ch0083s0028s0003li0118">118</link>).</para>
      <anchor id="ch0083s0019a0003"/>
      <beginpage pagenum="1267"/>
      <para id="ch0083s0019p0002">Past literature has suggested superior specimen sources on the basis of<emphasis>C. trachomatis</emphasis> target load measurement (<link linkend="ch0083s0028s0003li0119">119</link>). These typically include vaginal swabs and first-void urine, which often receive FDA indications for <emphasis>C. trachomatis</emphasis> NAAT (<anchor id="ch0083s0019a0004"/><link linkend="ch0083s0019a0008">Table 3</link>). Most commercially available NAATs are duplex assays which detect both <emphasis>C. trachomatis</emphasis> and <emphasis>Neisseria gonorrhoeae</emphasis>, two common bacterial STI agents. These tests detect all known <emphasis>C. trachomatis</emphasis> serovars, but while they detect the LGV serovars, these are not differentiated from serovars A through K. Since current treatment regimens are of longer duration for the more aggressive LGV strains (<link linkend="ch0083s0028s0003li0120">120</link>), diagnostic triage for further testing should be considered for at-risk populations. Laboratory-developed NAAT capable of differentiating LGV strains exists (<link linkend="ch0083s0028s0003li0121">121</link>) but is not commonplace in the clinical microbiology laboratory, because such assays are not FDA cleared. Within the past 5 years, at least four commercial assays have received FDA clearance for detection of <emphasis>C. trachomatis</emphasis>-specific nucleic acid from pharyngeal and rectal swab specimens (<link linkend="ch0083s0019a0008">Table 3</link>). Again, analysis of extragenital specimens is important from a clinical and a public health perspective. For example, adding extragenital-source screening significantly increases the number of MSM found to be infected with <emphasis>C. trachomatis</emphasis> compared to the number with urethral infection (<link linkend="ch0083s0028s0003li0122">122</link>–<link linkend="ch0083s0028s0003li0124">124</link>).</para>
      <para id="ch0083s0019p0003">At this writing, five manufacturers actively market FDA-cleared<emphasis>C. trachomatis</emphasis> NAAT in the United States: Abbott Molecular, Inc. (Des Plaines, IL); Becton, Dickinson and Company (Sparks, MD); Cepheid (Sunnyvale, CA); Hologic, Inc. (San Diego, CA); and Roche Molecular Diagnostics (Pleasanton, CA). Among the assays selected for presentation in <link linkend="ch0083s0019a0008">Table 3</link> are those cited by accreditation agency proficiency testing literature for frequent utilization in clinical laboratories (<link linkend="ch0083s0028s0003li0125">125</link>). These tests yield sensitivity values above 90% for detection of <emphasis>C. trachomatis</emphasis> nucleic acid in urogenital specimens, with specificity values approximating 99%. Confirmatory testing is not required (<link linkend="ch0083s0028s0003li0113">113</link>, <link linkend="ch0083s0028s0003li0126">126</link>). In both historic and contemporary assessments (<link linkend="ch0083s0028s0003li0127">127</link>, <link linkend="ch0083s0028s0003li0128">128</link>), performance characteristics of commercial NAAT for extragenital specimens have been reported as being more variable than those for urogenital specimens, though it should be noted that low disease prevalence and non-FDA-indicated assays contributed to some of the data. FDA-cleared tests additionally incorporate an element of automation to facilitate throughput and turnaround time for large-volume testing. Beyond performance characteristics, workflow, or even contractual/purchasing group considerations, the laboratory director or supervisor may choose to investigate FDA specimen source indications for <emphasis>C. trachomatis</emphasis> NAAT (<link linkend="ch0083s0019a0008">Table 3</link>) and attempt to meld these with clientele-driven demand for NAAT-based detection of other STI agents, such as <emphasis>N. gonorrhoeae, Trichomonas vaginalis</emphasis> (<link linkend="ch0083s0028s0003li0129">129</link>), and/or <emphasis>Mycoplasmoides genitalium</emphasis> (<link linkend="ch0083s0028s0003li0130">130</link>).</para>
      <para id="ch0083s0019p0004">Recently, a<emphasis>C. trachomatis</emphasis> variant was discovered in Sweden with a 377-bp deletion in the cryptic plasmid (<link linkend="ch0083s0028s0003li0131">131</link>). This deleted region impacted the ability of some commercial NAATs to identify <emphasis>C. trachomatis</emphasis> infection. This essentially created a unique epidemiologic phenomenon in which up to 64% <emphasis>C. trachomatis</emphasis> prevalence was observed in sexually active individuals in some nations where all assays missed the variant. Fortunately, the <emphasis>C. trachomatis</emphasis> mutation conveyed no particular biological advantage (<link linkend="ch0083s0028s0003li0132">132</link>). Manufacturers quickly changed primer configurations to target sequences outside the deleted region. A lesson was learned, and manufacturers now tend to target two separate determinants to avoid dependence on a single target that could mutate or become deleted.</para>
      <para id="ch0083s0019p0005">The major disadvantage of currently available NAATs is that they are rather expensive. Because testing is sometimes performed in relatively low-prevalence populations, pooling strategies have been developed to reduce costs (<link linkend="ch0083s0028s0003li0133">133</link>). These are relatively successful, and in populations where prevalence is only 1 to 3%, they can reduce costs by up to 50%. However, pooling strategies are associated with increased workload and reduced traceability and should therefore be considered only when pooling has been fully automated.</para>
      <para id="ch0083s0019p0006">Evaluating diagnostic tests for chlamydial infections is challenging due to a lack of traditional gold standards for comparative purposes. This is an issue in diagnosis of<emphasis>C. trachomatis</emphasis> infection. Because the above-described NAATs received FDA clearance, one would prefer to use sensitivity and specificity values presented in package inserts or data from published papers to choose assays based on best performance characteristics. However, sensitivity and specificity values are valid only in the context of the clinical trial cited; they are not directly comparable across studies. The lack of a gold standard has led the FDA to create reference standards for test evaluation. In recent years, the FDA has used “patient infected status.” In this case, if two different assays are positive for any specimen from a patient, that patient is considered infected and all specimens coming from that patient should be considered positive for purposes of measuring performance. Unfortunately, this is not always the case. It is known that a female can have a urethral infection but not a cervical infection or vice versa (<link linkend="ch0083s0028s0003li0134">134</link>). Thus, any specimen that yields a negative result in the face of a confirmed positive specimen from another anatomic site is considered a false negative, when in fact it is actually a true negative in the instances where the patient did not have infection at that site.</para>
      <para id="ch0083s0019p0007">The aforementioned systematic bias can impact sensitivity and specificity calculations. This is important, since one may wrongly consider a test inaccurate for a given sample type while the number only reflects the low rate of bacterial shedding from a given anatomic site. An alternative approach to precisely assess relative sensitivity of assays is to repeatedly test the same urine sample with several different assays (≥5) and consider all samples that are positive by at least one assay positive gold standards. Since modern NAATs generally no longer suffer from low specificity (due to the use of specific detection probes in addition to forward and reverse primers and to the fact that qualitative real-time PCR is performed in a closed-tube system), this approach provides very good estimates of NAAT sensitivity.</para>
      <para id="ch0083s0019p0008">Commercially available FDA-cleared assays for<emphasis>C. pneumoniae</emphasis> include the BioFire respiratory panel (bioMérieux) and the Curetis Unyvero assay (Curetis). Unfortunately, neither has been adequately evaluated for the diagnosis of <emphasis>C. pneumoniae</emphasis> infection. NAATs have been developed in many research laboratories, but it is not clear which, if any, of these is optimal, since there is considerable variation in comparative testing (<link linkend="ch0083s0028s0003li0135">135</link>) and because most laboratories only rarely identify cases of <emphasis>C. pneumoniae.</emphasis> A laboratory-developed assay proved sensitive enough to identify cases in subjects with asthmatic bronchitis and cystic fibrosis (<link linkend="ch0083s0028s0003li0086">86</link>, <link linkend="ch0083s0028s0003li0087">87</link>, <link linkend="ch0083s0028s0003li0089">89</link>). Noteworthily, the near absence of cases documented in subjects with atypical pneumonia contrasted with the number of cases documented in clinical situations where the diagnosis would not have been suspected based on classical textbook descriptions, again demonstrating the difficulties of achieving proper gold standards to assess the feasibility of current NAAT assays.</para>
      <anchor id="ch0083s0019a0005"/>
      <beginpage pagenum="1268"/>
      <anchor id="ch0083s0019a0006"/>
      <beginpage pagenum="1269"/>
      <anchor id="ch0083s0019a0007"/>
      <beginpage pagenum="1270"/>
      <table id="ch0083s0019t0001"><title><emphasis role="strong"><phrase role="figureLabel"><anchor id="ch0083s0019a0008"/><link linkend="ch0083s0019a0004">TABLE 3</link></phrase></emphasis> Selected commercial FDA-cleared NAAT modalities for <emphasis>Chlamydia trachomatis</emphasis>
</title>
        
        <tgroup cols="18">
          <tbody>
            <row>
              <entry><phrase role="left">Manufacturer</phrase>
              </entry>
              <entry><phrase role="left">Assay</phrase>
              </entry>
              <entry><phrase role="left">Technology</phrase>
              </entry>
              <entry><phrase role="left">Target nucleic acid</phrase>
              </entry>
              <entry><phrase role="left">Symptomatic/asymptomatic</phrase>
              </entry>
              <entry><phrase role="left">Provider-collected vaginal swab</phrase>
              </entry>
              <entry><phrase role="left">Self-collected vaginal swab</phrase>
              </entry>
              <entry><phrase role="left">Endocervical swab</phrase>
              </entry>
              <entry><phrase role="left">Female urine</phrase>
              </entry>
              <entry><phrase role="left">Liquid-based cytology</phrase>
              </entry>
              <entry><phrase role="left">Urethral swab</phrase>
              </entry>
              <entry><phrase role="left">Male urine</phrase>
              </entry>
              <entry><phrase role="left">Pharyngeal swab</phrase>
              </entry>
              <entry><phrase role="left">Rectal swab</phrase>
              </entry>
              <entry><phrase role="left">Automated platform</phrase>
              </entry>
              <entry><phrase role="left">FDA 510(k) number</phrase>
              </entry>
              <entry><phrase role="left">Notes</phrase>
              </entry>
              <entry><phrase role="left">Representative reference(s)</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Abbott Molecular, Inc.</phrase>
              </entry>
              <entry><phrase role="left">Abbott RealTime CT/NG</phrase>
              </entry>
              <entry><phrase role="left">Qualitative real-time PCR</phrase>
              </entry>
              <entry><phrase role="left">DNA</phrase>
              </entry>
              <entry><phrase role="left">Both (endocervical and urethral swabs only from symptomatic)</phrase>
              </entry>
              <entry><phrase role="left">✓</phrase>
              </entry>
              <entry><phrase role="left">✓</phrase>
              </entry>
              <entry><phrase role="left">✓</phrase>
              </entry>
              <entry><phrase role="left">✓</phrase>
              </entry>
              <entry/>
              <entry><phrase role="left">✓</phrase>
              </entry>
              <entry><phrase role="left">✓</phrase>
              </entry>
              <entry/>
              <entry/>
              <entry><phrase role="left">Abbott <emphasis>m</emphasis>2000 system</phrase>
              </entry>
              <entry><phrase role="left">K092704</phrase>
              </entry>
              <entry><phrase role="left">Also tests for <emphasis>Neisseria gonorrhoeae</emphasis> using same specimen sources and caveats</phrase>
              </entry>
              <entry><phrase role="left"><link linkend="ch0083s0028s0003li0169">169</link>–<link linkend="ch0083s0028s0003li0173">173</link></phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Alinity mSTI assay</phrase>
              </entry>
              <entry><phrase role="left">Qualitative real-time PCR</phrase>
              </entry>
              <entry><phrase role="left">rRNA sequence</phrase>
              </entry>
              <entry><phrase role="left">Both</phrase>
              </entry>
              <entry><phrase role="left">✓</phrase>
              </entry>
              <entry><phrase role="left">✓<superscript><emphasis><anchor id="ch0083s0019a0009"/><link linkend="ch0083s0019a0010">a</link></emphasis></superscript></phrase>
              </entry>
              <entry><phrase role="left">✓</phrase>
              </entry>
              <entry/>
              <entry/>
              <entry/>
              <entry><phrase role="left">✓</phrase>
              </entry>
              <entry><phrase role="left">✓</phrase>
              </entry>
              <entry><phrase role="left">✓</phrase>
              </entry>
              <entry><phrase role="left">Alinity m System</phrase>
              </entry>
              <entry><phrase role="left">K202977</phrase>
              </entry>
              <entry><phrase role="left">Also tests for <emphasis>Neisseria gonorrhoeae, Trichomonas vaginalis</emphasis>, and <emphasis>Mycoplasmoides genitalium</emphasis>; differences in indicated specimen sources exist</phrase>
              </entry>
              <entry><phrase role="left">
                  <link linkend="ch0083s0028s0003li0171">171</link>
                </phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Becton, Dickinson and Company</phrase>
              </entry>
              <entry><phrase role="left">BD ProbeTec <emphasis>Chlamydia trachomatis</emphasis> Q<emphasis>x</emphasis> amplified-DNA assay</phrase>
              </entry>
              <entry><phrase role="left">Strand displacement amplification</phrase>
              </entry>
              <entry><phrase role="left">DNA</phrase>
              </entry>
              <entry><phrase role="left">Both</phrase>
              </entry>
              <entry/>
              <entry><phrase role="left">✓<superscript><emphasis><link linkend="ch0083s0019a0010">a</link></emphasis></superscript></phrase>
              </entry>
              <entry><phrase role="left">✓</phrase>
              </entry>
              <entry><phrase role="left">✓</phrase>
              </entry>
              <entry><phrase role="left">✓</phrase>
              </entry>
              <entry><phrase role="left">✓</phrase>
              </entry>
              <entry><phrase role="left">✓</phrase>
              </entry>
              <entry/>
              <entry/>
              <entry><phrase role="left">BD Viper system; BD Viper LT system</phrase>
              </entry>
              <entry><phrase role="left">K081824</phrase>
              </entry>
              <entry><phrase role="left">Product analog tests for <emphasis>Neisseria gonorrhoeae</emphasis> using indicated specimen sources</phrase>
              </entry>
              <entry><phrase role="left"><link linkend="ch0083s0028s0003li0170">170</link>, <link linkend="ch0083s0028s0003li0172">172</link>–<link linkend="ch0083s0028s0003li0178">178</link></phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">BD Max CT/GC/TV</phrase>
              </entry>
              <entry><phrase role="left">Qualitative real-time PCR</phrase>
              </entry>
              <entry><phrase role="left">DNA</phrase>
              </entry>
              <entry><phrase role="left">Both</phrase>
              </entry>
              <entry/>
              <entry><phrase role="left">✓<superscript><emphasis><link linkend="ch0083s0019a0010">a</link></emphasis></superscript></phrase>
              </entry>
              <entry><phrase role="left">✓</phrase>
              </entry>
              <entry><phrase role="left">✓</phrase>
              </entry>
              <entry/>
              <entry/>
              <entry><phrase role="left">✓</phrase>
              </entry>
              <entry/>
              <entry/>
              <entry><phrase role="left">BD MAX system</phrase>
              </entry>
              <entry><phrase role="left">K151589</phrase>
              </entry>
              <entry><phrase role="left">Also tests for <emphasis>Neisseria gonorrhoeae</emphasis> and <emphasis>Trichomonas vaginalis</emphasis>; differences in indicated specimen sources exist</phrase>
              </entry>
              <entry><phrase role="left">
                  <link linkend="ch0083s0028s0003li0178">178</link>
                </phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">BD CTGCTV2</phrase>
              </entry>
              <entry><phrase role="left">Qualitative real-time PCR</phrase>
              </entry>
              <entry><phrase role="left">DNA</phrase>
              </entry>
              <entry><phrase role="left">Both</phrase>
              </entry>
              <entry><phrase role="left">✓</phrase>
              </entry>
              <entry><phrase role="left">✓<superscript><emphasis><link linkend="ch0083s0019a0010">a</link></emphasis></superscript></phrase>
              </entry>
              <entry><phrase role="left">✓</phrase>
              </entry>
              <entry><phrase role="left">✓</phrase>
              </entry>
              <entry><phrase role="left">✓</phrase>
              </entry>
              <entry/>
              <entry><phrase role="left">✓</phrase>
              </entry>
              <entry/>
              <entry/>
              <entry><phrase role="left">BD MAX system</phrase>
              </entry>
              <entry><phrase role="left">K182692</phrase>
              </entry>
              <entry><phrase role="left">Also tests for <emphasis>Neisseria gonorrhoeae</emphasis> using the indicated specimen sources; different indications for <emphasis>Trichomonas vaginalis</emphasis> testing</phrase>
              </entry>
              <entry><phrase role="left">
                  <link linkend="ch0083s0028s0003li0178">178</link>
                </phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">BD COR system</phrase>
              </entry>
              <entry><phrase role="left">K210585</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Cepheid</phrase>
              </entry>
              <entry><phrase role="left">Xpert CT/NG assay</phrase>
              </entry>
              <entry><phrase role="left">Qualitative real-time PCR</phrase>
              </entry>
              <entry><phrase role="left">DNA</phrase>
              </entry>
              <entry><phrase role="left">Both</phrase>
              </entry>
              <entry/>
              <entry><phrase role="center">✓<superscript><emphasis><link linkend="ch0083s0019a0010">a</link></emphasis></superscript></phrase>
              </entry>
              <entry><phrase role="center">✓</phrase>
              </entry>
              <entry><phrase role="center">✓</phrase>
              </entry>
              <entry/>
              <entry/>
              <entry><phrase role="center">✓</phrase>
              </entry>
              <entry><phrase role="center">✓</phrase>
              </entry>
              <entry><phrase role="center">✓</phrase>
              </entry>
              <entry><phrase role="left">GeneXpert instrument systems</phrase>
              </entry>
              <entry><phrase role="left">K190441</phrase>
              </entry>
              <entry><phrase role="left">Also tests for <emphasis>Neisseria gonorrhoeae</emphasis> using same indicated specimen sources</phrase>
              </entry>
              <entry><phrase role="left"><link linkend="ch0083s0028s0003li0169">169</link>, <link linkend="ch0083s0028s0003li0177">177</link>, <link linkend="ch0083s0028s0003li0179">179</link>, <link linkend="ch0083s0028s0003li0180">180</link></phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Hologic, Inc.</phrase>
              </entry>
              <entry><phrase role="left">Aptima Combo 2 assay</phrase>
              </entry>
              <entry><phrase role="left">Transcription-mediated amplification</phrase>
              </entry>
              <entry><phrase role="left">rRNA</phrase>
              </entry>
              <entry><phrase role="left">Both (self-collected vaginal swabs only from asymptomatic)</phrase>
              </entry>
              <entry><phrase role="center">✓</phrase>
              </entry>
              <entry><phrase role="center">✓</phrase>
              </entry>
              <entry><phrase role="center">✓</phrase>
              </entry>
              <entry><phrase role="center">✓</phrase>
              </entry>
              <entry><phrase role="center">✓</phrase>
              </entry>
              <entry><phrase role="center">✓</phrase>
              </entry>
              <entry><phrase role="center">✓</phrase>
              </entry>
              <entry/>
              <entry/>
              <entry><phrase role="left">Tigris DTS automated analyzer</phrase>
              </entry>
              <entry><phrase role="left">K060652</phrase>
              </entry>
              <entry><phrase role="left">Also tests for <emphasis>Neisseria gonorrhoeae</emphasis> using same indicated specimen sources</phrase>
              </entry>
              <entry><phrase role="left"><link linkend="ch0083s0028s0003li0170">170</link>, <link linkend="ch0083s0028s0003li0172">172</link>, <link linkend="ch0083s0028s0003li0173">173</link>, <link linkend="ch0083s0028s0003li0175">175</link>–<link linkend="ch0083s0028s0003li0178">178</link>, <link linkend="ch0083s0028s0003li0181">181</link></phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Aptima Combo 2 assay</phrase>
              </entry>
              <entry><phrase role="left">Transcription-mediated amplification</phrase>
              </entry>
              <entry><phrase role="left">rRNA</phrase>
              </entry>
              <entry><phrase role="left">Both</phrase>
              </entry>
              <entry><phrase role="center">✓</phrase>
              </entry>
              <entry><phrase role="center">✓</phrase>
              </entry>
              <entry><phrase role="center">✓</phrase>
              </entry>
              <entry><phrase role="center">✓</phrase>
              </entry>
              <entry><phrase role="center">✓</phrase>
              </entry>
              <entry><phrase role="center">✓</phrase>
              </entry>
              <entry><phrase role="center">✓</phrase>
              </entry>
              <entry><phrase role="center">✓</phrase>
              </entry>
              <entry><phrase role="center">✓</phrase>
              </entry>
              <entry><phrase role="left">Panther system</phrase>
              </entry>
              <entry><phrase role="left">K190515</phrase>
              </entry>
              <entry><phrase role="left">Also tests for <emphasis>Neisseria gonorrhoeae</emphasis> using same indicated specimen sources</phrase>
              </entry>
              <entry><phrase role="left"><link linkend="ch0083s0028s0003li0170">170</link>, <link linkend="ch0083s0028s0003li0172">172</link>, <link linkend="ch0083s0028s0003li0173">173</link>, <link linkend="ch0083s0028s0003li0175">175</link>–<link linkend="ch0083s0028s0003li0182">182</link></phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Roche Diagnostic Systems, Inc.</phrase>
              </entry>
              <entry><phrase role="left">cobas CT/NG v2.0 test</phrase>
              </entry>
              <entry><phrase role="left">Qualitative real-time PCR</phrase>
              </entry>
              <entry><phrase role="left">DNA</phrase>
              </entry>
              <entry><phrase role="left">Both</phrase>
              </entry>
              <entry><phrase role="center">✓</phrase>
              </entry>
              <entry><phrase role="center">✓<superscript><emphasis><link linkend="ch0083s0019a0010">a</link></emphasis></superscript></phrase>
              </entry>
              <entry><phrase role="center">✓</phrase>
              </entry>
              <entry><phrase role="center">✓</phrase>
              </entry>
              <entry><phrase role="center">✓</phrase>
              </entry>
              <entry/>
              <entry><phrase role="center">✓</phrase>
              </entry>
              <entry/>
              <entry/>
              <entry><phrase role="left">cobas 4800 CT/NG system</phrase>
              </entry>
              <entry><phrase role="left">K132270</phrase>
              </entry>
              <entry><phrase role="left">Also tests for <emphasis>Neisseria gonorrhoeae</emphasis> using same indicated specimen sources</phrase>
              </entry>
              <entry><phrase role="left"><link linkend="ch0083s0028s0003li0172">172</link>, <link linkend="ch0083s0028s0003li0173">173</link>, <link linkend="ch0083s0028s0003li0175">175</link>, <link linkend="ch0083s0028s0003li0176">176</link>, <link linkend="ch0083s0028s0003li0183">183</link>, <link linkend="ch0083s0028s0003li0184">184</link></phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">cobas CT/NG</phrase>
              </entry>
              <entry><phrase role="left">Qualitative real-time PCR</phrase>
              </entry>
              <entry><phrase role="left">DNA</phrase>
              </entry>
              <entry><phrase role="left">Both</phrase>
              </entry>
              <entry><phrase role="center">✓</phrase>
              </entry>
              <entry><phrase role="center">✓<superscript><emphasis><link linkend="ch0083s0019a0010">a</link></emphasis></superscript></phrase>
              </entry>
              <entry><phrase role="center">✓</phrase>
              </entry>
              <entry><phrase role="center">✓</phrase>
              </entry>
              <entry/>
              <entry/>
              <entry><phrase role="center">✓</phrase>
              </entry>
              <entry><phrase role="center">✓</phrase>
              </entry>
              <entry><phrase role="center">✓</phrase>
              </entry>
              <entry><phrase role="left">cobas 6800 and 8800 systems</phrase>
              </entry>
              <entry><phrase role="left">K202048</phrase>
              </entry>
              <entry><phrase role="left">Also tests for <emphasis>Neisseria gonorrhoeae</emphasis> using same indicated specimen sources</phrase>
              </entry>
              <entry><phrase role="left"><link linkend="ch0083s0028s0003li0128">128</link>, <link linkend="ch0083s0028s0003li0181">181</link>, <link linkend="ch0083s0028s0003li0182">182</link></phrase>
              </entry>
            </row>
          </tbody>
        </tgroup>
      </table>
      <para role="table-footnote"><superscript><emphasis><anchor id="ch0083s0019a0010"/><link linkend="ch0083s0019a0009">a</link></emphasis></superscript>Clinical setting.</para>
      <para id="ch0083s0019p0009">No commercially available NAATs exist for diagnosis of<emphasis>C. psittaci</emphasis> infection. Interested laboratories may invest in laboratory-developed assays. A duplex real-time PCR assay has been described for detection of <emphasis>C. psittaci</emphasis> and <emphasis>C. abortus</emphasis> (<link linkend="ch0083s0028s0003li0135">135</link>). Given the increasing number of <emphasis>Chlamydia</emphasis> spp. that could be candidates for laboratory diagnosis, a potential NAAT approach could involve use of a common chlamydial target followed by reflex testing using more specific targets or multiplex assays (<link linkend="ch0083s0028s0003li0135">135</link>). Additionally, specific PCR assays for <emphasis>P. acanthamoebae</emphasis> (<link linkend="ch0083s0028s0003li0104">104</link>), <emphasis>W. chondrophila</emphasis> (<link linkend="ch0083s0028s0003li0137">137</link>), and <emphasis>S. negevensis</emphasis> (<link linkend="ch0083s0028s0003li0035">35</link>) have been developed.</para>
    </sect1>
    <sect1 id="ch0083s0020">
      <title>Antigen and Microscopic Detection</title>
      <anchor id="ch0083s0020a0001"/>
      <anchor id="ch0083s0020a0002"/>
      <sect2 id="ch0083s0020s0001">
        <title>DFA</title>
        <anchor id="ch0083s0020s0001a0001"/>
        <anchor id="ch0083s0020s0001a0002"/>
        <para id="ch0083s0020s0001p0001">The direct fluorescent assay (DFA) is much less sensitive than culture and dramatically less sensitive than NAATs; thus, the routine clinical use of DFAs cannot be recommended (<link linkend="ch0083s0028s0003li0138">138</link>).</para>
      </sect2>
      <sect2 id="ch0083s0020s0002">
        <title>EIAs</title>
        <anchor id="ch0083s0020s0002a0001"/>
        <anchor id="ch0083s0020s0002a0002"/>
        <para id="ch0083s0020s0002p0001">Enzyme immunoassays (EIAs) to detect chlamydial antigens use polyclonal or monoclonal antibodies directed against chlamydial LPS, which is found free from EBs in infected cells and secretions and is thus easier to detect than materials bound within the EB cell wall. This approach is<emphasis>Chlamydia</emphasis> genus specific, but because some other bacteria share epitopes with the chlamydial LPS, there is a potential for cross-reactions and nonspecific false-positive results. Blocking antibodies may be used to inhibit positive results after an initial positive test, improving specificity (<link linkend="ch0083s0028s0003li0139">139</link>). EIAs are far less sensitive than current NAATs and are not recommended.</para>
      </sect2>
      <sect2 id="ch0083s0020s0003">
        <title>Cytology</title>
        <anchor id="ch0083s0020s0003a0001"/>
        <anchor id="ch0083s0020s0003a0002"/>
        <para id="ch0083s0020s0003p0001">Cytologic testing to detect inclusions with Giemsa staining can be useful in providing a diagnosis of acute inclusion conjunctivitis in newborns but is insensitive for adult conjunctival and genital tract infections. Staining methods can also be used to detect<emphasis>C. psittaci</emphasis> from avian sources of human infection. For evaluation in avian species, the most common approach is impression smears from any serofibrinous exudate over the liver or spleen, or impression smears from these organs, followed by the Gimenez modification of the Macchiavello stain (<link linkend="ch0083s0028s0003li0140">140</link>). With this procedure, EBs are observed as red against a green background. Inclusions are rarely seen. This staining method is discussed in <ulink url="ch0035#ch0035s0001">chapter 19</ulink> of this <emphasis>Manual</emphasis>.</para>
      </sect2>
      <sect2 id="ch0083s0020s0004">
        <title>Rapid Diagnostics and Point-of-Care Testing</title>
        <anchor id="ch0083s0020s0004a0001"/>
        <anchor id="ch0083s0020s0004a0002"/>
        <para id="ch0083s0020s0004p0001"><emphasis>C. trachomatis</emphasis> rapid antigen testing has demonstrated suboptimal performance and cannot be recommended (<link linkend="ch0083s0028s0003li0141">141</link>, <link linkend="ch0083s0028s0003li0142">142</link>). However, there is a clear need for rapid diagnostics (providing a result within 30 min) which can be performed at the point of care. Tests that have longer turnaround times carry the risk of losing a patient to follow-up. Other than providing convenience in a clinic setting, the need for such tests is most apparent in screening asymptomatic women for chlamydial infection. A proportion of women who screen positive take weeks to begin therapy, and some are never treated (<link linkend="ch0083s0028s0003li0143">143</link>, <link linkend="ch0083s0028s0003li0144">144</link>). Such women are at risk of transmitting infection to partners and developing PID in the interim. A rapid diagnostic test performed at the point of care would result in prompt treatment and mitigate these problems. However, despite encouraging results obtained using modern microfluidic systems (<link linkend="ch0083s0028s0003li0145">145</link>) and alternative antigenic determinants, data suggest that point-of-care antigen tests do not detect <emphasis>C. trachomatis</emphasis> when present at very low bacterial loads (&lt;100 copies/ml), which occur in about 20% of cases (<link linkend="ch0083s0028s0003li0146">146</link>). Thus, rapid point-of-care NAATs are being developed. Such tests would also benefit men with urethritis or proctitis. In most countries, there are no recommendations for routine screening of MSM despite the fact that high rates of proctitis (&gt;10%) have been documented when this high-risk population is systematically tested, even when asymptomatic (<link linkend="ch0083s0028s0003li0080">80</link>).</para>
      </sect2>
      <sect2 id="ch0083s0020s0005">
        <title>ISOLATION PROCEDURES</title>
        <anchor id="ch0083s0020s0005a0001"/>
        <anchor id="ch0083s0020s0005a0002"/>
      </sect2>
    </sect1>
    <sect1 id="ch0083s0021">
      <title>Biosafety Considerations</title>
      <anchor id="ch0083s0021a0001"/>
      <anchor id="ch0083s0021a0002"/>
      <para id="ch0083s0021p0001">Processing and examination of tissues for<emphasis>C. psittaci</emphasis> and the LGV biovar of <emphasis>C. trachomatis</emphasis> should be performed in a biosafety cabinet and under biosafety level 3 (BSL-3) conditions, since these organisms are considered BSL-3 agents; other <emphasis>Chlamydia</emphasis> spp. are BSL-2 pathogens. The current BSL classification does not reflect currently used nomenclature or include newly recognized species. Thus, prudence dictates caution in handling specimens thought to contain other <emphasis>Chlamydia</emphasis> species. Some <emphasis>C. psittaci</emphasis> strains, particularly those from psittacine species or turkeys, are highly infectious. During research on psittacosis, laboratory-acquired infections have been reported, often severe and occasionally fatal (<link linkend="ch0083s0028s0003li0147">147</link>). With the introduction of modern biosafety cabinets, the incidence of such infections has been dramatically reduced. Passage of LGV strains by intranasal inoculation of mice resulted in ocular infections (producing a clinical picture resembling Parinaud’s oculoglandular syndrome) as well as respiratory disease and lymphadenitis in laboratory workers.</para>
      <para id="ch0083s0021p0002">Current BSL recommendations do not address newly recognized taxa, such as “<emphasis>Estrella lausannensis</emphasis>” or “<emphasis>Candidatus</emphasis> Rhabdochlamydia helvetica.” Although all the other members of the phylum <emphasis>Chlamydiota</emphasis> are considered BSL-2 agents, prudence dictates caution in handling specimens thought to contain newer chlamydiae, since their pathogenic potential has yet to be determined and since members such as <emphasis>Waddlia</emphasis> spp. have shorter doubling times and high infectivity in cell culture and animal models.</para>
    </sect1>
    <sect1 id="ch0083s0022">
      <title>Specimen Processing</title>
      <anchor id="ch0083s0022a0001"/>
      <anchor id="ch0083s0022a0002"/>
      <para id="ch0083s0022p0001">Specimens for isolation of bacteria should be refrigerated as soon as possible, and a cold chain should be maintained until material is inoculated into the isolation system. There are circumstances where freezing specimens collected in the field could be necessary, but freeze-thaw cycles reduce the success of isolation efforts. In general,<emphasis>Chlamydia</emphasis> culture is performed using transport medium containing antibiotics (not active against chlamydiae) to reduce or prevent bacterial and fungal contamination, as most specimens being tested for the presence of chlamydiae can also contain other microorganisms. An example of a collection and transport medium is tissue culture medium supplemented with 10% fetal calf serum, <phrase role="small">L</phrase>-glutamine, glucose, gentamicin (10 μg/mL), vancomycin (50 μg/mL), and nystatin (10 U/mL).</para>
    </sect1>
    <sect1 id="ch0083s0023">
      <title>Ocular and Genital Tract Specimens</title>
      <anchor id="ch0083s0023a0001"/>
      <anchor id="ch0083s0023a0002"/>
      <para id="ch0083s0023p0001">To isolate<emphasis>C. trachomatis</emphasis> from ocular or genital tract specimens, swabs should be collected from the affected site by rubbing vigorously while rotating the swab across the conjunctivae or inserting it 2 to 3 cm into the male urethra or within the endocervical canal after the removal of superficial discharge. Swabs should be placed directly into antibiotic-containing transport medium. If samples are frozen and thawed, the success of culture efforts will be reduced. FVU samples and vaginal swabs are not appropriate for culture attempts. After collection, the specimen should be sent to the laboratory as soon as possible, and a cold chain should be maintained.</para>
      <anchor id="ch0083s0023a0003"/>
      <beginpage pagenum="1271"/>
    </sect1>
    <sect1 id="ch0083s0024">
      <title>Bubo Pus, Blood, Sputum, Throat Washings and Other Secretions from the Respiratory Tract, Tissue Samples, and Fecal Samples</title>
      <anchor id="ch0083s0024a0001"/>
      <anchor id="ch0083s0024a0002"/>
      <para id="ch0083s0024p0001">Bubo pus, blood, sputum, throat washings and other secretions from the respiratory tract, tissue samples, and rectal/fecal samples present similar problems for the laboratory attempting to isolate chlamydiae. The specimens are often toxic to cell culture systems, and bacterial contamination is common. The approach for dealing with these specimens is essentially the same. Specimens are collected or homogenized in tissue culture transport medium containing antibiotics. The homogenization step may involve vortex mixing with glass beads or grinding with a mortar and pestle. This step should be performed in a biosafety cabinet. The specimens are then diluted (to 10 to 20%) and centrifuged at low speed (300 ×<emphasis>g</emphasis> for 10 min) to remove coarse materials and further diluted to reduce toxicity. Serial dilutions are prepared in cell culture medium for inoculation into susceptible cells. For tissue specimens, bubo pus, and fecal samples, such serial dilutions (1:10 to 1:1,000) are often required to prevent toxicity.</para>
    </sect1>
    <sect1 id="ch0083s0025">
      <title>Cell Culture</title>
      <anchor id="ch0083s0025a0001"/>
      <anchor id="ch0083s0025a0002"/>
      <para id="ch0083s0025p0001">For many years, isolation in cell culture was considered the most sensitive test for the diagnosis of<emphasis>C. trachomatis</emphasis> infection. It has been replaced by NAATs, which are far more sensitive, easier to perform, and amenable to performance on specimens collected with less invasive techniques. The first isolations of chlamydiae from trachoma cases and genital infections were performed using yolk sac inoculation of embryonated hen eggs. Mice were also used to isolate LGV and psittacosis strains. Yolk sac inoculation continues to be used for antigen preparation but not for routine isolation. At this point, <emphasis>C. trachomatis</emphasis> isolation is recommended only for situations where legal ramifications exist, such as in cases of child abuse (<link linkend="ch0083s0028s0003li0148">148</link>). This is due to misguided concerns about specificity of nonculture tests, yet it is clear that NAATs and genotyping procedures are more sensitive and provide more information about type specificity. Laboratories that are likely to process specimens for which the results can have medicolegal ramifications should be aware of which test results are accepted by courts of law and may need to develop chain-of-custody protocols.</para>
      <para id="ch0083s0025p0002">Cell culture is performed only in specialized laboratories. For purposes of determining antimicrobial susceptibility, cell culture procedures should be maintained. The following describes a generally useful isolation procedure in cell culture that could be fine-tuned for specific uses. For example, incubation at 35°C may be optimal for<emphasis>C. trachomatis</emphasis>, while 37°C may be preferred for <emphasis>C. psittaci.</emphasis> Many different cell lines can be used. For example, HL and Hep2 cells may be slightly better for growing <emphasis>C. pneumoniae.</emphasis> The cells most used for <emphasis>C. trachomatis</emphasis> isolation are McCoy cells (an L cell line), HeLa cells, and BGM cells. Cells are grown on coverslips in 1-dram vials or directly on multiwell plates, depending on the volume of specimen being processed in the laboratory. Early confluent cell monolayers should be inoculated by removing the maintenance tissue culture medium, replacing it with the clinical specimen, and centrifuging at approximately 2,500 × <emphasis>g</emphasis> for 1 h. The inoculum is then removed and replaced with tissue culture medium (minimal essential medium plus 10% fetal calf serum, supplemented with glutamine and glucose) containing cycloheximide (1 μg/mL) (<link linkend="ch0083s0028s0003li0149">149</link>). The latter inhibits mammalian cell metabolism, providing chlamydiae with a growth advantage. The cells are then incubated at 35°C in an environment with 5% CO<subscript>2</subscript> for 48 to 72 h. Monolayers are then fixed with methanol and stained with DFA reagents to detect the presence of chlamydial inclusions. Coverslips are removed from the vials and examined by direct microscopy, and inverted microscopes are used to examine the stained monolayers in wells in plates. For maximal sensitivity, a blind passage is performed with specimens negative for inclusions on the first inoculation.</para>
      <para id="ch0083s0025p0003">Similar cell culture approaches may be used to culture<emphasis>S. negevensis</emphasis> and <emphasis>W. chondrophila</emphasis>, with Vero and McCoy cells having been shown to be permissive cell lines. However, for <emphasis>Parachlamydia</emphasis> spp., only amoeba cells have been shown to be permissive. Amoeba cell coculture is similar to classical cell culture except that (i) antifungals such as amphotericin B cannot be used due to amoeba cell toxicity and (ii) an incubation temperature of 28 to 32°C should be considered, since amoebae encyst rapidly at higher temperatures.</para>
      <para id="ch0083s0025p0004">Attention must be paid to many details to maintain a sensitive isolation system. It starts with a well-educated clinician who supplies an appropriate specimen that includes an adequate sample of epithelial cells. It continues with maintenance of a cold chain and rapid transport of specimen to the laboratory. Maintenance of a sensitive, contamination-free cell line is required for maximum sensitivity. Blind passage of all negative specimens is also required. There should be routine quality control checks of all reagents and media. For example, cycloheximide should be titrated to assure that the optimal amount is being used. Moreover, for some chlamydial species, cycloheximide should not be used, since it may decrease the isolation sensitivity.</para>
      <sect2 id="ch0083s0025s0001">
        <title>IDENTIFICATION</title>
        <anchor id="ch0083s0025s0001a0001"/>
        <anchor id="ch0083s0025s0001a0002"/>
        <para id="ch0083s0025s0001p0001">For<emphasis>C. trachomatis</emphasis>, one effective method for identification of the organism in cell culture is to stain the monolayers with species-specific fluorescein-conjugated monoclonal antibodies. When other <emphasis>Chlamydia</emphasis> spp. are being sought, genus-specific fluorescein-conjugated monoclonal antibodies against the genus-specific LPS are the first choice. These reagents allow visualization of chlamydial inclusions and identify specific antigens, allowing confidence in calling a positive result. These antibody reagents are commercially available (MeriFluor <emphasis>Chlamydia</emphasis> direct fluorescent reagent; Meridian Bioscience, Cincinnati, OH). Specific PCR and/or fluorescent <emphasis>in situ</emphasis> hybridization with specific probes can also be used.</para>
      </sect2>
      <sect2 id="ch0083s0025s0002">
        <title>TYPING SYSTEMS</title>
        <anchor id="ch0083s0025s0002a0001"/>
        <anchor id="ch0083s0025s0002a0002"/>
        <para id="ch0083s0025s0002p0001">Given the rapid development of genotyping procedures, it is likely that before long, a practical approach for typing unknown chlamydiae will be whole-genome sequencing. For routine purposes, phenotyping or serotyping is not necessary but could be useful for epidemiologic studies or for medicolegal purposes. Differentiating the LGV biovar of<emphasis>C. trachomatis</emphasis> in MSM with rectal chlamydial infections can be of value due to different treatment durations (<link linkend="ch0083s0028s0003li0120">120</link>), a concept not yet investigated in a randomized clinical trial. Serotyping is used for epidemiologic purposes, but reagents are difficult to obtain. There are research procedures for typing, with the most popular genotyping method being multilocus sequence typing (MLST) (<link linkend="ch0083s0028s0003li0150">150</link>). MLST uses DNA sequences of several housekeeping genes (generally ≥7) and assesses the relatedness of the wild-type isolate and clinical sequences. It has better discriminatory ability than serotyping or <emphasis>ompA</emphasis> genotyping (<emphasis>ompA</emphasis> may be subject to recombination). Sequences of housekeeping genes are available at the <emphasis>Chlamydiales</emphasis> MLST database (<ulink url="http://pubmlst.org/chlamydiales/">http://pubmlst.org/chlamydiales/</ulink>). Neither MLST nor other genotyping research procedures are routinely used in clinical laboratories. These procedures do not require cultured organisms and may be performed directly on residual NAAT-positive specimens. The international subcommittee for chlamydial taxonomy recently published guidelines on using proper nomenclature when referring to MLST results (genotype) or genome-based results (genomotype). The serotype designation will be abandoned progressively, since it should be used only when typing was based on serological reactivity (i.e., an approach that completely disappeared due to lack of reagents and due to its lower precision) (<link linkend="ch0083s0028s0003li0020">20</link>).</para>
        <anchor id="ch0083s0025s0002a0003"/>
        <beginpage pagenum="1272"/>
      </sect2>
      <sect2 id="ch0083s0025s0003">
        <title>SEROLOGIC TESTS</title>
        <anchor id="ch0083s0025s0003a0001"/>
        <anchor id="ch0083s0025s0003a0002"/>
        <para id="ch0083s0025s0003p0001">Serology plays a limited role in the diagnosis of chlamydial infection. It can be useful in diagnosis of human psittacosis and supports clinical diagnosis of LGV. It can be helpful in the diagnosis of<emphasis>C. pneumoniae</emphasis> respiratory disease (particularly because culture is so difficult) (<link linkend="ch0083s0028s0003li0084">84</link>). Serology is considered a diagnostic test of choice for pneumonia in infants caused by <emphasis>C. trachomatis</emphasis>, where detection of high levels of IgM antibody to <emphasis>C. trachomatis</emphasis> could be diagnostic because of the defined time of exposure (<link linkend="ch0083s0028s0003li0151">151</link>). The infant is exposed to chlamydiae during passage through an infected birth canal.</para>
        <para id="ch0083s0025s0003p0002">While the infant will have IgG antibody levels that may reflect maternal levels, antichlamydial IgM will be present only in case of primary infection in the child, since IgM does not cross the placental barrier. However, in the NAAT era, the usefulness of serology for acute lung infections is clearly decreasing.</para>
        <para id="ch0083s0025s0003p0003">Serology has been more useful in clinical epidemiologic studies and in research aimed at defining the clinical spectrum of<emphasis>C. trachomatis</emphasis> infection. The role this organism plays in Fitz-Hugh-Curtis syndrome, epididymitis in men, tubal factor infertility, and ectopic pregnancy was elucidated largely based on serologic studies. These conditions are serious complications of superficial infection, and higher levels of antibody are generally found in patients with these complications than in subjects with uncomplicated cervicitis or urethritis.</para>
        <para id="ch0083s0025s0003p0004">Among the barriers to the use of serology for diagnosis are the high levels of antibody to<emphasis>C. pneumoniae</emphasis> in adult populations and to <emphasis>C. trachomatis</emphasis> in populations at high risk for sexually transmitted chlamydial infection and the common cross-reactivity between <emphasis>C. pneumoniae</emphasis> and <emphasis>C. psittaci.</emphasis> In addition, there are no accepted standard antibody preparations to help in evaluating tests. Detection of antibodies to <emphasis>C. trachomatis</emphasis> could be of use in evaluating the effects of trachoma control efforts, as measuring age-specific seroprevalence rates can be useful in confirming the time of cessation of transmission of what had been an endemic infection (<link linkend="ch0083s0028s0003li0152">152</link>).</para>
      </sect2>
    </sect1>
    <sect1 id="ch0083s0026">
      <title>CF Test</title>
      <anchor id="ch0083s0026a0001"/>
      <anchor id="ch0083s0026a0002"/>
      <para id="ch0083s0026p0001">The genus-specific complement fixation test was used for the diagnosis of human psittacosis and to support the diagnosis of LGV. Access to testing is limited, as complement fixation antigen is not commercially available. The complement fixation antigen was relatively easy to prepare from infected yolk sac suspensions, but this is not a useful enough test to encourage the effort, and this test is not used anymore.</para>
    </sect1>
    <sect1 id="ch0083s0027">
      <title>Microimmunofluorescence Test</title>
      <anchor id="ch0083s0027a0001"/>
      <anchor id="ch0083s0027a0002"/>
      <para id="ch0083s0027p0001">The microimmunofluorescence test was the most used serodiagnostic method after it was introduced by Wang and Grayston in 1970 for typing<emphasis>C. trachomatis</emphasis> (<link linkend="ch0083s0028s0003li0153">153</link>). The procedure allows detection of species- and serovar-specific antibody responses as well as the immunoglobulin class of reactive antibodies. Greater-than-fourfold increases in antibody levels in acute- and convalescent-phase sera can be used to support a clinical diagnosis of chlamydial infection. A problem with this method is the high prevalence of antichlamydial antibody in the populations at risk for infection (young adults for STIs, adults for <emphasis>C. pneumoniae</emphasis> infection). Given the asymptomatic nature of most of these infections, it is difficult to obtain specimens that are timed appropriately to demonstrate seroconversion or fourfold increases in antibody titer. High levels of IgG, variously defined as titers of ≥32 or ≥256, may support a diagnosis of LGV, human psittacosis, chlamydial epididymitis, ectopic pregnancy, or tubal factor infertility. Reagents for these tests are commercially available (Chlamydia MIF IgG; Focus Diagnostics, Cypress, CA). The American Type Culture Collection (Manassas, VA) offers a <emphasis>C. trachoma</emphasis><emphasis>tis</emphasis> panel.</para>
      <para id="ch0083s0027p0002">Immunofluorescence based on whole bacterial cells is considered by several experts the gold standard approach for chlamydia-related bacteria serology (<link linkend="ch0083s0028s0003li0154">154</link>), since the assay is relatively straightforward to prepare from cell culture. The cutoff titers used for <emphasis>C. pneumoniae</emphasis> serologic reactivity are generally used for chlamydia-related bacteria, i.e., 64 for IgG and 32 for IgM (<link linkend="ch0083s0028s0003li0101">101</link>).</para>
      <para id="ch0083s0027p0003">Major problems relative to microimmunofluorescence include the lack of standardization and subjective interpretation of antibody reactivity. The use of automated reading is promising, providing both increased reproducibility and increased sensitivity, without negatively impacting specificity (<link linkend="ch0083s0028s0003li0155">155</link>).</para>
    </sect1>
    <sect1 id="ch0083s0028">
      <title>EIAs</title>
      <anchor id="ch0083s0028a0001"/>
      <anchor id="ch0083s0028a0002"/>
      <para id="ch0083s0028p0001">EIAs against synthetic chlamydial peptides, purified EB suspensions, LPS, and LPS-extracted<emphasis>C. trachomatis</emphasis> EBs (Liaison <emphasis>Chlamydia trachomatis</emphasis> IgG and IgA [DiaSorin Ltd., Dublin, Ireland] and Captia Chlamydia IgG EIA [Trinity Biotech Plc, Wicklow, Ireland]) are commercially available. Most commercial assays have been compared, especially in subjects with tubal infertility and miscarriage (<link linkend="ch0083s0028s0003li0156">156</link>, <link linkend="ch0083s0028s0003li0157">157</link>). These tests demonstrate acceptable performance, especially when based on the major outer membrane protein as the antigen; conversely, the use of Hsp60 as the antigen in ELISA was associated with lower sensitivity and lower specificity (<link linkend="ch0083s0028s0003li0157">157</link>).</para>
      <para id="ch0083s0028p0002">Some researchers have used purified chlamydial proteins or plasmid-encoded proteins as antigen for diagnostic and epidemiologic studies (<link linkend="ch0083s0028s0003li0158">158</link>). Some results are promising, particularly those obtained with Pgp3, but there is inadequate experience to allow recommendations for routine diagnostic use. The most promising results have been in epidemiologic studies.</para>
      <anchor id="ch0083s0028a0003"/>
      <beginpage pagenum="1273"/>
      <para id="ch0083s0028p0003">For chlamydia-related bacteria, EIAs have been developed using either specific immunogenic proteins (<link linkend="ch0083s0028s0003li0059">59</link>, <link linkend="ch0083s0028s0003li0159">159</link>) or surface protein extracts (<link linkend="ch0083s0028s0003li0160">160</link>). This is particularly true for <emphasis>W. chondrophila</emphasis>, for which serology is indicated to document infection at a first-trimester miscarriage with the hope of avoiding recurrent miscarriages. However, commercial assays are not available for chlamydia-related bacteria; <emphasis>Waddlia</emphasis> sp. serology is mainly available in selected reference laboratories. For the other chlamydia-related bacteria, EIAs are research tools to investigate potential pathogenicity in these organisms.</para>
      <sect2 id="ch0083s0028s0001">
        <title>ANTIMICROBIAL SUSCEPTIBILITIES</title>
        <anchor id="ch0083s0028s0001a0001"/>
        <anchor id="ch0083s0028s0001a0002"/>
        <para id="ch0083s0028s0001p0001">Current CDC-recommended treatment regimens for uncomplicated<emphasis>C. trachomatis</emphasis> infection in adolescents and adults include 100 mg doxycycline orally twice a day for 7 days (<link linkend="ch0083s0028s0003li0148">148</link>). Alternative regimens may include azithromycin or levofloxacin. While treatment failures do occur with <emphasis>C. trachomatis</emphasis> infection, there is currently no convincing evidence for antibiotic resistance to the commonly used antibiotics (doxycycline or azithromycin). Over the years, there have been scattered reports of tetracycline or macrolide resistance in humans, but the main concern is in regard to pigs, as tetracycline resistance in <emphasis>C. suis</emphasis> has been widely documented. When treatment failures occur, the recommendation is to re-treat. However, it is important to be vigilant for emergence of resistance, especially in trachoma due to the mass azithromycin treatment used, even when no resistance has been documented in <emphasis>C. trachomatis</emphasis> strains (<link linkend="ch0083s0028s0003li0161">161</link>). A longer duration of treatment is recommended for LGV and human psittacosis, but there is a need for clinical trials to obtain evidence in support of this recommendation.</para>
        <para id="ch0083s0028s0001p0002">Testing for antibiotic resistance is not particularly challenging. A standardized inoculum, approximately 100 to 300 infection-forming units per coverslip, is used to infect susceptible cells. When the inoculum is removed, tissue culture medium with doubling dilutions of the antibiotic being tested is used to replace it. Infection proceeds using the tissue culture isolation procedure described above. Inclusions are detected by staining monolayers with DFA reagents after 48 h of incubation. The minimal chlamydiacidal level is defined as the lowest concentration of antibiotic producing no inclusions and no growth on subsequent passage. The MIC is defined as the level of antibiotic that reduces inclusion counts by 50%. The observed levels correspond well with clinical efficacy (<link linkend="ch0083s0028s0003li0162">162</link>). Alternatively, antibiotic susceptibility testing may be performed in 24- to 96-well microplates with antibiotics in serial dilution. Bacterial growth is assessed at 3 or 4 days postinfection by quantitative PCR (<link linkend="ch0083s0028s0003li0163">163</link>–<link linkend="ch0083s0028s0003li0165">165</link>).</para>
        <para id="ch0083s0028s0001p0003">Resistance to rifampin and fluoroquinolones is relatively easy to induce<emphasis>in vitro</emphasis> (<link linkend="ch0083s0028s0003li0049">49</link>, <link linkend="ch0083s0028s0003li0166">166</link>, <link linkend="ch0083s0028s0003li0167">167</link>), and all chlamydia-related bacteria studied to date exhibit constitutive resistance to fluoroquinolones due to mutations in the quinolone-resistance determining region of GyrA- and ParC-encoding genes (<link linkend="ch0083s0028s0003li0164">164</link>, <link linkend="ch0083s0028s0003li0165">165</link>). Exposure to beta-lactam agents may result in the appearance of aberrant chlamydial particles and inclusions. The organism regains structural integrity and replicates when the beta-lactam drug is removed. Similar effects are also noted with (i) fosfomycin, which acts on MurA, the first enzyme involved in peptidoglycan biosynthesis, and (ii) vancomycin and teicoplanin that target the <phrase role="small">D</phrase>-Ala–<phrase role="small">D</phrase>-Ala moiety of Gram-positive peptidoglycan (<link linkend="ch0083s0028s0003li0168">168</link>). These aberrant bodies are also documented upon exposure to clavulanate (<link linkend="ch0083s0028s0003li0168">168</link>), demonstrating that the effect is not due to an impact on the sacculus but rather on division, since the peptidoglycan of <emphasis>Chlamydia</emphasis> has been retained upon evolution due to its role in division of the bacterial cells (<link linkend="ch0083s0028s0003li0049">49</link>, <link linkend="ch0083s0028s0003li0050">50</link>). This explains the fact that the aberrant bodies, due to selective toxicity on peptidoglycan, exhibit high DNA content per bacterial cell (replication is not inhibited).</para>
      </sect2>
      <sect2 id="ch0083s0028s0002">
        <title>EVALUATION, INTERPRETATION, AND REPORTING OF RESULTS</title>
        <anchor id="ch0083s0028s0002a0001"/>
        <anchor id="ch0083s0028s0002a0002"/>
        <para id="ch0083s0028s0002p0001">Reporting of a test result should include the type of test used and a clinical interpretation when possible. Most reports will result from performing a NAAT. Attention should be paid to the interpretation section of the package insert and whether the specimen tested is indicated for the test. Nonindicated specimen sources require some degree of test validation, and that should be stated on the report form. Reports should always state that<emphasis>C. trachomatis</emphasis> nucleic acid was (or was not) detected and should not discuss infection status.</para>
        <para id="ch0083s0028s0002p0002">If tests that have not been cleared by the FDA are used, specific details of the testing methods should be supplied with the results.</para>
        <para id="ch0083s0028s0002p0003">The currently available antigen detection tests are not recommended because of poor sensitivity. Unless paired acute- and convalescent-phase sera are tested, a positive serologic test reflects infection only at some time, not necessarily at the time of testing, and reports should state only that antibodies were detected.</para>
      </sect2>
      <sect2 id="ch0083s0028s0003">
        <title>REFERENCES</title>
        <anchor id="ch0083s0028s0003a0001"/>
        <anchor id="ch0083s0028s0003a0002"/>
        <itemizedlist mark="none" role="biblioEntryList">
          <listitem id="ch0083s0028s0003li0001" role="bibliographyEntry">
            <para>1.<emphasis role="strong">Taylor-Brown A, Vaughan L, Greub G, Timms P, Polkinghorne A.</emphasis> 2015. Twenty years of research into <citetitle><emphasis>Chlamydia</emphasis></citetitle>-like organisms: a revolution in our understanding of the biology and pathogenicity of members of the phylum <citetitle><emphasis>Chlamydiae. Pathog Dis</emphasis></citetitle> <emphasis role="strong">73:</emphasis>1–15.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0002" role="bibliographyEntry">
            <para>2.<emphasis role="strong">Greub G, Raoult D.</emphasis> 2004. Microorganisms resistant to free-living amoebae. <citetitle><emphasis>Clin Microbiol Rev</emphasis></citetitle> <emphasis role="strong">17</emphasis><emphasis role="strong">:</emphasis>413–433.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0003" role="bibliographyEntry">
            <para>3.<emphasis role="strong">Tamura A, Matsumoto A, Manire GP, Higashi N.</emphasis> 1971. Electron microscopic observations on the structure of the envelopes of mature elementary bodies and developmental reticulate forms of <citetitle><emphasis>Chlamydia psittaci. J Bacteriol</emphasis></citetitle> <emphasis role="strong">105</emphasis><emphasis role="strong">:</emphasis>355–360.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0004" role="bibliographyEntry">
            <para>4.<emphasis role="strong">Greub G, Raoult D.</emphasis> 2002. Crescent bodies of <citetitle><emphasis>Parachlamydia acanthamoeba</emphasis></citetitle> and its life cycle within <citetitle><emphasis>Acanthamoeba polyphaga</emphasis></citetitle>: an electron micrograph study. <citetitle><emphasis>Appl Environ Microbiol</emphasis></citetitle> <emphasis role="strong">68:</emphasis>3076–3084.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0005" role="bibliographyEntry">
            <para>5.<emphasis role="strong">Rusconi B, Lienard J, Aeby S, Croxatto A, Bertelli C, Greub G.</emphasis> 2013. Crescent and star shapes of members of the <citetitle><emphasis>Chlamydiales</emphasis></citetitle> order: impact of fixative methods. <citetitle><emphasis>Antonie van Leeuwenhoek</emphasis></citetitle> <emphasis role="strong">104</emphasis><emphasis role="strong">:</emphasis>521–532.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0006" role="bibliographyEntry">
            <para>6.<emphasis role="strong">Greub G.</emphasis> 2010. International Committee on Systematics of Prokaryotes. Subcommittee on the taxonomy of the <citetitle><emphasis>Chlamydiae</emphasis></citetitle>: minutes of the inaugural closed meeting, 21 March 2009, Little Rock, AR, USA. <citetitle><emphasis>Int J Syst Evol Microbiol</emphasis></citetitle> <emphasis role="strong">60:</emphasis>2691–2693.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0007" role="bibliographyEntry">
            <para>7.<emphasis role="strong">Greub G, Bavoil P.</emphasis> 2018. International Committee on Systematics of Prokaryotes Subcommittee on the taxonomy of <citetitle><emphasis>Chlamydiae</emphasis></citetitle>. Minutes of the closed meeting, 7 September 2016, Oxford, UK. <citetitle><emphasis>Int J Syst Evol Microbiol</emphasis></citetitle> <emphasis role="strong">68:</emphasis>3683–3684.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0008" role="bibliographyEntry">
            <para>8.<emphasis role="strong">de Barsy M, Greub G.</emphasis> 2013. <citetitle><emphasis>Waddlia chondrophila</emphasis></citetitle>: from biology to pathogenicity. <citetitle><emphasis>Microbes Infect</emphasis></citetitle> <emphasis role="strong">15:</emphasis>1033–1041.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0009" role="bibliographyEntry">
            <para>9.<emphasis role="strong">Vouga M, Baud D, Greub G.</emphasis> 2017. <citetitle><emphasis>Simkania negevensis</emphasis></citetitle>, an insight into the biology and clinical importance of a novel member of the Chlamydiales order. <citetitle><emphasis>Crit Rev Microbiol</emphasis></citetitle> <emphasis role="strong">43:</emphasis>62–80.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0010" role="bibliographyEntry">
            <para>10.<emphasis role="strong">Ammerdorffer A, Stojanov M, Greub G, Baud D.</emphasis> 2017. <citetitle><emphasis>Chlamydia trachomatis</emphasis></citetitle> and <citetitle><emphasis>Chlamydia</emphasis></citetitle>-like bacteria: new enemies of human pregnancies. <citetitle><emphasis>Curr Opin Infect Dis</emphasis></citetitle> <emphasis role="strong">30</emphasis><emphasis role="strong">:</emphasis>289–296.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0011" role="bibliographyEntry">
            <para>11.<emphasis role="strong">Lamoth F, Pillonel T, Greub G.</emphasis> 2015. <citetitle><emphasis>Waddlia</emphasis></citetitle>: an emerging pathogen and a model organism to study the biology of chlamydiae. <citetitle><emphasis>Microbes Infect</emphasis></citetitle> <emphasis role="strong">17</emphasis><emphasis role="strong">:</emphasis>732–737.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0012" role="bibliographyEntry">
            <para>12.<emphasis role="strong">Lamoth F, Greub G.</emphasis> 2010. Amoebal pathogens as emerging causal agents of pneumonia. <citetitle><emphasis>FEMS Microbiol Rev</emphasis></citetitle> <emphasis role="strong">34</emphasis><emphasis role="strong">:</emphasis>260–280.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0013" role="bibliographyEntry">
            <para>13.<emphasis role="strong">Greub G.</emphasis> 2009. <citetitle><emphasis>Parachlamydia acanthamoebae</emphasis></citetitle>, an emerging agent of pneumonia. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">15:</emphasis>18–28.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0014" role="bibliographyEntry">
            <para>14.<emphasis role="strong">Friedman MG, Dvoskin B, Kahane S.</emphasis> 2003. Infections with the <citetitle><emphasis>Chlamydia</emphasis></citetitle>-like microorganism <citetitle><emphasis>Simkania negevensis</emphasis></citetitle>, a possible emerging pathogen. <citetitle><emphasis>Microbes Infect</emphasis></citetitle> <emphasis role="strong">5:</emphasis>1013–1021.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0015" role="bibliographyEntry">
            <para>15.<emphasis role="strong">Birtles RJ, Rowbotham TJ, Storey C, Marrie TJ, Raoult D.</emphasis> 1997. <citetitle><emphasis>Chlamydia</emphasis></citetitle>-like obligate parasite of free-living amoebae. <citetitle><emphasis>Lancet</emphasis></citetitle> <emphasis role="strong">349</emphasis><emphasis role="strong">:</emphasis>925–926.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0016" role="bibliographyEntry">
            <para>16.<emphasis role="strong">Casson N, Michel R, Müller KD, Aubert JD, Greub G.</emphasis> 2008. <citetitle><emphasis>Protochlamydia naegleriophila</emphasis></citetitle> as etiologic agent of pneumonia. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">14</emphasis><emphasis role="strong">:</emphasis>168–172.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0017" role="bibliographyEntry">
            <para>17.<emphasis role="strong">Pillonel T, Bertelli C, Salamin N, Greub G.</emphasis> 2015. Taxogenomics of the order Chlamydiales. <citetitle><emphasis>Int J Syst Evol Microbiol</emphasis></citetitle> <emphasis role="strong">65</emphasis>(Pt 4)<emphasis role="strong">:</emphasis>1381–1393.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0018" role="bibliographyEntry">
            <para>18.<emphasis role="strong">Sachse K, Bavoil PM, Kaltenboeck B, Stephens RS, Kuo CC, Rosselló-Móra R, Horn M.</emphasis> 2015. Emendation of the family <citetitle><emphasis>Chlamydiaceae</emphasis></citetitle>: proposal of a single genus, <citetitle><emphasis>Chlamydia</emphasis></citetitle>, to include all currently recognized species. <citetitle><emphasis>Syst Appl Microbiol</emphasis></citetitle> <emphasis role="strong">38:</emphasis>99–103.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0019" role="bibliographyEntry">
            <para>19.<emphasis role="strong">Bavoil P, Kaltenboeck B, Greub G.</emphasis> 2013. In <citetitle><emphasis>Chlamydia</emphasis></citetitle> veritas. <citetitle><emphasis>Pathog Dis</emphasis></citetitle> <emphasis role="strong">67:</emphasis>89–90.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0020" role="bibliographyEntry">
            <para>20.<emphasis role="strong">de Vries HJC, Pannekoek Y, Dean D, Bavoil PM, Borel N, Greub G, Morré SA, ICSP Subcommittee on the Taxonomy of Chlamydiae.</emphasis> 2022. Call for consensus in <citetitle><emphasis>Chlamydia trachomatis</emphasis></citetitle> nomenclature: moving from biovars, serovars, and serotypes to genovariants and genotypes. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">28</emphasis><emphasis role="strong">:</emphasis>761–763.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0021" role="bibliographyEntry">
            <para>21.<emphasis role="strong">Opota O, Brouillet R, Greub G, Jaton K.</emphasis> 2017. Methods for real-time PCR-based diagnosis of <citetitle><emphasis>Chlamydia pneumoniae</emphasis></citetitle>, <citetitle><emphasis>Chlamydia psittaci</emphasis></citetitle>, and <citetitle><emphasis>Chlamydia abortus</emphasis></citetitle> infections in an opened molecular diagnostic platform. <citetitle><emphasis>Methods Mol Biol</emphasis></citetitle> <emphasis role="strong">1616</emphasis><emphasis role="strong">:</emphasis>171–181.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0022" role="bibliographyEntry">
            <para>22.<emphasis role="strong">Fajardo KA, Zorich SC, Voss JD, Thervil JW.</emphasis> 2015. Pneumonia outbreak caused by <citetitle><emphasis>Chlamydophila pneumoniae</emphasis></citetitle> among US Air Force Academy cadets, Colorado, USA. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">21:</emphasis>1049–1051.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0023" role="bibliographyEntry">
            <para>23.<emphasis role="strong">Polkinghorne A, Hanger J, Timms P.</emphasis> 2013. Recent advances in understanding the biology, epidemiology and control of chlamydial infections in koalas. <citetitle><emphasis>Vet Microbiol</emphasis></citetitle> <emphasis role="strong">165</emphasis><emphasis role="strong">:</emphasis>214–223.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0024" role="bibliographyEntry">
            <para>24.<emphasis role="strong">Hogerwerf L, De Gier B, Baan B, Van Der Hoek W.</emphasis> 2017. <citetitle><emphasis>Chlamydia psittaci</emphasis></citetitle> (psittacosis) as a cause of community-acquired pneumonia: a systematic review and meta-analysis. <citetitle><emphasis>Epidemiol Infect</emphasis></citetitle> <emphasis role="strong">145:</emphasis>3096–3105.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0025" role="bibliographyEntry">
            <para>25.<emphasis role="strong">Baud D, Greub G.</emphasis> 2011. Intracellular bacteria and adverse pregnancy outcomes. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">17:</emphasis>1312–1322.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0026" role="bibliographyEntry">
            <para>26.<emphasis role="strong">Borel N, Casson N, Entenza JM, Kaiser C, Pospischil A, Greub G.</emphasis> 2009. Tissue microarray and immunohistochemistry as tools for evaluation of antibodies against <citetitle><emphasis>Chlamydia</emphasis></citetitle>-like bacteria. <citetitle><emphasis>J Med Microbiol</emphasis></citetitle> <emphasis role="strong">58</emphasis><emphasis role="strong">:</emphasis>863–866.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0027" role="bibliographyEntry">
            <para>27.<emphasis role="strong">Casson N, Entenza JM, Greub G.</emphasis> 2007. Serological cross-reactivity between different <citetitle><emphasis>Chlamydia</emphasis></citetitle>-like organisms. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">45</emphasis><emphasis role="strong">:</emphasis>234–236.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0028" role="bibliographyEntry">
            <para>28.<emphasis role="strong">Lienard J, Croxatto A, Prod’hom G</emphasis>, <emphasis role="strong">Greub G.</emphasis> 2011. <citetitle><emphasis>Estrella lausannensis</emphasis></citetitle>, a new star in the <citetitle><emphasis>Chlamydiales</emphasis></citetitle> order. <citetitle><emphasis>Microbes Infect</emphasis></citetitle> <emphasis role="strong">13:</emphasis>1232–1241.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0029" role="bibliographyEntry">
            <para>29.<emphasis role="strong">Croxatto A, Greub G.</emphasis> 2010. Early intracellular trafficking of <citetitle><emphasis>Waddlia chondrophila</emphasis></citetitle> in human macrophages. <citetitle><emphasis>Microbiology (Reading)</emphasis></citetitle> <emphasis role="strong">156</emphasis><emphasis role="strong">:</emphasis>340–355.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0030" role="bibliographyEntry">
            <para>30.<emphasis role="strong">Rurangirwa FR, Dilbeck PM, Crawford TB, McGuire TC, McElwain TF.</emphasis> 1999. Analysis of the 16S rRNA gene of micro-organism WSU 86-1044 from an aborted bovine foetus reveals that it is a member of the order <citetitle><emphasis>Chlamydiales</emphasis></citetitle>: proposal of <citetitle><emphasis>Waddliaceae</emphasis></citetitle> fam. nov., <citetitle><emphasis>Waddlia chondrophila</emphasis></citetitle> gen. nov., sp. nov. <citetitle><emphasis>Int J Syst Bacteriol</emphasis></citetitle> <emphasis role="strong">49</emphasis><emphasis role="strong">:</emphasis>577–581.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0031" role="bibliographyEntry">
            <para>31.<emphasis role="strong">Kebbi-Beghdadi C, Cisse O, Greub G.</emphasis> 2011. Permissivity of Vero cells, human pneumocytes and human endometrial cells to <citetitle><emphasis>Waddlia chondrophila. Microbes Infect</emphasis></citetitle> <emphasis role="strong">13</emphasis><emphasis role="strong">:</emphasis>566–574.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0032" role="bibliographyEntry">
            <para>32.<emphasis role="strong">Kebbi-Beghdadi C, Batista C, Greub G.</emphasis> 2011. Permissivity of fish cell lines to three <citetitle><emphasis>Chlamydia</emphasis></citetitle>-related bacteria: <citetitle><emphasis>Waddlia chondrophila</emphasis></citetitle>, <citetitle><emphasis>Estrella lausannensis</emphasis></citetitle> and <citetitle><emphasis>Parachlamydia acanthamoebae. FEMS Immunol Med Microbiol</emphasis></citetitle> <emphasis role="strong">63</emphasis><emphasis role="strong">:</emphasis>339–345.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0033" role="bibliographyEntry">
            <para>33.<emphasis role="strong">Kebbi-Beghdadi C, Fatton M, Greub G.</emphasis> 2015. Permissivity of insect cells to <citetitle><emphasis>Waddlia chondrophila</emphasis></citetitle>, <citetitle><emphasis>Estrella lausannensis</emphasis></citetitle> and <citetitle><emphasis>Parachlamydia acanthamoebae. Microbes Infect</emphasis></citetitle> <emphasis role="strong">17</emphasis><emphasis role="strong">:</emphasis>749–754.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0034" role="bibliographyEntry">
            <para>34.<emphasis role="strong">Goy G, Croxatto A, Greub G.</emphasis> 2008. <citetitle><emphasis>Waddlia chondrophila</emphasis></citetitle> enters and multiplies within human macrophages. <citetitle><emphasis>Microbes Infect</emphasis></citetitle> <emphasis role="strong">10</emphasis><emphasis role="strong">:</emphasis>556–562.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0035" role="bibliographyEntry">
            <para>35.<emphasis role="strong">Vouga M, Kebbi-Beghdadi C, Liénard J, Baskin L, Baud D, Greub G.</emphasis> 2018. What is the true clinical relevance of <citetitle><emphasis>Simkania negevensis</emphasis></citetitle> and other emerging <citetitle><emphasis>Chlamydiales</emphasis></citetitle> members? <citetitle><emphasis>New Microbes New Infect</emphasis></citetitle> <emphasis role="strong">23:</emphasis>1–5.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0036" role="bibliographyEntry">
            <para>36.<emphasis role="strong">Vouga M, Baud D, Greub G.</emphasis> 2017. <citetitle><emphasis>Simkania negevensis</emphasis></citetitle> may produce long-lasting infections in human pneumocytes and endometrial cells. <citetitle><emphasis>Pathog Dis</emphasis></citetitle> <emphasis role="strong">75:</emphasis>ftw115.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0037" role="bibliographyEntry">
            <para>37.<emphasis role="strong">Kahane S, Everett KD, Kimmel N, Friedman MG.</emphasis> 1999. <citetitle><emphasis>Simkania negevensis</emphasis></citetitle> strain ZT: growth, antigenic and genome characteristics. <citetitle><emphasis>Int J Syst Bacteriol</emphasis></citetitle> <emphasis role="strong">49</emphasis><emphasis role="strong">:</emphasis>815–820.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0038" role="bibliographyEntry">
            <para>38.<emphasis role="strong">Moulder JW, Hatch TT, Kuo C-C, Schachter J, Storz J.</emphasis> 1984. Order II. Chlamydiales Storz and Page 1971, 334, p 729–739. <citetitle><emphasis>In</emphasis></citetitle> Krieg NR, Holt JG (ed), <citetitle><emphasis>Bergey’s Manual of Systematic Bacteriology.</emphasis></citetitle> Williams and Wilkins, Baltimore, MD.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0039" role="bibliographyEntry">
            <para>39.<emphasis role="strong">Byrne GI, Moulder JW.</emphasis> 1978. Parasite-specified phagocytosis of <citetitle><emphasis>Chlamydia psittaci</emphasis></citetitle> and <citetitle><emphasis>Chlamydia trachomatis</emphasis></citetitle> by L and HeLa cells. <citetitle><emphasis>Infect Immun</emphasis></citetitle> <emphasis role="strong">19</emphasis><emphasis role="strong">:</emphasis>598–606.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0040" role="bibliographyEntry">
            <para>40.<emphasis role="strong">Hackstadt T, Scidmore MA, Rockey DD.</emphasis> 1995. Lipid metabolism in <citetitle><emphasis>Chlamydia trachomatis</emphasis></citetitle>-infected cells: directed trafficking of Golgi-derived sphingolipids to the chlamydial inclusion. <citetitle><emphasis>Proc Natl Acad Sci USA</emphasis></citetitle> <emphasis role="strong">92:</emphasis>4877–4881.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0041" role="bibliographyEntry">
            <para>41.<emphasis role="strong">Greub G, Mege JL, Gorvel JP, Raoult D, Méresse S.</emphasis> 2005. Intracellular trafficking of <citetitle><emphasis>Parachlamydia acanthamoebae. Cell Microbiol</emphasis></citetitle> <emphasis role="strong">7</emphasis><emphasis role="strong">:</emphasis>581–589.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0042" role="bibliographyEntry">
            <para>42.<emphasis role="strong">Croxatto A, Murset V, Chassot B, Greub G.</emphasis> 2013. Early expression of the type III secretion system of <citetitle><emphasis>Parachlamydia acanthamoebae</emphasis></citetitle> during a replicative cycle within its natural host cell <citetitle><emphasis>Acanthamoeba castellanii. Pathog Dis</emphasis></citetitle> <emphasis role="strong">69</emphasis><emphasis role="strong">:</emphasis>159–175.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0043" role="bibliographyEntry">
            <para>43.<emphasis role="strong">Bertelli C, Aeby S, Chassot B, Clulow J, Hilfiker O, Rappo S, Ritzmann S, Schumacher P, Terrettaz C, Benaglio P, Falquet L, Farinelli L, Gharib WH, Goesmann A, Harshman K, Linke B, Miyazaki R, Rivolta C, Robinson-Rechavi M, van der Meer JR, Greub G.</emphasis> 2015. Sequencing and characterizing the genome of <citetitle><emphasis>Estrella lausannensis</emphasis></citetitle> as an undergraduate project: training students and biological insights. <citetitle><emphasis>Front Microbi</emphasis></citetitle><citetitle><emphasis>ol</emphasis></citetitle> <emphasis role="strong">6:</emphasis>101.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0044" role="bibliographyEntry">
            <para>44.<emphasis role="strong">Bertelli C, Collyn F, Croxatto A, Rückert C, Polkinghorne A, Kebbi-Beghdadi C, Goesmann A, Vaughan L, Greub G.</emphasis> 2010. The <citetitle><emphasis>Waddlia</emphasis></citetitle> genome: a window into chlamydial biology. <citetitle><emphasis>PLoS One</emphasis></citetitle> <emphasis role="strong">5:</emphasis>e10890.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0045" role="bibliographyEntry">
            <para>45.<emphasis role="strong">Bastidas RJ, Elwell CA, Engel JN, Valdivia RH.</emphasis> 2013. Chlamydial intracellular survival strategies. <citetitle><emphasis>Cold Spring Harb Perspect Med</emphasis></citetitle> <emphasis role="strong">3</emphasis><emphasis role="strong">:</emphasis>a010256.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0046" role="bibliographyEntry">
            <para>46.<emphasis role="strong">Marquis B, Ardissone S, Greub G.</emphasis> 2022. Temperature affects the host range of <citetitle><emphasis>Rhabdochlamydia porcellionis</emphasis></citetitle> and the infectivity of <citetitle><emphasis>Waddlia chondrophila</emphasis></citetitle> and <citetitle><emphasis>Chlamydia trachomatis</emphasis></citetitle> elementary bodies. <citetitle><emphasis>bioRxiv.</emphasis></citetitle> <ulink url="https://www.biorxiv.org/content/10.1101/2022.09.02.506449v1">https://www.biorxiv.org/content/10.1101/2022.09.02.506449v1</ulink>.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0047" role="bibliographyEntry">
            <para>47.<emphasis role="strong">Hybiske K, Stephens RS.</emphasis> 2007. Mechanisms of host cell exit by the intracellular bacterium <citetitle><emphasis>Chlamydia. Proc Natl Acad Sci USA</emphasis></citetitle> <emphasis role="strong">104:</emphasis>11430–11435.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0048" role="bibliographyEntry">
            <para>48.<emphasis role="strong">Corsaro D, Thomas V, Goy G, Venditti D, Radek R, Greub G.</emphasis> 2007. ‘<citetitle><emphasis>Candidatus</emphasis></citetitle> Rhabdochlamydia crassificans’, an intracellular bacterial pathogen of the cockroach <citetitle><emphasis>Blatta orientalis</emphasis></citetitle> (Insecta: Blattodea). <citetitle><emphasis>Syst Appl Microbiol</emphasis></citetitle> <emphasis role="strong">30</emphasis><emphasis role="strong">:</emphasis>221–228.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0049" role="bibliographyEntry">
            <para>49.<emphasis role="strong">Jacquier N, Viollier PH, Greub G.</emphasis> 2015. The role of peptidoglycan in chlamydial cell division: towards resolving the chlamydial anomaly. <citetitle><emphasis>FEMS Microbiol Rev</emphasis></citetitle> <emphasis role="strong">39</emphasis><emphasis role="strong">:</emphasis>262–275.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0050" role="bibliographyEntry">
            <para>50.<emphasis role="strong">Jacquier N, Frandi A, Pillonel T, Viollier PH, Greub G.</emphasis> 2014. Cell wall precursors are required to organize the chlamydial division septum. <citetitle><emphasis>Nat Commun</emphasis></citetitle> <emphasis role="strong">5:</emphasis>3578.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0051" role="bibliographyEntry">
            <para>51.<emphasis role="strong">Jacquier N, Yadav AK, Pillonel T, Viollier PH, Cava F, Greub G.</emphasis> 2019. A SpoIID homolog cleaves glycan strands at the chlamydial division septum. <citetitle><emphasis>mBio</emphasis></citetitle> <emphasis role="strong">10:</emphasis>e01128-19.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0052" role="bibliographyEntry">
            <anchor id="ch0083s0028s0003a0003"/>
            <para>52.<emphasis role="strong">Newhall WJ, Jones RB.</emphasis> 1983. Disulfide-linked oligomers of the major outer membrane protein of chlamydiae. <citetitle><emphasis>J Bacteriol</emphasis></citetitle> <emphasis role="strong">154:</emphasis>998–1001.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0053" role="bibliographyEntry">
            <para>53.<emphasis role="strong">Newhall WJV.</emphasis> 1987. Biosynthesis and disulfide cross-linking of outer membrane components during the growth cycle of <citetitle><emphasis>Chlamydia trachomatis. Infect Immun</emphasis></citetitle> <emphasis role="strong">55</emphasis><emphasis role="strong">:</emphasis>162–168.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0054" role="bibliographyEntry">
            <para>54.<emphasis role="strong">Caldwell HD, Kromhout J, Schachter J.</emphasis> 1981. Purification and partial characterization of the major outer membrane protein of <citetitle><emphasis>Chlamydia trachomatis. Infect Immun</emphasis></citetitle> <emphasis role="strong">31:</emphasis>1161–1176.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0055" role="bibliographyEntry">
            <para>55.<emphasis role="strong">Stephens RS, Wagar EA, Schoolnik GK.</emphasis> 1988. High-resolution mapping of serovar-specific and common antigenic determinants of the major outer membrane protein of <citetitle><emphasis>Chlamydia trachomatis. J Exp Med</emphasis></citetitle> <emphasis role="strong">167</emphasis><emphasis role="strong">:</emphasis>817–831.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0056" role="bibliographyEntry">
            <para>56.<emphasis role="strong">Vasilevsky S, Stojanov M, Greub G, Baud D.</emphasis> 2016. Chlamydial polymorphic membrane proteins: regulation, function and potential vaccine candidates. <citetitle><emphasis>Virulence</emphasis></citetitle> <emphasis role="strong">7:</emphasis>11–22.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0057" role="bibliographyEntry">
            <para>57.<emphasis role="strong">Favaroni A, Hegemann JH.</emphasis> 2021. <citetitle><emphasis>Chlamydia trachomatis</emphasis></citetitle> polymorphic membrane proteins (Pmps) form functional homomeric and heteromeric oligomers. <citetitle><emphasis>Front Microbiol</emphasis></citetitle> <emphasis role="strong">12:</emphasis>709724.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0058" role="bibliographyEntry">
            <para>58.<emphasis role="strong">Kebbi-Beghdadi C, Domröse A, Becker E, Cisse OH, Hegemann JH, Greub G.</emphasis> 2015. OmpA family proteins and Pmp-like autotransporter: new adhesins of <citetitle><emphasis>Waddlia chondrophila. Pathog Dis</emphasis></citetitle> <emphasis role="strong">73:</emphasis>ftv035.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0059" role="bibliographyEntry">
            <para>59.<emphasis role="strong">Greub G, Kebbi-Beghdadi C, Bertelli C, Collyn F, Riederer BM, Yersin C, Croxatto A, Raoult D.</emphasis> 2009. High throughput sequencing and proteomics to identify immunogenic proteins of a new pathogen: the dirty genome approach. <citetitle><emphasis>PLoS One</emphasis></citetitle> <emphasis role="strong">4:</emphasis>e8423.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0060" role="bibliographyEntry">
            <para>60.<emphasis role="strong">Thomas V, Greub G.</emphasis> 2010. Amoeba/amoebal symbiont genetic transfers: lessons from giant virus neighbours. <citetitle><emphasis>Intervirology</emphasis></citetitle> <emphasis role="strong">53</emphasis><emphasis role="strong">:</emphasis>254–267.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0061" role="bibliographyEntry">
            <para>61.<emphasis role="strong">Greub G, Collyn F, Guy L, Roten CA.</emphasis> 2004. A genomic island present along the bacterial chromosome of the <citetitle><emphasis>Parachlamydiaceae</emphasis></citetitle> UWE25, an obligate amoebal endosymbiont, encodes a potentially functional F-like conjugative DNA transfer system. <citetitle><emphasis>BMC Microbiol</emphasis></citetitle> <emphasis role="strong">4:</emphasis>48.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0062" role="bibliographyEntry">
            <para>62.<emphasis role="strong">World Health Organization.</emphasis> 2021. Trachoma fact sheet. <ulink url="http://www.who.int/news-room/fact-sheets/detail/trachoma">www.who.int/news-room/fact-sheets/detail/trachoma</ulink>. Accessed 27 July 2021.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0063" role="bibliographyEntry">
            <para>63.<emphasis role="strong">Schachter J, Dawson CR.</emphasis> 1978. <citetitle><emphasis>Human chlamydial infections.</emphasis></citetitle> PSG Publishing Company, Littleton, MA.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0064" role="bibliographyEntry">
            <para>64.<emphasis role="strong">Rowley J, Vander Hoorn S, Korenromp E, Low N, Unemo M, Abu-Raddad LJ, Chico RM, Smolak A, Newman L, Gottlieb S, Thwin SS, Broutet N, Taylor MM.</emphasis> 2019. <citetitle><emphasis>Chlamydia</emphasis></citetitle>, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016. <citetitle><emphasis>Bull World Health Organ</emphasis></citetitle> <emphasis role="strong">97:</emphasis>548–562P.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0065" role="bibliographyEntry">
            <para>65.<emphasis role="strong">Centers for Disease Control and Prevention.</emphasis> 2021. National overview—sexually transmitted disease surveillance, 2019. <ulink url="https://www.cdc.gov/std/statistics/2019/std-surveillance-2019.pdf">https://www.cdc.gov/std/statistics/2019/std-surveillance-2019.pdf</ulink>. Accessed 28 July 2021.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0066" role="bibliographyEntry">
            <para>66.<emphasis role="strong">Munson E, Napierala M, Schell RF.</emphasis> 2013. Insights into trichomoniasis as a result of highly sensitive molecular diagnostics screening in a high-prevalence sexually transmitted infection community. <citetitle><emphasis>Expert Rev Anti Infect Ther</emphasis></citetitle> <emphasis role="strong">11:</emphasis>845–863.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0067" role="bibliographyEntry">
            <para>67.<emphasis role="strong">Centers for Disease Control and Prevention.</emphasis> 2021. Diagnoses of HIV infection in the United States and dependent areas 2019. <ulink url="http://www.cdc.gov/hiv/library/reports/hiv-surveillance/vol-32/index.html">www.cdc.gov/hiv/library/reports/hiv-surveillance/vol-32/index.html</ulink>. Accessed 28 July 2021.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0068" role="bibliographyEntry">
            <para>68.<emphasis role="strong">Haggerty CL, Gottlieb SL, Taylor BD, Low N, Xu F, Ness RB.</emphasis> 2010. Risk of sequelae after <citetitle><emphasis>Chlamydia trachomatis</emphasis></citetitle> genital infection in women. <citetitle><emphasis>J Infect Dis</emphasis></citetitle> <emphasis role="strong">201</emphasis>(Suppl 2)<emphasis role="strong">:</emphasis>S134–S155.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0069" role="bibliographyEntry">
            <para>69.<emphasis role="strong">Weström L, Joesoef R, Reynolds G, Hagdu A, Thompson SE.</emphasis> 1992. Pelvic inflammatory disease and fertility. A cohort study of 1,844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results. <citetitle><emphasis>Sex Transm Dis</emphasis></citetitle> <emphasis role="strong">19</emphasis><emphasis role="strong">:</emphasis>185–192.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0070" role="bibliographyEntry">
            <para>70.<emphasis role="strong">Chow JM, Yonekura ML, Richwald GA, Greenland S, Sweet RL, Schachter J.</emphasis> 1990. The association between <citetitle><emphasis>Chlamydia trachomatis</emphasis></citetitle> and ectopic pregnancy. A matched-pair, case-control study. <citetitle><emphasis>JAMA</emphasis></citetitle> <emphasis role="strong">263:</emphasis>3164–3167.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0071" role="bibliographyEntry">
            <para>71.<emphasis role="strong">Horne AW, Wheelhouse N, Horner PJ, Duncan WC.</emphasis> 2020. Association of past <citetitle><emphasis>Chlamydia trachomatis</emphasis></citetitle> infection with miscarriage. <citetitle><emphasis>JAMA Netw Open</emphasis></citetitle> <emphasis role="strong">3:</emphasis>e2018799.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0072" role="bibliographyEntry">
            <para>72.<emphasis role="strong">Baud D, Goy G, Jaton K, Osterheld MC, Blumer S, Borel N, Vial Y, Hohlfeld P, Pospischil A, Greub G.</emphasis> 2011. Role of <citetitle><emphasis>Chlamydia trachomatis</emphasis></citetitle> in miscarriage. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">17:</emphasis>1630–1635.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0073" role="bibliographyEntry">
            <para>73.<emphasis role="strong">Schachter J, Grossman M, Sweet RL, Holt J, Jordan C, Bishop E.</emphasis> 1986. Prospective study of perinatal transmission of <citetitle><emphasis>Chlamydia trachomatis. JAMA</emphasis></citetitle> <emphasis role="strong">255:</emphasis>3374–3377.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0074" role="bibliographyEntry">
            <para>74.<emphasis role="strong">Gottlieb SL, Xu F, Brunham RC.</emphasis> 2013. Screening and treating <citetitle><emphasis>Chlamydia trachomatis</emphasis></citetitle> genital infection to prevent pelvic inflammatory disease: interpretation of findings from randomized controlled trials. <citetitle><emphasis>Sex Transm Dis</emphasis></citetitle> <emphasis role="strong">40:</emphasis>97–102.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0075" role="bibliographyEntry">
            <para>75.<emphasis role="strong">Rekart ML, Gilbert M, Meza R, Kim PH, Chang M, Money DM, Brunham RC.</emphasis> 2013. <citetitle><emphasis>Chlamydia</emphasis></citetitle> public health programs and the epidemiology of pelvic inflammatory disease and ectopic pregnancy. <citetitle><emphasis>J Infect Dis</emphasis></citetitle> <emphasis role="strong">207:</emphasis>30–38.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0076" role="bibliographyEntry">
            <para>76.<emphasis role="strong">Nieuwenhuis RF, Ossewaarde JM, Götz HM, Dees J, Thio HB, Thomeer MG, den Hollander JC, Neumann MH, van der Meijden WI.</emphasis> 2004. Resurgence of lymphogranuloma venereum in Western Europe: an outbreak of <citetitle><emphasis>Chlamydia trachomatis</emphasis></citetitle> serovar l2 proctitis in The Netherlands among men who have sex with men. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">39:</emphasis>996–1003.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0077" role="bibliographyEntry">
            <para>77.<emphasis role="strong">Cole MJ, Field N, Pitt R, Amato-Gauci AJ, Begovac J, French PD, Keše D, Klavs I, Zidovec Lepej S, Pöcher K, Stary A, Schalk H, Spiteri G, Hughes G.</emphasis> 2020. Substantial underdiagnosis of lymphogranuloma venereum in men who have sex with men in Europe: preliminary findings from a multicentre surveillance pilot. <citetitle><emphasis>Sex Transm Infect</emphasis></citetitle> <emphasis role="strong">96</emphasis><emphasis role="strong">:</emphasis>137–142.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0078" role="bibliographyEntry">
            <para>78.<emphasis role="strong">Totten S, MacLean R, Payne E, Severini A.</emphasis> 2015. <citetitle><emphasis>Chlamydia</emphasis></citetitle> and lymphogranuloma venereum in Canada: 2003-2012 summary report. <citetitle><emphasis>Can Commun Dis Rep</emphasis></citetitle> <emphasis role="strong">41:</emphasis>20–25.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0079" role="bibliographyEntry">
            <para>79.<emphasis role="strong">Pathela P, Jamison K, Kornblum J, Quinlan T, Halse TA, Schillinger JA.</emphasis> 2019. Lymphogranuloma venereum: an increasingly common anorectal infection among men who have sex with men attending New York City sexual health clinics. <citetitle><emphasis>Sex Transm Dis</emphasis></citetitle> <emphasis role="strong">46</emphasis><emphasis role="strong">:</emphasis>e14–e17.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0080" role="bibliographyEntry">
            <para>80.<emphasis role="strong">Dang T, Jaton-Ogay K, Flepp M, Kovari H, Evison JM, Fehr J, Schmid P, Boffi El Amari E, Cavassini M, Odorico M, Tarr PE, Greub G.</emphasis> 2009. High prevalence of anorectal chlamydial infection in HIV-infected men who have sex with men in Switzerland. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">49:</emphasis>1532–1535.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0081" role="bibliographyEntry">
            <para>81.<emphasis role="strong">Spaargaren J, Fennema HS, Morré SA, de Vries HJ, Coutinho RA.</emphasis> 2005. New lymphogranuloma venereum <citetitle><emphasis>Chlamydia trachomatis</emphasis></citetitle> variant, Amsterdam. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">11:</emphasis>1090–1092.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0082" role="bibliographyEntry">
            <para>82.<emphasis role="strong">Spaargaren J, Schachter J, Moncada J, de Vries HJ, Fennema HS, Peña AS, Coutinho RA, Morré SA.</emphasis> 2005. Slow epidemic of lymphogranuloma venereum L2b strain. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">11:</emphasis>1787–1788.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0083" role="bibliographyEntry">
            <para>83.<emphasis role="strong">Grayston JT.</emphasis> 1989. <citetitle><emphasis>Chlamydia pneumoniae</emphasis></citetitle>, strain TWAR. <citetitle><emphasis>Chest</emphasis></citetitle> <emphasis role="strong">95</emphasis><emphasis role="strong">:</emphasis>664–669.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0084" role="bibliographyEntry">
            <para>84.<emphasis role="strong">Grayston JT.</emphasis> 1992. Infections caused by <citetitle><emphasis>Chlamydia pneumoniae</emphasis></citetitle> strain TWAR. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">15</emphasis><emphasis role="strong">:</emphasis>757–761.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0085" role="bibliographyEntry">
            <para>85.<emphasis role="strong">Kleemola M, Saikku P, Visakorpi R, Wang SP, Grayston JT.</emphasis> 1988. Epidemics of pneumonia caused by TWAR, a new <citetitle><emphasis>Chlamydia</emphasis></citetitle> organism, in military trainees in Finland. <citetitle><emphasis>J Infect Dis</emphasis></citetitle> <emphasis role="strong">157</emphasis><emphasis role="strong">:</emphasis>230–236.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0086" role="bibliographyEntry">
            <para>86.<emphasis role="strong">Senn L, Jaton K, Fitting JW, Greub G.</emphasis> 2011. Does respiratory infection due to <citetitle><emphasis>Chlamydia pneumoniae</emphasis></citetitle> still exist? <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">53</emphasis><emphasis role="strong">:</emphasis>847–848.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0087" role="bibliographyEntry">
            <para>87.<emphasis role="strong">Asner SA, Jaton K, Kyprianidou S, Nowak AM, Greub G.</emphasis> 2014. <citetitle><emphasis>Chlamydia pneumoniae</emphasis></citetitle>: possible association with asthma in children. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">58:</emphasis>1198–1199.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0088" role="bibliographyEntry">
            <para>88.<emphasis role="strong">Webley WC, Hahn DL.</emphasis> 2017. Infection-mediated asthma: etiology, mechanisms and treatment options, with focus on <citetitle><emphasis>Chlamydia pneumoniae</emphasis></citetitle> and macrolides. <citetitle><emphasis>Respir Res</emphasis></citetitle> <emphasis role="strong">18:</emphasis>98.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0089" role="bibliographyEntry">
            <para>89.<emphasis role="strong">Pittet LF, Bertelli C, Scherz V, Rochat I, Mardegan C, Brouillet R, Jaton K, Mornand A, Kaiser L, Posfay-Barbe K, Asner SA, Greub G.</emphasis> 2021. <citetitle><emphasis>Chlamydia pneumoniae</emphasis></citetitle> and <citetitle><emphasis>Mycoplasma pneumoniae</emphasis></citetitle> in children with cystic fibrosis: impact on bacterial respiratory microbiota diversity. <citetitle><emphasis>Pathog D</emphasis></citetitle><citetitle><emphasis>is</emphasis></citetitle> <emphasis role="strong">79:</emphasis>74.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0090" role="bibliographyEntry">
            <para>90.<emphasis role="strong">Saikku P.</emphasis> 2000. Epidemiologic association of <citetitle><emphasis>Chlamydia pneumoniae</emphasis></citetitle> and atherosclerosis: the initial serologic observation and more. <citetitle><emphasis>J Infect Dis</emphasis></citetitle> <emphasis role="strong">181</emphasis>(Suppl 3)<emphasis role="strong">:</emphasis>S411–S413.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0091" role="bibliographyEntry">
            <para>91.<emphasis role="strong">Grayston JT, Kronmal RA, Jackson LA, Parisi AF, Muhlestein JB, Cohen JD, Rogers WJ, Crouse JR, Borrowdale SL, Schron E, Knirsch C, ACES Investigators.</emphasis> 2005. Azithromycin for the secondary prevention of coronary events. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">352:</emphasis>1637–1645.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0092" role="bibliographyEntry">
            <anchor id="ch0083s0028s0003a0004"/>
            <para>92.<emphasis role="strong">Olson BJ, Treuting WL.</emphasis> 1944. An epidemic of a severe pneumonitis in the bayou region of Louisiana: I. Epidemiological study. <citetitle><emphasis>Public Health Rep</emphasis></citetitle> <emphasis role="strong">59:</emphasis>1299–1311.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0093" role="bibliographyEntry">
            <para>93.<emphasis role="strong">Wallensten A, Fredlund H, Runehagen A.</emphasis> 2014. Multiple human-to-human transmission from a severe case of psittacosis, Sweden, January-February 2013. <citetitle><emphasis>Euro Surveill</emphasis></citetitle> <emphasis role="strong">19:</emphasis>1–6.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0094" role="bibliographyEntry">
            <para>94.<emphasis role="strong">Irons JV, Sullivan TD, Rowen J.</emphasis> 1951. Outbreak of psittacosis (ornithosis) from working with turkeys or chickens. <citetitle><emphasis>Am J Public Health Nations Health</emphasis></citetitle> <emphasis role="strong">41</emphasis><emphasis role="strong">:</emphasis>931–937.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0095" role="bibliographyEntry">
            <para>95.<emphasis role="strong">Hedberg K, White KE, Forfang JC, Korlath JA, Friendshuh KA, Hedberg CW, MacDonald KL, Osterholm MT.</emphasis> 1989. An outbreak of psittacosis in Minnesota turkey industry workers: implications for modes of transmission and control. <citetitle><emphasis>Am J Epidemiol</emphasis></citetitle> <emphasis role="strong">130</emphasis><emphasis role="strong">:</emphasis>569–577.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0096" role="bibliographyEntry">
            <para>96.<emphasis role="strong">Shivaprasad HL, Carnaccini S, Bland M, Aaziz R, Moeller R, Laroucau K.</emphasis> 2015. An unusual outbreak of chlamydiosis in commercial turkeys involving the nasal glands. <citetitle><emphasis>Avian Dis</emphasis></citetitle> <emphasis role="strong">59</emphasis><emphasis role="strong">:</emphasis>315–322.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0097" role="bibliographyEntry">
            <para>97.<emphasis role="strong">Belchior E, Barataud D, Ollivier R, Capek I, Laroucau K, de Barbeyrac B, Hubert B.</emphasis> 2011. Psittacosis outbreak after participation in a bird fair, Western France, December 2008. <citetitle><emphasis>Epidemiol Infect</emphasis></citetitle> <emphasis role="strong">139:</emphasis>1637–1641.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0098" role="bibliographyEntry">
            <para>98.<emphasis role="strong">Polkinghorne A, Greub G.</emphasis> 2017. A new equine and zoonotic threat emerges from an old avian pathogen, <citetitle><emphasis>Chlamydia psittaci. Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">23</emphasis><emphasis role="strong">:</emphasis>693–694.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0099" role="bibliographyEntry">
            <para>99.<emphasis role="strong">Johnson FW, Matheson BA, Williams H, Laing AG, Jandial V, Davidson-Lamb R, Halliday GJ, Hobson D, Wong SY, Hadley KM.</emphasis> 1985. Abortion due to infection with <citetitle><emphasis>Chlamydia psittaci</emphasis></citetitle> in a sheep farmer’s wife. <citetitle><emphasis>Br Med J (Clin Res Ed)</emphasis></citetitle> <emphasis role="strong">290</emphasis><emphasis role="strong">:</emphasis>592–594.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0100" role="bibliographyEntry">
            <para>100.<emphasis role="strong">Ostler HB, Schachter J, Dawson CR.</emphasis> 1969. Acute follicular conjunctivitis of epizootic origin. Feline pneumontis. <citetitle><emphasis>Arch Ophthalmol</emphasis></citetitle> <emphasis role="strong">82</emphasis><emphasis role="strong">:</emphasis>587–591.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0101" role="bibliographyEntry">
            <para>101.<emphasis role="strong">Greub G, Boyadjiev I, La Scola B, Raoult D, Martin C.</emphasis> 2003. Serological hint suggesting that <citetitle><emphasis>Parachlamydiaceae</emphasis></citetitle> are agents of pneumonia in polytraumatized intensive care patients. <citetitle><emphasis>Ann N Y Acad Sci</emphasis></citetitle> <emphasis role="strong">990</emphasis><emphasis role="strong">:</emphasis>311–319.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0102" role="bibliographyEntry">
            <para>102.<emphasis role="strong">Marrie TJ, Raoult D, La Scola B, Birtles RJ, de Carolis E, Canadian Community-Acquired Pneumonia Study Group.</emphasis> 2001. <citetitle><emphasis>Legionella</emphasis></citetitle>-like and other amoebal pathogens as agents of community-acquired pneumonia. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">7:</emphasis>1026–1029.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0103" role="bibliographyEntry">
            <para>103.<emphasis role="strong">Greub G, Berger P, Papazian L, Raoult D.</emphasis> 2003. <citetitle><emphasis>Parachlamydiaceae</emphasis></citetitle> as rare agents of pneumonia. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">9</emphasis><emphasis role="strong">:</emphasis>755–756.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0104" role="bibliographyEntry">
            <para>104.<emphasis role="strong">Casson N, Posfay-Barbe KM, Gervaix A, Greub G.</emphasis> 2008. New diagnostic real-time PCR for specific detection of <citetitle><emphasis>Parachlamydia acanthamoebae</emphasis></citetitle> DNA in clinical samples. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">46:</emphasis>1491–1493.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0105" role="bibliographyEntry">
            <para>105.<emphasis role="strong">Borel N, Ruhl S, Casson N, Kaiser C, Pospischil A, Greub G.</emphasis> 2007. <citetitle><emphasis>Parachlamydia</emphasis></citetitle> spp. and related <citetitle><emphasis>Chlamydia</emphasis></citetitle>-like organisms and bovine abortion. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">13:</emphasis>1904–1907.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0106" role="bibliographyEntry">
            <para>106.<emphasis role="strong">Deuchande R, Gidlow J, Caldow G, Baily J, Longbottom D, Wheelhouse N, Borel N, Greub G.</emphasis> 2010. <citetitle><emphasis>Parachlamydia</emphasis></citetitle> involvement in bovine abortions in a beef herd in Scotland. <citetitle><emphasis>Vet Rec</emphasis></citetitle> <emphasis role="strong">166</emphasis><emphasis role="strong">:</emphasis>598–599.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0107" role="bibliographyEntry">
            <para>107.<emphasis role="strong">Richter M, Matheis F, Gönczi E, Aeby S, Spiess B, Greub G.</emphasis> 2010. <citetitle><emphasis>Parachlamydia acanthamoebae</emphasis></citetitle> in domestic cats with and without corneal disease. <citetitle><emphasis>Vet Ophthalmol</emphasis></citetitle> <emphasis role="strong">13</emphasis><emphasis role="strong">:</emphasis>235–237.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0108" role="bibliographyEntry">
            <para>108.<emphasis role="strong">Baud D, Thomas V, Arafa A, Regan L, Greub G.</emphasis> 2007. <citetitle><emphasis>Waddlia chondrophila</emphasis></citetitle>, a potential agent of human fetal death. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">13:</emphasis>1239–1243.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0109" role="bibliographyEntry">
            <para>109.<emphasis role="strong">Baud D, Goy G, Osterheld MC, Croxatto A, Borel N, Vial Y, Pospischil A, Greub G.</emphasis> 2014. Role of <citetitle><emphasis>Waddlia chondrophila</emphasis></citetitle> placental infection in miscarriage. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">20</emphasis><emphasis role="strong">:</emphasis>460–464.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0110" role="bibliographyEntry">
            <para>110.<emphasis role="strong">Pilloux L, LeRoy D, Brunel C, Roger T, Greub G.</emphasis> 2016. Mouse model of respiratory tract infection induced by <citetitle><emphasis>Waddlia chondrophila. PLoS One</emphasis></citetitle> <emphasis role="strong">11:</emphasis>e0150909.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0111" role="bibliographyEntry">
            <para>111.<emphasis role="strong">Niemi S, Greub G, Puolakkainen M.</emphasis> 2011. <citetitle><emphasis>Chlamydia</emphasis></citetitle>-related bacteria in respiratory samples in Finland. <citetitle><emphasis>Microbes Infect</emphasis></citetitle> <emphasis role="strong">13</emphasis><emphasis role="strong">:</emphasis>824–827.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0112" role="bibliographyEntry">
            <para>112.<emphasis role="strong">Kumar S, Kohlhoff SA, Gelling M, Roblin PM, Kutlin A, Kahane S, Friedman MG, Hammerschlag MR.</emphasis> 2005. Infection with <citetitle><emphasis>Simkania negevensis</emphasis></citetitle> in Brooklyn, New York. <citetitle><emphasis>Pediatr Infect Dis J</emphasis></citetitle> <emphasis role="strong">24</emphasis><emphasis role="strong">:</emphasis>989–992.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0113" role="bibliographyEntry">
            <para>113.<emphasis role="strong">Papp JR, Schachter J, Gaydos CA, Van Der Pol B, Centers for Disease Control and Prevention.</emphasis> 2014. Recommendations for the laboratory-based detection of <citetitle><emphasis>Chlamydia trachomatis</emphasis></citetitle> and Neisseria gonorrhoeae—2014. <citetitle><emphasis>MMWR Recomm Rep</emphasis></citetitle> <emphasis role="strong">63</emphasis>(RR-02)<emphasis role="strong">:</emphasis>1–19.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0114" role="bibliographyEntry">
            <para>114.<emphasis role="strong">Chernesky MA, Hook EW III, Martin DH, Lane J, Johnson R, Jordan JA, Fuller D, Willis DE, Fine PM, Janda WM, Schachter J.</emphasis> 2005. Women find it easy and prefer to collect their own vaginal swabs to diagnose <citetitle><emphasis>Chlamydia trachomatis</emphasis></citetitle> or <citetitle><emphasis>Neisseria gonorrhoeae</emphasis></citetitle> infections. <citetitle><emphasis>Sex Transm Dis</emphasis></citetitle> <emphasis role="strong">32</emphasis><emphasis role="strong">:</emphasis>729–733.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0115" role="bibliographyEntry">
            <para>115.<emphasis role="strong">Schachter J, Chernesky MA, Willis DE, Fine PM, Martin DH, Fuller D, Jordan JA, Janda W, Hook EW III.</emphasis> 2005. Vaginal swabs are the specimens of choice when screening for <citetitle><emphasis>Chlamydia trachomatis</emphasis></citetitle> and <citetitle><emphasis>Neisseria gonorrhoeae</emphasis></citetitle>: results from a multicenter evaluation of the APTIMA assays for both infections. <citetitle><emphasis>Sex Transm Dis</emphasis></citetitle> <emphasis role="strong">32</emphasis><emphasis role="strong">:</emphasis>725–728.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0116" role="bibliographyEntry">
            <para>116.<emphasis role="strong">Chernesky MA, Jang D, Portillo E, Smieja M, Gilchrist J, Ewert R, Macritchie C.</emphasis> 2013. Self-collected swabs of the urinary meatus diagnose more <citetitle><emphasis>Chlamydia trachomatis</emphasis></citetitle> and <citetitle><emphasis>Neisseria gonorrhoeae</emphasis></citetitle> infections than first catch urine from men. <citetitle><emphasis>Sex Transm Infect</emphasis></citetitle> <emphasis role="strong">89</emphasis><emphasis role="strong">:</emphasis>102–104.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0117" role="bibliographyEntry">
            <para>117.<emphasis role="strong">Chernesky M, Jang D, Portillo E, Chong S, Smieja M, Luinstra K, Petrich A, Macritchie C, Ewert R, Hayhoe B, Sarabia A, Thompson F.</emphasis> 2007. Abilities of APTIMA, AMPLICOR, and ProbeTec assays to detect <citetitle><emphasis>Chlamydia trachomatis</emphasis></citetitle> and <citetitle><emphasis>Neisseria gonorrhoeae</emphasis></citetitle> in PreservCyt ThinPrep liquid-based Pap samples. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">45:</emphasis>2355–2358.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0118" role="bibliographyEntry">
            <para>118.<emphasis role="strong">Gaydos CA, Dwyer K, Barnes M, Rizzo-Price PA, Wood BJ, Flemming T, Hogan MT.</emphasis> 2006. Internet-based screening for <citetitle><emphasis>Chlamydia trachomatis</emphasis></citetitle> to reach non-clinic populations with mailed self-administered vaginal swabs. <citetitle><emphasis>Sex Transm Dis</emphasis></citetitle> <emphasis role="strong">33</emphasis><emphasis role="strong">:</emphasis>451–457.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0119" role="bibliographyEntry">
            <para>119.<emphasis role="strong">Michel CE, Sonnex C, Carne CA, White JA, Magbanua JP, Nadala EC Jr, Lee HH.</emphasis> 2007. <citetitle><emphasis>Chlamydia trachomatis</emphasis></citetitle> load at matched anatomic sites: implications for screening strategies. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">45:</emphasis>1395–1402.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0120" role="bibliographyEntry">
            <para>120.<emphasis role="strong">Workowski KA.</emphasis> 2015. Centers for Disease Control and Prevention sexually transmitted diseases treatment guidelines. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">61</emphasis>(Suppl 8)<emphasis role="strong">:</emphasis>S759–S762.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0121" role="bibliographyEntry">
            <para>121.<emphasis role="strong">Chen CY, Chi KH, Alexander S, Martin IM, Liu H, Ison CA, Ballard RC.</emphasis> 2007. The molecular diagnosis of lymphogranuloma venereum: evaluation of a real-time multiplex polymerase chain reaction test using rectal and urethral specimens. <citetitle><emphasis>Sex Transm Dis</emphasis></citetitle> <emphasis role="strong">34</emphasis><emphasis role="strong">:</emphasis>451–455.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0122" role="bibliographyEntry">
            <para>122.<emphasis role="strong">Kent CK, Chaw JK, Wong W, Liska S, Gibson S, Hubbard G, Klausner JD.</emphasis> 2005. Prevalence of rectal, urethral, and pharyngeal <citetitle><emphasis>Chlamydia</emphasis></citetitle> and gonorrhea detected in 2 clinical settings among men who have sex with men: San Francisco, California, 2003. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">41:</emphasis>67–74.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0123" role="bibliographyEntry">
            <para>123.<emphasis role="strong">Schachter J, Philip SS.</emphasis> 2011. Testing men who have sex with men for urethral infection with <citetitle><emphasis>Chlamydia trachomatis</emphasis></citetitle> and <citetitle><emphasis>Neisseria gonorrhoeae</emphasis></citetitle> is only half the job, and we need the right tools. <citetitle><emphasis>Sex Transm Dis</emphasis></citetitle> <emphasis role="strong">38</emphasis><emphasis role="strong">:</emphasis>925–927.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0124" role="bibliographyEntry">
            <para>124.<emphasis role="strong">Munson E, Reynoso A, Pass M, Buehler K, Ryan D, Clifford A, Morgan E, Mustanski B.</emphasis> 2020. Comprehensive molecular screening in a cohort of young men who have sex with men and transgender women: effect of additive rectal specimen source collection and analyte testing. <citetitle><emphasis>Sex Transm Dis</emphasis></citetitle> <emphasis role="strong">47</emphasis><emphasis role="strong">:</emphasis>748–753.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0125" role="bibliographyEntry">
            <para>125.<emphasis role="strong">College of American Pathologists.</emphasis> 2022. C. trachomatis <citetitle><emphasis>and</emphasis></citetitle> N. gonorrhoeae <citetitle><emphasis>by Nucleic Acid Amplification Survey HC6.</emphasis></citetitle> College of American Pathologists, Northfield, IL.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0126" role="bibliographyEntry">
            <para>126.<emphasis role="strong">Schachter J, Chow JM, Howard H, Bolan G, Moncada J.</emphasis> 2006. Detection of <citetitle><emphasis>Chlamydia trachomatis</emphasis></citetitle> by nucleic acid amplification testing: our evaluation suggests that CDC-recommended approaches for confirmatory testing are ill-advised. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">44:</emphasis>2512–2517.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0127" role="bibliographyEntry">
            <para>127.<emphasis role="strong">Schachter J, Moncada J, Liska S, Shayevich C, Klausner JD.</emphasis> 2008. Nucleic acid amplification tests in the diagnosis of chlamydial and gonococcal infections of the oropharynx and rectum in men who have sex with men. <citetitle><emphasis>Sex Transm Dis</emphasis></citetitle> <emphasis role="strong">35</emphasis><emphasis role="strong">:</emphasis>637–642.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0128" role="bibliographyEntry">
            <anchor id="ch0083s0028s0003a0005"/>
            <para>128.<emphasis role="strong">Van Der Pol B, Chernesky M, Gaydos CA, Hook EW III, Joseph AM, Christensen K, Arcenas R, Boutwell A, Wiesenfeld HC, Taylor SN, Mayer KH, Golden MR, Moncada J, Jang D, Schachter J, ExGen Study Group Kristal Aaron University of Alabama at Birmingham, Paula Dixon University of Alabama at Birmingham, Karen Eckert Becton, Dickinson and Company, BD Life Sciences – Integrated Diagnostic Solutions, Shiaolan Y. Ho Abbott, Medical Affairs, Michael Lewinski Roche Diagnostic Solutions, Kevin Luk Roche Diagnostic Solutions, Carl McGill Abbott, Medical Affairs, Shiv Parmar Becton, Dickinson and Company, BD Life Sciences – Integrated Diagnostic Solutions, James Price Becton, Dickinson and Company, BD Life Sciences – Integrated Diagnostic Solutions, Charles Rivers University of Alabama at Birmingham.</emphasis> 2022. Multicenter comparison of nucleic acid amplification tests for the diagnosis of rectal and oropharyngeal <citetitle><emphasis>Chlamydia trachomatis</emphasis></citetitle> and <citetitle><emphasis>Neisseria gonorrhoeae</emphasis></citetitle> infections. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">60:</emphasis>e01363-21.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0129" role="bibliographyEntry">
            <para>129.<emphasis role="strong">Napierala M, Munson E, Munson KL, Kramme T, Miller C, Burtch J, Olson R, Hryciuk JE.</emphasis> 2011. Three-year history of transcription-mediated amplification-based <citetitle><emphasis>Trichomonas vaginalis</emphasis></citetitle> analyte-specific reagent testing in a subacute care patient population. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">49:</emphasis>4190–4194.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0130" role="bibliographyEntry">
            <para>130.<emphasis role="strong">Munson E, Bykowski H, Munson KL, Napierala M, Reiss PJ, Schell RF, Hryciuk JE.</emphasis> 2016. Clinical laboratory assessment of <citetitle><emphasis>Mycoplasma genitalium</emphasis></citetitle> transcription-mediated amplification using primary female urogenital specimens. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">54</emphasis><emphasis role="strong">:</emphasis>432–438.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0131" role="bibliographyEntry">
            <para>131.<emphasis role="strong">Ripa T, Nilsson PA.</emphasis> 2007. A <citetitle><emphasis>Chlamydia trachomatis</emphasis></citetitle> strain with a 377-bp deletion in the cryptic plasmid causing false-negative nucleic acid amplification tests. <citetitle><emphasis>Sex Transm Dis</emphasis></citetitle> <emphasis role="strong">34</emphasis><emphasis role="strong">:</emphasis>255–256.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0132" role="bibliographyEntry">
            <para>132.<emphasis role="strong">Persson K, Hammas B, Janson H, Bjartling C, Dillner J, Dillner L.</emphasis> 2012. Decline of the new Swedish variant of <citetitle><emphasis>Chlamydia trachomatis</emphasis></citetitle> after introduction of appropriate testing. <citetitle><emphasis>Sex Transm Infect</emphasis></citetitle> <emphasis role="strong">88</emphasis><emphasis role="strong">:</emphasis>451–455.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0133" role="bibliographyEntry">
            <para>133.<emphasis role="strong">Kacena KA, Quinn SB, Howell MR, Madico GE, Quinn TC, Gaydos CA.</emphasis> 1998. Pooling urine samples for ligase chain reaction screening for genital <citetitle><emphasis>Chlamydia trachomatis</emphasis></citetitle> infection in asymptomatic women. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">36</emphasis><emphasis role="strong">:</emphasis>481–485.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0134" role="bibliographyEntry">
            <para>134.<emphasis role="strong">Moncada J, Schachter J, Hook EW III, Ferrero D, Gaydos C, Quinn TC, Willis D, Weissfeld A, Martin DH.</emphasis> 2004. The effect of urine testing in evaluations of the sensitivity of the Gen-Probe Aptima Combo 2 assay on endocervical swabs for <citetitle><emphasis>Chlamydia trachomatis</emphasis></citetitle> and N<citetitle><emphasis>eisseria gonorrhoeae</emphasis></citetitle>: the infected patient standard reduces sensitivity of single site evaluation. <citetitle><emphasis>Sex Transm Dis</emphasis></citetitle> <emphasis role="strong">31</emphasis><emphasis role="strong">:</emphasis>273–277.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0135" role="bibliographyEntry">
            <para>135.<emphasis role="strong">Chernesky M, Smieja M, Schachter J, Summersgill J, Schindler L, Solomon N, Campbell K, Campbell L, Cappuccio A, Gaydos C, Chong S, Moncada J, Phillips J, Jang D, Wood BJ, Petrich A, Hammerschlag M, Cerney M, Mahony J.</emphasis> 2002. Comparison of an industry-derived LCx <citetitle><emphasis>Chlamydia pneumoniae</emphasis></citetitle> PCR research kit to in-house assays performed in five laboratories. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">40:</emphasis>2357–2362.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0136" role="bibliographyEntry">
            <para>136.<emphasis role="strong">Opota O, Jaton K, Branley J, Vanrompay D, Erard V, Borel N, Longbottom D, Greub G.</emphasis> 2015. Improving the molecular diagnosis of <citetitle><emphasis>Chlamydia psittaci</emphasis></citetitle> and <citetitle><emphasis>Chlamydia abortus</emphasis></citetitle> infection with a species-specific duplex real-time PCR. <citetitle><emphasis>J Med Microbiol</emphasis></citetitle> <emphasis role="strong">64:</emphasis>1174–1185.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0137" role="bibliographyEntry">
            <para>137.<emphasis role="strong">Goy G, Croxatto A, Posfay-Barbe KM, Gervaix A, Greub G.</emphasis> 2009. Development of a real-time PCR for the specific detection of <citetitle><emphasis>Waddlia chondrophila</emphasis></citetitle> in clinical samples. <citetitle><emphasis>Eur J Clin Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">28:</emphasis>1483–1486.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0138" role="bibliographyEntry">
            <para>138.<emphasis role="strong">Schachter J.</emphasis> 1997. DFA, EIA, PCR, LCR and other technologies: what tests should be used for diagnosis of <citetitle><emphasis>Chlamydia</emphasis></citetitle> infections? <citetitle><emphasis>Immunol Invest</emphasis></citetitle> <emphasis role="strong">26</emphasis><emphasis role="strong">:</emphasis>157–161.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0139" role="bibliographyEntry">
            <para>139.<emphasis role="strong">Moncada J, Schachter J, Bolan G, Engelman J, Howard L, Mushahwar I, Ridgway G, Mumtaz G, Stamm W, Clark A.</emphasis> 1990. Confirmatory assay increases specificity of the chlamydiazyme test for <citetitle><emphasis>Chlamydia trachomatis</emphasis></citetitle> infection of the cervix. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">28:</emphasis>1770–1773.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0140" role="bibliographyEntry">
            <para>140.<emphasis role="strong">Giménez DF.</emphasis> 1964. Staining rickettsiae in yolk-sac cultures. <citetitle><emphasis>Stain Technol</emphasis></citetitle> <emphasis role="strong">39</emphasis><emphasis role="strong">:</emphasis>135–140.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0141" role="bibliographyEntry">
            <para>141.<emphasis role="strong">Donders GG, van Gerven V, de Wet HG, van Straten AM, de Boer F.</emphasis> 1996. Rapid antigen tests for <citetitle><emphasis>Neisseria gonorrhoeae</emphasis></citetitle> and <citetitle><emphasis>Chlamydia trachomatis</emphasis></citetitle> are not accurate for screening women with disturbed vaginal lactobacillary flora. <citetitle><emphasis>Scand J Infect Dis</emphasis></citetitle> <emphasis role="strong">28</emphasis><emphasis role="strong">:</emphasis>559–562.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0142" role="bibliographyEntry">
            <para>142.<emphasis role="strong">van Dommelen L, van Tiel FH, Ouburg S, Brouwers EE, Terporten PH, Savelkoul PH, Morré SA, Bruggeman CA, Hoebe CJ.</emphasis> 2010. Alarmingly poor performance in <citetitle><emphasis>Chlamydia trachomatis</emphasis></citetitle> point-of-care testing. <citetitle><emphasis>Sex Transm Infect</emphasis></citetitle> <emphasis role="strong">86</emphasis><emphasis role="strong">:</emphasis>355–359.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0143" role="bibliographyEntry">
            <para>143.<emphasis role="strong">Schwebke JR, Sadler R, Sutton JM, Hook EW III.</emphasis> 1997. Positive screening tests for gonorrhea and chlamydial infection fail to lead consistently to treatment of patients attending a sexually transmitted disease clinic. <citetitle><emphasis>Sex Transm Dis</emphasis></citetitle> <emphasis role="strong">24</emphasis><emphasis role="strong">:</emphasis>181–184.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0144" role="bibliographyEntry">
            <para>144.<emphasis role="strong">Gift TL, Pate MS, Hook EW III, Kassler WJ.</emphasis> 1999. The rapid test paradox: when fewer cases detected lead to more cases treated: a decision analysis of tests for <citetitle><emphasis>Chlamydia trachomatis. Sex Transm Dis</emphasis></citetitle> <emphasis role="strong">26</emphasis><emphasis role="strong">:</emphasis>232–240.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0145" role="bibliographyEntry">
            <para>145.<emphasis role="strong">Soler M, Belushkin A, Cavallini A, Kebbi-Beghdadi C, Greub G, Altug H.</emphasis> 2017. Multiplexed nanoplasmonic biosensor for one-step simultaneous detection of <citetitle><emphasis>Chlamydia trachomatis</emphasis></citetitle> and <citetitle><emphasis>Neisseria gonorrhoeae</emphasis></citetitle> in urine. <citetitle><emphasis>Biosens Bioelectron</emphasis></citetitle> <emphasis role="strong">94</emphasis><emphasis role="strong">:</emphasis>560–567.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0146" role="bibliographyEntry">
            <para>146.<emphasis role="strong">Jaton K, Bille J, Greub G.</emphasis> 2006. A novel real-time PCR to detect <citetitle><emphasis>Chlamydia trachomatis</emphasis></citetitle> in first-void urine or genital swabs. <citetitle><emphasis>J Med Microbiol</emphasis></citetitle> <emphasis role="strong">55:</emphasis>1667–1674.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0147" role="bibliographyEntry">
            <para>147.<emphasis role="strong">Pike RM.</emphasis> 1976. Laboratory-associated infections: summary and analysis of 3921 cases. <citetitle><emphasis>Health Lab Sci</emphasis></citetitle> <emphasis role="strong">13</emphasis><emphasis role="strong">:</emphasis>105–114.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0148" role="bibliographyEntry">
            <para>148.<emphasis role="strong">Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I, Reno H, Zenilman JM, Bolan GA.</emphasis> 2021. Sexually transmitted infections treatment guidelines, 2021. <citetitle><emphasis>MMWR Recomm Rep</emphasis></citetitle> <emphasis role="strong">70</emphasis>(RR-04)<emphasis role="strong">:</emphasis>1–187.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0149" role="bibliographyEntry">
            <para>149.<emphasis role="strong">Ripa KT, Mårdh PA.</emphasis> 1977. Cultivation of <citetitle><emphasis>Chlamydia trachomatis</emphasis></citetitle> in cycloheximide-treated McCoy cells. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">6</emphasis><emphasis role="strong">:</emphasis>328–331.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0150" role="bibliographyEntry">
            <para>150.<emphasis role="strong">Quint KD, Bom RJ, Bruisten SM, van Doorn LJ, Nassir Hajipour N, Melchers WJ, de Vries HJ, Morre SA, Quint WG.</emphasis> 2010. Comparison of three genotyping methods to identify <citetitle><emphasis>Chlamydia trachomatis</emphasis></citetitle> genotypes in positive men and women. <citetitle><emphasis>Mol Cell Probes</emphasis></citetitle> <emphasis role="strong">24</emphasis><emphasis role="strong">:</emphasis>266–270.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0151" role="bibliographyEntry">
            <para>151.<emphasis role="strong">Schachter J, Grossman M, Azimi PH.</emphasis> 1982. Serology of <citetitle><emphasis>Chlamydia trachomatis</emphasis></citetitle> in infants. <citetitle><emphasis>J Infect Dis</emphasis></citetitle> <emphasis role="strong">146</emphasis><emphasis role="strong">:</emphasis>530–535.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0152" role="bibliographyEntry">
            <para>152.<emphasis role="strong">Martin DL, Bid R, Sandi F, Goodhew EB, Massae PA, Lasway A, Philippin H, Makupa W, Molina S, Holland MJ, Mabey DC, Drakeley C, Lammie PJ, Solomon AW.</emphasis> 2015. Serology for trachoma surveillance after cessation of mass drug administration. <citetitle><emphasis>PLoS Negl Trop Dis</emphasis></citetitle> <emphasis role="strong">9:</emphasis>e0003555.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0153" role="bibliographyEntry">
            <para>153.<emphasis role="strong">Wang SP, Grayston JT.</emphasis> 1970. Immunologic relationship between genital TRIC, lymphogranuloma venereum, and related organisms in a new microtiter indirect immunofluorescence test. <citetitle><emphasis>Am J Ophthalmol</emphasis></citetitle> <emphasis role="strong">70</emphasis><emphasis role="strong">:</emphasis>367–374.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0154" role="bibliographyEntry">
            <para>154.<emphasis role="strong">Corsaro D, Greub G.</emphasis> 2006. Pathogenic potential of novel chlamydiae and diagnostic approaches to infections due to these obligate intracellular bacteria. <citetitle><emphasis>Clin Microbiol Rev</emphasis></citetitle> <emphasis role="strong">19</emphasis><emphasis role="strong">:</emphasis>283–297.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0155" role="bibliographyEntry">
            <para>155.<emphasis role="strong">Baud D, Zufferey J, Hohlfeld P, Greub G.</emphasis> 2014. Performance of an automated multiplex immunofluorescence assay for detection of <citetitle><emphasis>Chlamydia trachomatis</emphasis></citetitle> immunoglobulin G. <citetitle><emphasis>Diagn Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">78</emphasis><emphasis role="strong">:</emphasis>217–219.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0156" role="bibliographyEntry">
            <para>156.<emphasis role="strong">Morré SA, Munk C, Persson K, Krüger-Kjaer S, van Dijk R, Meijer CJ, van Den Brule AJ.</emphasis> 2002. Comparison of three commercially available peptide-based immunoglobulin G (IgG) and IgA assays to microimmunofluorescence assay for detection of <citetitle><emphasis>Chlamydia trachomatis</emphasis></citetitle> antibodies. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">40</emphasis><emphasis role="strong">:</emphasis>584–587.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0157" role="bibliographyEntry">
            <para>157.<emphasis role="strong">Baud D, Regan L, Greub G.</emphasis> 2010. Comparison of five commercial serological tests for the detection of anti-<citetitle><emphasis>Chlamydia trachomatis</emphasis></citetitle> antibodies. <citetitle><emphasis>Eur J Clin Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">29</emphasis><emphasis role="strong">:</emphasis>669–675.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0158" role="bibliographyEntry">
            <para>158.<emphasis role="strong">Wills GS, Horner PJ, Reynolds R, Johnson AM, Muir DA, Brown DW, Winston A, Broadbent AJ, Parker D, McClure MO.</emphasis> 2009. Pgp3 antibody enzyme-linked immunosorbent assay, a sensitive and specific assay for seroepidemiological analysis of <citetitle><emphasis>Chlamydia trachomatis</emphasis></citetitle> infection. <citetitle><emphasis>Clin Vaccine Immunol</emphasis></citetitle> <emphasis role="strong">16</emphasis><emphasis role="strong">:</emphasis>835–843.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0159" role="bibliographyEntry">
            <anchor id="ch0083s0028s0003a0006"/>
            <para>159.<emphasis role="strong">Kebbi-Beghdadi C, Lienard J, Uyttebroeck F, Baud D, Riederer BM, Greub G.</emphasis> 2012. Identification of immunogenic proteins of <citetitle><emphasis>Waddlia chondrophila. PLoS One</emphasis></citetitle> <emphasis role="strong">7:</emphasis>e28605.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0160" role="bibliographyEntry">
            <para>160.<emphasis role="strong">Lienard J, Croxatto A, Gervaix A, Posfay-Barbe K, Baud D, Kebbi-Beghdadi C, Greub G.</emphasis> 2014. Undressing of Waddlia chondrophila to enrich its outer membrane proteins to develop a new species-specific ELISA. New Microbes New Infect <emphasis role="strong">2</emphasis>:13–24.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0161" role="bibliographyEntry">
            <para>161.<emphasis role="strong">Pickering H, Chernet A, Sata E, Zerihun M, Williams CA, Breuer J, Nute AW, Haile M, Zeru T, Tadesse Z, Bailey RL, Callahan EK, Holland MJ, Nash SD.</emphasis> 2022. Genomics of ocular <citetitle><emphasis>Chlamydia trachomatis</emphasis></citetitle> after 5 years of SAFE interventions for trachoma in Amhara, Ethiopia. <citetitle><emphasis>J Infect Dis</emphasis></citetitle> <emphasis role="strong">225:</emphasis>994–1004.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0162" role="bibliographyEntry">
            <para>162.<emphasis role="strong">Donati M, Di Francesco A, D’Antuono A, Delucca F, Shurdhi A, Moroni A, Baldelli R, Cevenini R.</emphasis> 2010. In vitro activities of several antimicrobial agents against recently isolated and genotyped <citetitle><emphasis>Chlamydia trachomatis</emphasis></citetitle> urogenital serovars D through K. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">54:</emphasis>5379–5380.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0163" role="bibliographyEntry">
            <para>163.<emphasis role="strong">Pitt R, Alexander S, Ison C, Horner P, Hathorn E, Goold P, Woodford N, Cole MJ.</emphasis> 2018. Phenotypic antimicrobial susceptibility testing of <citetitle><emphasis>Chlamydia trachomatis</emphasis></citetitle> isolates from patients with persistent or successfully treated infections. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">73</emphasis><emphasis role="strong">:</emphasis>680–686.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0164" role="bibliographyEntry">
            <para>164.<emphasis role="strong">Goy G, Greub G.</emphasis> 2009. Antibiotic susceptibility of <citetitle><emphasis>Waddlia chondrophila</emphasis></citetitle> in <citetitle><emphasis>Acanthamoeba castellanii</emphasis></citetitle> amoebae. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">53:</emphasis>2663–2666.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0165" role="bibliographyEntry">
            <para>165.<emphasis role="strong">Casson N, Greub G.</emphasis> 2006. Resistance of different <citetitle><emphasis>Chlamydia</emphasis></citetitle>-like organisms to quinolones and mutations in the quinoline resistance-determining region of the DNA gyrase A- and topoisomerase-encoding genes. <citetitle><emphasis>Int J Antimicrob Agents</emphasis></citetitle> <emphasis role="strong">27</emphasis><emphasis role="strong">:</emphasis>541–544.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0166" role="bibliographyEntry">
            <para>166.<emphasis role="strong">Morrissey I, Salman H, Bakker S, Farrell D, Bébéar CM, Ridgway G.</emphasis> 2002. Serial passage of <citetitle><emphasis>Chlamydia</emphasis></citetitle> spp. in sub-inhibitory fluoroquinolone concentrations. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">49</emphasis><emphasis role="strong">:</emphasis>757–761.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0167" role="bibliographyEntry">
            <para>167.<emphasis role="strong">Jones RB, Ridgway GL, Boulding S, Hunley KL.</emphasis> 1983. In vitro activity of rifamycins alone and in combination with other antibiotics against <citetitle><emphasis>Chlamydia trachomatis. Rev Infect Dis</emphasis></citetitle> <emphasis role="strong">5</emphasis>(Suppl 3)<emphasis role="strong">:</emphasis>S556–S561.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0168" role="bibliographyEntry">
            <para>168.<emphasis role="strong">Scherler A, Jacquier N, Kebbi-Beghdadi C, Greub G.</emphasis> 2020. Diverse stress-inducing treatments cause distinct aberrant body morphologies in the <citetitle><emphasis>Chlamydia</emphasis></citetitle>-related bacterium, <citetitle><emphasis>Waddlia chondrophila. Microorganisms</emphasis></citetitle> <emphasis role="strong">8:</emphasis>89.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0169" role="bibliographyEntry">
            <para>169.<emphasis role="strong">Dize L, West S, Williams JA, Van Der Pol B, Quinn TC, Gaydos CA.</emphasis> 2013. Comparison of the Abbott m2000 RealTime CT assay and the Cepheid GeneXpert CT/NG assay to the Roche Amplicor CT assay for detection of <citetitle><emphasis>Chlamydia trachomatis</emphasis></citetitle> in ocular samples from Tanzania. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">51:</emphasis>1611–1613.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0170" role="bibliographyEntry">
            <para>170.<emphasis role="strong">Gaydos CA, Cartwright CP, Colaninno P, Welsch J, Holden J, Ho SY, Webb EM, Anderson C, Bertuzis R, Zhang L, Miller T, Leckie G, Abravaya K, Robinson J.</emphasis> 2010. Performance of the Abbott RealTime CT/NG for detection of <citetitle><emphasis>Chlamydia trachomatis</emphasis></citetitle> and <citetitle><emphasis>Neisseria gonorrhoeae. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">48:</emphasis>3236–3243.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0171" role="bibliographyEntry">
            <para>171.<emphasis role="strong">Herrmann B, Malm K.</emphasis> 2021. Comparison between Abbott m2000 RealTime and Alinity m STI systems for detection of <citetitle><emphasis>Chlamydia trachomatis</emphasis></citetitle>, <citetitle><emphasis>Neisseria gonorrhoeae</emphasis></citetitle>, and <citetitle><emphasis>Mycoplasma genitalium. Eur J Clin Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">40:</emphasis>2217–2220.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0172" role="bibliographyEntry">
            <para>172.<emphasis role="strong">Williams JA, Eddleman L, Pantone A, Martinez R, Young S, Van Der Pol B.</emphasis> 2014. Time-motion analysis of four automated systems for the detection of <citetitle><emphasis>Chlamydia trachomatis</emphasis></citetitle> and <citetitle><emphasis>Neisseria gonorrhoeae</emphasis></citetitle> by nucleic acid amplification testing. <citetitle><emphasis>J Lab Autom</emphasis></citetitle> <emphasis role="strong">19</emphasis><emphasis role="strong">:</emphasis>423–426.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0173" role="bibliographyEntry">
            <para>173.<emphasis role="strong">Ratnam S, Jang D, Gilchrist J, Smieja M, Poirier A, Hatchette T, Flandin JF, Chernesky M.</emphasis> 2014. Workflow and maintenance characteristics of five automated laboratory instruments for the diagnosis of sexually transmitted infections. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">52:</emphasis>2299–2304.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0174" role="bibliographyEntry">
            <para>174.<emphasis role="strong">Taylor SN, Van Der Pol B, Lillis R, Hook EW III, Lebar W, Davis T, Fuller D, Mena L, Fine P, Gaydos CA, Martin DH.</emphasis> 2011. Clinical evaluation of the BD ProbeTec™ <citetitle><emphasis>Chlamydia trachomatis</emphasis></citetitle> Qx amplified DNA assay on the BD Viper™ system with XTR™ technology. <citetitle><emphasis>Sex Transm Dis</emphasis></citetitle> <emphasis role="strong">38</emphasis><emphasis role="strong">:</emphasis>603–609.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0175" role="bibliographyEntry">
            <para>175.<emphasis role="strong">Taylor SN, Liesenfeld O, Lillis RA, Body BA, Nye M, Williams J, Eisenhut C, Hook EW III, Van Der Pol B.</emphasis> 2012. Evaluation of the Roche cobas CT/NG test for detection of <citetitle><emphasis>Chlamydia trachomatis</emphasis></citetitle> and <citetitle><emphasis>Neisseria gonorrhoeae</emphasis></citetitle> in male urine. <citetitle><emphasis>Sex Transm Dis</emphasis></citetitle> <emphasis role="strong">39</emphasis><emphasis role="strong">:</emphasis>543–549.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0176" role="bibliographyEntry">
            <para>176.<emphasis role="strong">Van Der Pol B, Liesenfeld O, Williams JA, Taylor SN, Lillis RA, Body BA, Nye M, Eisenhut C, Hook EW III.</emphasis> 2012. Performance of the cobas CT/NG test compared to the Aptima AC2 and Viper CTQ/GCQ assays for detection of <citetitle><emphasis>Chlamydia trachomatis</emphasis></citetitle> and <citetitle><emphasis>Neisseria gonorrhoeae. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">50:</emphasis>2244–2249.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0177" role="bibliographyEntry">
            <para>177.<emphasis role="strong">Gaydos CA, Van Der Pol B, Jett-Goheen M, Barnes M, Quinn N, Clark C, Daniel GE, Dixon PB, Hook EW III, CT/NG Study Group.</emphasis> 2013. Performance of the Cepheid CT/NG Xpert Rapid PCR test for detection of <citetitle><emphasis>Chlamydia trachomatis</emphasis></citetitle> and <citetitle><emphasis>Neisseria gonorrhoeae. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">51:</emphasis>1666–1672.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0178" role="bibliographyEntry">
            <para>178.<emphasis role="strong">Van Der Pol B, Williams JA, Fuller D, Taylor SN, Hook EW III.</emphasis> 2016. Combined testing for chlamydia, gonorrhea, and trichomonas by use of the BD Max CT/GC/TV assay with genitourinary specimen types. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">55</emphasis><emphasis role="strong">:</emphasis>155–164.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0179" role="bibliographyEntry">
            <para>179.<emphasis role="strong">Footman A, Dionne-Odom J, Aaron KJ, Raper JL, Van Der Pol B.</emphasis> 2020. Performance of 4 molecular assays for detection of chlamydia and gonorrhea in a sample of human immunodeficiency virus-positive men who have sex with men. <citetitle><emphasis>Sex Transm Dis</emphasis></citetitle> <emphasis role="strong">47</emphasis><emphasis role="strong">:</emphasis>158–161.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0180" role="bibliographyEntry">
            <para>180.<emphasis role="strong">Jang D, Ratnam S, Gilchrist J, Arias M, Smieja M, Mayne D, Chernesky MA.</emphasis> 2016. Comparison of workflow, maintenance, and consumables in the GeneXpert Infinity 80 and Panther instruments while testing for <citetitle><emphasis>Chlamydia trachomatis</emphasis></citetitle> and <citetitle><emphasis>Neisseria gonorrhoeae. Sex Transm Dis</emphasis></citetitle> <emphasis role="strong">43</emphasis><emphasis role="strong">:</emphasis>377–381.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0181" role="bibliographyEntry">
            <para>181.<emphasis role="strong">Frontzek A, Aretzweiler G, Winkens D, Duncan D, Marlowe EM.</emphasis> 2019. High-volume workflow and performance comparisons for <citetitle><emphasis>Chlamydia trachomatis</emphasis></citetitle> and <citetitle><emphasis>Neisseria gonorrhoeae</emphasis></citetitle> testing using automated molecular platforms. <citetitle><emphasis>BMC Infect Dis</emphasis></citetitle> <emphasis role="strong">19:</emphasis>797.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0182" role="bibliographyEntry">
            <para>182.<emphasis role="strong">Barrientos-Durán A, de Salazar A, Fuentes-López A, Serrano-Conde E, Espadafor B, Chueca N, Álvarez-Estévez M, Garcia F.</emphasis> 2021. Comparison between Aptima assays (Hologic) and the CoBAS 6800 system (Roche) for the diagnosis of sexually transmitted infections caused by <citetitle><emphasis>Chlamydia trachomatis</emphasis></citetitle>, <citetitle><emphasis>Neisseria gonorrhoeae</emphasis></citetitle>, and <citetitle><emphasis>Mycoplasma genitalium. Eur J Clin Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">40:</emphasis>1337–1342.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0183" role="bibliographyEntry">
            <para>183.<emphasis role="strong">Van Der Pol B, Taylor SN, Liesenfeld O, Williams JA, Hook EW III.</emphasis> 2013. Vaginal swabs are the optimal specimen for detection of genital <citetitle><emphasis>Chlamydia trachomatis</emphasis></citetitle> or <citetitle><emphasis>Neisseria gonorrhoeae</emphasis></citetitle> using the Cobas 4800 CT/NG test. <citetitle><emphasis>Sex Transm Dis</emphasis></citetitle> <emphasis role="strong">40</emphasis><emphasis role="strong">:</emphasis>247–250.</para>
          </listitem>
          <listitem id="ch0083s0028s0003li0184" role="bibliographyEntry">
            <para>184.<emphasis role="strong">Nye MB, Osiecki J, Lewinski M, Liesenfeld O, Young S, Taylor SN, Lillis RA, Body BA, Eisenhut C, Hook EW Iii, Van Der Pol B.</emphasis> 2019. Detection of <citetitle><emphasis>Chlamydia trachomatis</emphasis></citetitle> and <citetitle><emphasis>Neisseria gonorrhoeae</emphasis></citetitle> with the cobas CT/NG v2.0 test: performance compared with the BD ProbeTec CT Q<superscript>x</superscript> and GC Q<superscript>x</superscript> amplified DNA and Aptima AC2 assays. <citetitle><emphasis>Sex Transm Infect</emphasis></citetitle> <emphasis role="strong">95:</emphasis>87–93.</para>
          </listitem>
        </itemizedlist>
        <anchor id="ch0083s0028s0003a0007"/>
        <beginpage pagenum="1274"/>
      </sect2>
    </sect1>
  </chapter>
